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Human subfertility 
Subfertility, defined as the failure to conceive after 1 year of regular, 
unprotected intercourse with the same partner, is a prevalent disorder affecting 
approximately 10-17% of all couples in the Western world (Buckett and 
Bentick, 1997; Philippov et al. 1998; Snick et al. 1997). 
Zargar et al. reported in 1997 that in approximately 22% of the patients the 
cause of subfertility was predominantly originating from the male, and in 58% 
mainly of female origin. In 5% of the patients fertility abnormalities were found 
in both partners, while in the remaining 15% no clear cause of subfertility was 
identified. An overview of several causes for subfertility in men and women, 
ranging from congenital, genetic, endocrine, infective and environmental 
causes, is given in Table I. Although there are many known causes, in up to 
40% of men with abnormal sperm parameters or abnormal sperm function, the 
aetiology remains unknown. This group is called idiopathic subfertile. 
Since involuntary childlessness is a heavy burden for most subfertile couples 
(Verhaak et al. 2002; Whiteford and Gonzalez 1995), it is not surprising that 
many couples seek help by means of artificial reproduction techniques (ART) 
like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) to 
achieve pregnancy. 
Although these techniques have improved the treatment of subfertile couples, 
the success rate is still low, being around 20% ongoing pregnancies per started 
cycle (Kremer et al. 2002), and with a cumulative probability of achieving an 
ongoing pregnancy of approximately 55% after five IVF or ICSI cycles (Stolwijk 
et al. 2000). Furthermore, hardly any alternative treatment exists. Moreover, 
ART is a symptomatic, rather than a causal treatment for subfertility.  
Targeted treatment and, possibly, prevention of subfertility is indicated. To that 
end we need more knowledge and understanding of the pathophysiology and 
causal determinants of (the large group of idiopathic) subfertility. 
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Objectives of the thesis 
Research has been performed on many of the variables presented in Table I. 
However, many couples with idiopathic subfertility still persist of which the 
aetiology is not clear. Our general aim was to increase the knowledge and 
understanding of the pathophysiology of human subfertility by performing 
explorative studies with emphasis on some biochemical and biological aspects.  
 
Of particular interest are the environmental and lifestyle factors implicated in 
subfertility, because unlike genetic causes these can be targeted for curative or 
preventive measures. A significant but largely neglected lifestyle factor is 
nutrition. Micronutrients like folate and zinc, present in nutrition, are essential 
for DNA synthesis. In turn, DNA synthesis is important for the development of 
spermatozoa and oocytes. Therefore, nutritional deficiencies may be an 
important neglected cause of human reproductive impairment. Moreover, both 
zinc and folate have been implicated in human reproduction (Favier 1992; 
Steegers-Theunissen 1995). From this background a double-blind, placebo-
controlled randomised intervention study has been conducted by Wong et al. 
(2002) investigating the effect of folic acid and/or zinc sulphate supplemen-
tation on sperm parameters in fertile and subfertile men. The results of this 
study understated the importance of these 2 micronutrients, since our group 
demonstrated a 74% increase in total normal sperm count in subfertile men 
supplemented with both folic acid and zinc sulphate for 26 weeks. However, 
the underlying mechanism of this beneficial effect of folic acid and zinc 
sulphate was not clear. 
 
This resulted in the first objective of this thesis: 
1. To investigate the underlying mechanism of increased sperm count 
after folic acid and zinc sulphate intervention, observed in our previous 
study. 
Chapter 1 
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Table I Aetiology of human subfertility  
MEN WOMEN 
Pretesticular disorders 
Endocrine 
 Diabetes 
 Kallmann syndrome 
 Pituitary adenomas 
Coital disorders  
 Impotence 
 Ejaculatory failure 
 
Testicular disorders 
Genetic 
 Klinefelter syndrome 
 Y-chromosome deletions 
 Kartagener syndrome 
 Androgen insensitivity 
 Autosomal rearrangements 
 Spermatocytic arrest 
Congenital  
 Anorchism 
 Cryptorchidism 
Infective  
 Orchitis 
Neoplastic  
 Testicular cancer 
Environmental agents 
 Temperature 
 (Ir)radiation  
 Chemotherapy 
 Medications 
 Occupational exposures 
  
'Pre-ovarian disorders' 
Age 
Endocrine 
 Diabetes 
 Thyroid disease 
 Cushing syndrome 
 Pituitary adenomas 
 Panhypopituitarism  
 Sheehan syndrome 
 Kallmann syndrome 
 Anorexia or bulimia nervosa 
Coital disorders 
 Decreased libido 
 Lubrication disorders  
 Vaginism 
 Idiopathic 
 
Pelvic disorders 
Endometriosis 
Infective  
 Pelvic inflammatory disease 
Neoplastic 
 
Ovarian disorders 
Genetic 
 Turner syndrome 
 Swyer syndrome 
Congenital or functional  
 Resistant ovary syndrome 
 Premature ovarian failure 
 Polycystic ovarian syndrome 
General Introduction 
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Table I Aetiology of human subfertility (continued) 
MEN WOMEN 
 Stimulants 
  drugs 
  alcohol 
  tobacco abuse 
 Nutritional deficiency 
 trace elements 
  vitamins 
Vascular  
 Torsion 
 Varicocele 
Immunological 
Idiopathic 
 
Epididymal disorders 
Obstructive  
 Congenital 
 Infective 
Epididymal hostility 
 
Vasal disorders 
Genetic  
 Cystic fibrosis 
Acquired  
 Vasectomy 
 
Accessory gland disorders  
Infective 
 
Immunological  
Post-vasectomy 
Idiopathic 
Infective 
 Adnexitis 
Neoplastic 
Environmental agents  
 (Ir)radiation 
 Chemotherapy 
 Medications 
 Occupational exposures 
 Stimulants 
 drugs 
 alcohol 
 tobacco abuse 
 Nutritional deficiency 
 trace elements 
 vitamins 
 
Tubal disorders 
Congenital 
 Mayer-Rokitansky-Küster syndrome 
Infective  
 Salpingitis 
Neoplastic 
Acquired 
 Previous extra uterine pregnancy 
 Sterilisation 
 
Uterine abnormalities 
Congenital 
 Mayer-Rokitansky-Küster syndrome 
 
Cervical mucus defects / dysfunction 
 
(Modified from Skakkebaek et al. 1994 and de Kretser 1997). 
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Bezold et al. (2001) investigated the involvement of the C677T polymorphism 
in methylenetetrahydrofolate reductase (MTHFR), one of the key enzymes in 
folate metabolism. This polymorphism is common and is accompanied by an 
altered folate metabolism, resulting in an increased folate need. The authors 
reported a higher frequency of the 677TT genotype in infertile males, and 
suggested that these males in particular may benefit from folic acid 
supplementation. We hypothesized that differences in prevalence of the C677T 
MTHFR polymorphism could explain the beneficial effect of folic acid and zinc 
sulphate in subfertile men. 
Another of our hypotheses was that folic acid and zinc sulphate may affect 
endocrine parameters, for instance by stimulating the function of the Sertoli 
cells. These cells provide the essential microenvironment for normal germ cell 
production and could therefore be relevant. Sertoli cells are the main producers 
of inhibin B in the human body and the inhibin B concentration reflects the 
quality of the Sertoli cell function and spermatogenesis and as such can be 
used as a sensitive marker of spermatogenesis in humans. 
Finally, it is known from literature that both folate and zinc are related to 
apoptosis, a programmed and physiological mode of cell death. Both folate and 
zinc deficiency results in significant apoptosis in several cell types, and zinc 
possesses anti-apoptotic properties, indicated by the observation that zinc 
supplementation can prevent apoptosis. Therefore, the final hypothesis we 
investigated to explain the beneficial effect of folic acid and zinc sulphate on 
sperm count was the effect of these 2 micronutrients on apoptosis.  
 
Other observations reported in literature regarding folate and zinc were that 
both these nutrients are important for several antioxidant functions. 
Antioxidants can provide protection of cells against oxidative stress caused by 
reactive oxygen species (ROS), leading to damage of DNA, proteins or cell 
membranes. Another important antioxidant system in human tissues is the 
endogenous thiol glutathione (GSH) and the glutathione-related enzyme 
system, quantitatively one of the most important protective systems in human 
physiology. Many investigators have shown evidence for the role of both ROS 
and thiols in the physiology and pathology of both male and female 
reproductive function. 
General Introduction 
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Overproduction of ROS results in a pro-oxidant state in which the vascular 
endothelial growth factor (VEGF) is expressed. VEGF is a protein produced by 
many different tissues in response to hypoxia, with the endothelial cell as its 
main target. VEGF is best known for its actions in angiogenesis, but it also 
seems to have important functions in male and female reproduction. In the 
female reproductive organs angiogenesis is necessary for the physiological 
periodical growth and regression of tissues. In the male very high concen-
trations of VEGF have been found in seminal plasma. The exact role of this 
growth factor in the male is still unknown, but the presence of very high 
concentrations in seminal plasma argues for an important role in male fertility 
and reproduction.  
Finally, for angiogenesis to occur, matrix degradation is necessary. One of the 
systems involved in matrix degradation in humans is the plasminogen activator 
(PA)-system. The components of the PA-system occur in a variety of different 
cell types and are involved in several biological processes. Degradation of the 
extracellular matrix resulting from plasminogen activation is important in cell 
migration, necessary for morphogenesis, tissue repair, neovascularization or 
invasion of malignant cells. One of the interesting areas in which the PA-
system appears to play an important role is reproduction. 
 
These observations in literature resulted in the second objective of this thesis: 
2. To systematically investigate the role of thiols, the PA-system and 
VEGF in human (sub)fertility by a) measuring the levels of these 
different parameters in the ejaculate, purified spermatozoa and 
follicular fluid of couples undergoing assisted reproduction techniques, 
and b) to determine associations between the concentrations of thiols, 
PA components and VEGF and fertility outcome parameters.  
Chapter 1 
 
 
18 
Outline of the thesis 
The objectives are described in part I and part II, respectively. 
 
PART I  
Folic acid, zinc sulphate and human subfertility  
Chapter 2 gives a review of the literature regarding the involvement of folate, 
zinc, antioxidants, and apoptosis on human subfertility. The following studies 
described in part I are an extension of a previous double-blind, placebo-
controlled randomised intervention study conducted by our research group 
(Wong et al. 2002). This study evaluated the effects of a daily intake of 5 mg of 
folic acid, 66 mg of zinc sulphate, a combination of these 2 micronutrients or 
placebo treatment for 26 weeks on semen quality in 103 subfertile and 107 
fertile males. The results of this study indicated a 74% increase in total normal 
sperm count for the subfertile group supplemented with the combination 
treatment. The same trend was found for the fertile group although no 
significance was reached. 
Since the underlying mechanism for this beneficial effect of folic acid and zinc 
sulphate intervention on semen quality is unclear, we investigated possible 
influences of folate related gene polymorphisms, hormones, and apoptosis. 
Chapter 3 investigated the frequency of the C677T methylenetetrahydrofolate 
reductase (MTHFR) polymorphism in this male population, and the MTHFR-
dependent response of sperm concentration after folic acid and zinc sulphate 
intervention. Chapter 4 evaluated pre- and post-intervention serum endocrine 
parameters, and in Chapter 5 we determined seminal plasma annexin A5 
concentrations, which is a marker of apoptosis, before and after the 
intervention treatment. 
 
PART II 
VEGF and determinants of the oxidative and plasminogen pathway in human 
subfertile couples 
The literature on the involvement of the plasminogen activator system and 
vascular endothelial growth factor in human subfertility is reviewed in Chapter 
6. To further explore these 2 processes as possible underlying causes of 
human subfertility, besides nutritional ‘deficiencies’ of folic acid and zinc 
sulphate discussed in part I, we collected various fluids from 156 couples 
General Introduction 
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participating in an IVF or ICSI procedure in the Radboud University Nijmegen 
Medical Centre in Nijmegen, The Netherlands. These couples had several 
different indications for ART, varying from male factor subfertility characterised 
by oligoasthenoteratozoospermia (n = 52), female factor subfertility divided into 
women with Fallopian tube pathology (n = 26) or endometriosis (n = 26), and 
idiopathic subfertile couples (n = 52).  
We measured concentrations of the endogenous antioxidant family of thiols in 
the ejaculate, and purified spermatozoa of the men, and in follicular fluid of the 
women. We compared these concentrations between the different diagnostic 
subgroups, and investigated possible associations between these thiol 
concentrations and fertility outcome parameters after ART (Chapter 7). Similar 
investigations were conducted, by measuring in the same study population 
different components of the plasminogen activator system involved in matrix 
degradation (Chapter 8), and vascular endothelial growth factor (Chapter 9).  
 
In the general discussion (Chapter 10) we reflect on all these different results in 
light of the methodological strengths and weaknesses; in relation to literature 
we try to synthesise what knowledge about the pathophysiology of subfertility 
has been achieved and what the links can be between all the different 
hypotheses and results described in the separate chapters. 
This enables us to propose recommendations for new research and potential 
clinical aspects. 
 20 
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Chapter 2 
 
The importance of folate, zinc, and antioxidants in the 
pathogenesis and prevention of subfertility, a review 
 
Inge M.W. Ebisch, Chris M.G. Thomas, Wilbert H.M. Peters,  
Didi D.M. Braat, and Régine P.M. Steegers-Theunissen 
 
Human Reproduction update, in press
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Abstract 
 
Background: Many subfertile couples have to be treated by artificial 
reproduction techniques for having children. This is, however, not a causal 
treatment for subfertility. In this review we outline the importance of nutritional 
and biochemical factors like folate and zinc, implicated in underlying processes 
such as detoxification and apoptosis in (sub)fertility. 
Method: A literature search was performed using MEDLINE, Science Direct 
and bibliographies of published works. 
Results: Evidence on the role of folate determined by food intake, synthetic 
folic acid intake, and folate related enzymes on sperm parameters is 
inconclusive. More data are available on the importance of folate on female 
reproduction, known to be important for the quality and maturation of oocytes, 
and in the prevention of early abortion, placenta abruption or infarction, foetal 
growth retardation, and neural crest related congenital malformations.  
Zinc in males is implicated in testicular development, chromatin deconden-
sation and stabilization, acrosome reaction, synthesis of testosterone and the 
conversion of testosterone into 5α-dihydrotestosterone. In the female, zinc 
plays a role in sexual development, ovulation, and the menstrual cycle. 
Folate and or zinc have antioxidant properties. Reactive oxygen species (ROS) 
are produced by spermatozoa and play a role in hyperactivation of spermato-
zoa, acrosome reactions, and binding to the zona pellucida of the oocyte. 
Thiols like glutathione are important to balance the level of ROS and function in 
DNA compaction, tail structure stability and motility of spermatozoa. An excess 
of ROS is detrimental to the motility, morphology, and function of spermatozoa. 
In the female, ROS affect oocyte maturation, luteolysis, progesterone 
production by the corpus luteum, ovulation, and follicle atresia, while gluta-
thione in the oocyte is important for sperm nucleus decondensation and male 
pronucleus formation. 
An underlying process influenced by folate, zinc, ROS and thiols is apoptosis. 
Apoptosis in males is important for the release of sperm. Disorders in 
apoptosis contribute to an excess of abnormal spermatozoa possibly resulting 
in subfertility. In women apoptosis regulates follicle atresia, degeneration of the 
corpus luteum, and the cyclic shedding of endometrium during menstruation.
Nutrients, antioxidants and subfertility 
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Conclusions: Nutrition and biochemical factors play an important role in 
(sub)fertility, and affect biological processes in male and female reproduction. 
The parameters reviewed in this paper have been shown to be involved in 
reproduction, but their relative contribution to subfertility in humans is not clear. 
Therefore, this review may stimulate further research in humans to unravel 
underlying mechanisms and identify amendable environmental factors to 
improve the diagnosis and treatment of subfertility. 
Chapter 2 
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Introduction 
Subfertility is defined as the failure to conceive after 1 year of regular, 
unprotected intercourse with the same partner. Approximately 10 to 17% of all 
couples experience primary or secondary subfertility at some time during their 
reproductive life (Buckett and Bentick, 1997; Mosher and Pratt, 1990; Philippov 
et al., 1998; Snick et al., 1997; Templeton et al., 1990; Wallace, 1995). In Table 
I various causes of subfertility and the corresponding frequencies are summa-
rized.  
 
Table I The cause of subfertility and their approximate frequencies (Modified 
from Cahill and Wardle, 2002) 
CAUSE FREQUENCY (%) 
Male factor subfertility 
 Sperm defects or dysfunction 
 
30 
Female factor subfertility 
 Ovulation failure (amenorrhoea or oligomenorrhoea) 
 Tubal infective damage 
 Endometriosis  
 Cervical mucus defects or dysfunction 
 Uterine abnormalities (such as fibroids or abnormalities of shape) 
 
25 
20 
5 
3 
(< 1) 
Unexplained subfertility 25 
Coital failure or infrequency 5 
Note: total exceeds 100% as 15% of couples have more than one cause of subfertility 
 
Subfertility resulting in permanent childlessness is very difficult for couples to 
cope with (Downey et al., 1989; Whiteford and Gonzalez, 1995) and, therefore, 
subfertile couples try to conceive with all possible techniques that, however, do 
not treat the cause of the subfertility, such as artificial reproduction techniques 
(ART). Therefore there is a need to unravel the multifactorial origin of sub-
fertility in which many genetic and environmental factors act together.  
Of particular interest are the environmental and lifestyle factors implicated in 
subfertility, because unlike genetic causes, these can be targeted for curative 
or preventive measures. A significant but largely neglected lifestyle factor is 
nutrition. Nutrition is important for DNA synthesis, because most of its essential 
compounds are derived from the diet. Moreover, several enzymes involved in 
DNA synthesis are zinc or B-vitamin dependent (Figure 1).  
Nutrients, antioxidants and subfertility 
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Figure 1 DNA synthesis, the folate cycle and glutathione metabolism 
 
Numbers: 1. Methionine-adenosyltransferase; 2. Methyltransferase; 3. S-adenosylhomocysteine 
hydrolase; 4. Betaine-homocysteine-methyltransferase (BHMT) (zinc dependent); 5. Methionine-
synthase (vitamin B12 and zinc dependent); 6. Serineoxidase; 7. Methylenetetrahydrofolate 
reductase (MTHFR; vitamin B2 dependent); 8. Thymidylate-synthase; 9. Cystathionine-β-synthase 
(vitamin B6 dependent); 10. γ-Cystathionase (vitamin B12 dependent); 11. γ-Glutamyl-cysteine-
synthase; 12. Glutathione-synthase; 13. Glutathione peroxidase; 14. GSSG reductase; 15. γ-
Glutamyl transpeptidase; 16. γ-Glutamyl cyclotransferase; 17. 5-Oxoprolinase. 
Abbreviations: ATP, adenosine triphosphate; DNA, deoxyribonuleic acid; dTMP, deoxythymidine 
monophosphate; dUMP, deoxyuridine monophosphate; GSSG, glutathione disulphide; H2O, 
water; Pi, orthophosphate; PPi, pyrophosphate; THF, tetrahydrofolate. 
 
DNA synthesis is important for the development of spermatozoa and oocytes. 
Animal studies have demonstrated that deficiencies of vitamins A, C and D 
resulted in diminished fertility in rats and rainbow trout (Ciereszko and 
Dabrowski, 1995; Kwiecinski et al., 1989; van Pelt and de Rooij, 1991). In
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humans the effects of nutrition on fertility have scarcely been investigated. 
Recently, our group found a 74% increase in normal sperm count in subfertile 
men after supplementation of folic acid in combination with zinc sulphate 
(Wong et al., 2002).  
The diet is a source of exogenous antioxidants (vitamins C and E), but also 
several endogenously synthesized antioxidants are essential, such as 
glutathione, bilirubin and uric acid. These antioxidants protect DNA and other 
important molecules from oxidation and damage, which otherwise would result 
in apoptosis. A more detailed overview of the glutathione metabolism is 
displayed in Figure 1.  
The role of folate, zinc, glutathione and related thiols in biological processes 
involved in (sub)fertility are described in this review. We are aware that the 
pathways discussed here are only part of the complex processes implicated in 
reproduction, but we hope that this review will stimulate research into these 
issues in order to contribute to a better diagnosis and treatment of subfertility in 
humans in the future. 
 
Materials and Methods  
A thorough literature search was performed on MEDLINE, Science Direct, and 
via bibliographies of published works. The literature reviewed consisted of 
papers in English and Dutch published between 1950 and 2005, discussing 
both animal and human studies. The following words combined in different 
ways were used as search terms: fertilization, subfertility, folate, folic acid, zinc, 
antioxidants, glutathione, thiols, apoptosis, methylenetetrahydrofolate reduc-
tase (MTHFR), and ROS. 
 
Folate 
The micronutrient folate is present in a wide variety of foods, such as green-
leafy vegetables, liver, bread, yeast and fruits. Folate is important for the 
synthesis of DNA, transfer RNA, and the amino acids cysteine and methonine 
(Figure 1). DNA synthesis plays an important role in germ cell development 
and therefore it is obvious that folate is important for reproduction. It has also 
been reported that folic acid, the synthetic form of folate, effectively scavenges 
oxidizing free-radicals, and as such can be regarded as an antioxidant (Joshi et 
al., 2001). Despite of its water soluble property, folic acid inhibits lipid
Nutrients, antioxidants and subfertility 
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peroxidation. Therefore, folic acid can protect bio-constituents like cellular 
membranes or DNA from free-radical damage (Joshi et al., 2001). Only limited 
knowledge is available on the impact of dietary folate and synthetic folic acid 
on (sub)fertility.  
 
Folate in males 
Wong et al. (2002) found that folic acid administration (5 mg) to subfertile and 
fertile men for twenty-six weeks resulted in a significant increase of folate 
concentrations in seminal plasma, but no effect of this intervention was 
observed on sperm count or motility of spermatozoa. The percentage of normal 
sperm morphology, as determined according to strict criteria (Menkveld et al., 
1990) even decreased after folic acid intervention. However, a 74% increase in 
total normal sperm count after the combination intervention with folic acid and 
zinc sulphate for twenty-six weeks was observed. An intervention study by 
Bentivoglio et al. (1993) reported an increase in number and motility of mature 
spermatozoa, and a decrease in round cell number (the presence of many 
immature cells) after 3 months of supplementation with 15 mg folinic acid (5-
formyl tetrahydrofolate) in sixty-five men of infertile couples with round cell 
idiopathic syndrome. Another intervention study by Landau et al. (1978) did not 
observe a beneficial effect of folic acid supplementation on sperm count in 40 
normo- and oligozoospermic men, however, both the dose and the duration 
was different as compared to the study of Bentivoglio et al. (10 mg during 30 
days).  
When folic acid is administrated, it has to be converted into the biologically 
active form 5-methyl tetrahydrofolate to exert its functions. This conversion is 
carried out by methylenetetrahydrofolate reductase (MTHFR), one of the key 
enzymes in folate metabolism. MTHFR converts 5,10-methylenetetrahydro-
folate into 5-methyltetrahydrofolate, which subsequently donates a methyl 
group to cobalamin to form methylcobalamin and tetrahydrofolate. Methyl-
cobalamin serves as a cofactor in the conversion of 5-methyltetrahydro-folate 
to tetrahydrofolate, in which homocysteine is remethylated to the essential 
amino acid methionine in humans (Figure 1). In the MTHFR-gene, a common 
polymorphism, resulting from a cytosine to thymine substitution (C677T) may 
be present. The prevalence of heterozygosity or homozygosity for this variant 
is approximately 40% and 10% in Caucasians, respectively (Ueland et al.,
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2001), and these values vary between populations. This polymorphism is 
associated with an increased thermolability and reduced specific activity of 
MTHFR in vivo, resulting in a residual enzyme activity of 65% for heterozygous 
carriers and of only 30% for homozygous carriers (Frosst et al., 1995; Van der 
Put et al., 1995). Individuals with the homozygous genotype have mildly, 
though significantly elevated plasma homocysteine concentrations compared 
with heterozygotes and wild-types, especially when folate concentrations are 
low (Malinow et al., 1997). 
The C677T polymorphism in the MTHFR-gene is accompanied by an altered 
folate metabolism and an impaired homocysteine remethylation, resulting in an 
increased folate need. The effect of supplementation with folic acid on semen 
parameters therefore is likely to be dependent on the MTHFR genotype. 
Information on the effects of the MTHFR genotype on biological parameters is 
scarce. Stern et al. (2000) found that the 677T-homozygous genotype was 
associated with lower DNA methylation capacity compared with the 677C-
homozygous genotype. This was explained by the reduced availability of 5-
methyl tetrahydrofolate, required for S-adenosylmethionine biosynthesis. 
Bezold et al. (2001) reported a higher frequency of the homozygous 677T 
MTHFR genotype in infertile men, and suggested that products of MTHFR may 
have a role in the pathogenesis of male infertility. They furthermore stated that 
homozygous men in particular may benefit from folic acid supplementation. We 
reported that, in contrast to 677T MTHFR heterozygotes and homozygotes, 
sperm concentration in 677C homozygotes significantly improved after folic 
acid and zinc sulphate intervention, and concluded for this reason that the 
residual MTHFR activity in homozygote and heterozygote patients for the 
C677T MTHFR polymorphism might be insufficient to improve spermato-
genesis compared with wild-type individuals (Ebisch et al., 2003). Animal in 
vivo and in vitro studies have shown that zinc deficiency decreases the 
absorption and metabolism of dietary folate (Favier et al., 1993; Ghishan et al., 
1986; Quinn et al., 1990), due to its function as a cofactor for the folate 
metabolising enzymes dihydrofolate reductase and γ-glutamyl hydrolase. Zinc 
in itself, however, is not a cofactor of the MTHFR enzyme, but a cofactor for 
methionine synthetase and betaine-homocysteine methyltransferase (Figure 
1). 
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Folate in females 
Not much is known about the effects of folate or folic acid on oocyte 
development. A study by Lo et al. (1991) demonstrated the existence of an 
endogenous carrier-mediated uptake system for folate in frog oocytes. Similar 
studies on the existence of such an uptake system in human oocytes were not 
found. A study on homocysteine concentrations in follicular fluid (FF) in women 
opting for in vitro fertilization (IVF) treatment reported that women receiving 
folic acid supplementation had significantly lower homocysteine concentrations 
in their FF (the microenvironment surrounding the oocyte) (Steegers-
Theunissen et al., 1993; Brouns et al., 2003; Szymanski and Kazdepka-
Zieminska, 2003). The latter authors found that women receiving folic acid 
supplementation (and subsequent lower homocysteine FF concentrations) had 
a better quality and a higher degree of maturity of oocytes compared with 
women who did not receive folic acid supplementation (Szymanski and 
Kazdepka-Zieminska, 2003). Moreover, it was shown that folic acid present in 
mouse preimplantation embryos was absolutely essential for early embryo 
development, probably because of its essential role in the synthesis of 
thymidine required for DNA synthesis and repair. Also, all of the folic acid 
necessary for this process was present within the gametes at the time of 
fertilization (O'Neill, 1998). 
 
Zinc 
Zinc is a micronutrient abundantly present in meat and seafood. Zinc serves as 
a cofactor for more than eighty metalloenzymes involved in DNA transcription 
and protein synthesis (Figure 1). Since DNA transcription is a main part of 
germ cell development, zinc is likely to be important for reproduction. 
Furthermore, zinc finger proteins are implicated in the genetic expression of 
steroid hormone receptors (Favier, 1992; Freedman, 1992), while also zinc has 
anti-apoptotic (Chimienti et al., 2003), and antioxidant properties (Zago and 
Oteiza, 2001). Two mechanisms for this antioxidant function have been 
described. Zinc can bind sulfhydryl groups in proteins to counteract oxidation, 
and lipid peroxidation is prevented by occupying binding sites for iron and 
copper in lipids, proteins and DNA (Bray and Bettger, 1990; Zago and Oteiza, 
2001). To substantiate these antioxidant effects of zinc, evidence was found for 
oxidative damage of proteins, lipids and DNA in zinc deficient rat and mice
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(Bagchi et al., 1998; Oteiza et al., 1995), whereas zinc salts could protect 
against oxidative damage and glutathione depletion in mice (Bagchi et al., 
1998). 
 
Zinc in males 
Zinc directly acts on testicular steroidogenesis (Favier, 1992; Hamdi et al., 
1997). It has been shown that zinc is important in testicular development 
(Hamdi et al., 1997) and influences the oxygen consumption of spermatozoa in 
seminal plasma (Eliasson et al., 1971; Huacuja et al., 1973), nuclear chromatin 
condensation (Kvist, 1980), acrosome reaction (Riffo et al., 1992) and acrosin 
activity (Steven et al., 1982). Zinc also is important in sperm chromatin 
stabilization (Kvist et al., 1990), and in the synthesis of testosterone in Leydig 
cells and the conversion of testosterone to the biologically active 5α-dihydro-
testosterone (Leake et al., 1984; Netter et al., 1981).  
Zinc concentrations are very high in the male genital organs as compared to 
other tissues and body fluids (Mann, 1964), in particular in the prostate gland 
which is largely responsible for the high zinc content in seminal plasma. 
Spermatozoa themselves also contain zinc, which is derived from the testis. 
The relationship between zinc concentrations in seminal plasma and semen 
fertility parameters, however, is not clear. Kvist et al. (1990) found that zinc 
concentrations in seminal plasma were lower in men with idiopathic subfertility, 
compared with fertile controls. Low seminal zinc levels have been correlated 
with decreased fertility potential (Caldamone et al., 1979; Marmar et al., 1975). 
Furthermore, it was shown that men with sperm count of less than 20 million 
cells per millilitre, had slightly lower seminal plasma zinc concentrations 
compared with men with normal sperm counts (Saaranen et al., 1987). 
However, other authors reported that total seminal plasma zinc concentrations 
were similar between normozoospermic and oligoasthenozoospermic patients 
(Carpino et al., 1998). 
Several intervention studies indicated that zinc supplementation accelerates 
the onset in sexual function in zinc-deficient males (Halsted et al., 1972). 
Furthermore, it seems to improve sperm count (Hartoma et al., 1977; Mahajan 
et al., 1982; Marmar et al., 1975; Wong et al., 2002), sperm motility and 
morphology (Caldamone et al., 1979; Marmar et al., 1975), testosterone 
concentration (Antoniou et al., 1977; Hartoma et al., 1977; Mahajan et al.,
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1982) and sexual potency (Antoniou et al., 1977; Mahajan et al., 1982) in 
subfertile men. Ronaghy et al. (1974) found a higher, though not statistically 
significant proportion of already developed genitalia in malnourished school 
boys after zinc supplementation, as compared to boys not receiving extra zinc. 
The induction of mild zinc deficiency in 5 healthy, fertile men resulted in a 
reversible drop in sperm concentration and count, sexual drive, and testos-
terone in all study subjects, explained by a reduction in Leydig cell function 
(Abbasi et al., 1980). The underlying mechanisms of zinc on the fertility 
parameters, however, are not yet clear. 
 
Zinc in females 
In females, zinc also seems to be important in reproduction, however, only 
relatively few investigations have been performed. Shaw et al. (1974) found 
that zinc deficiency in female rabbits resulted in disinterest in their male 
counterparts and therefore in failure of ovulation. Furthermore, the endo-
metrium of these rabbits was pale and inactive, and these rabbits were unable 
to conceive. However, the authors could not exclude that the observed effects 
were related to deficiencies in other critical nutrients (Shaw et al., 1974). Zinc 
deficiency also led to abnormal oestrous cycles in female rats (Swenerton and 
Hurley, 1968). In addition, the effects of zinc deficiency in 2 species of 
monkeys have been investigated, and it was found that normal reproduction 
was impaired in both species. The pregnancy rate in zinc deficient monkeys 
was significantly lower compared with the original stock colony, because of 
cessartion of the seasonal menstrual cycles. However, some zinc deficient 
monkeys were still able to conceive (Swenerton and Hurley, 1980).  
Studies on the effects of zinc deficiency in women are scarce. Ronaghy and 
Halsted (1975) described 2 women of 19 and 20 years old, suffering from 
nutritional dwarfism with delayed sexual maturation. These women had no 
breast tissue, pubic hair and had infantile external genitalia with extremely low 
plasma and erythrocyte zinc levels. After zinc supplementation these women 
experienced their first menstrual period, developed breast tissue as well as 
pubic hair growth. Jameson (1976) reported longstanding infertility in 7, normal 
sexually developed women with celiac disease. These women all had normal 
menstrual cycles, but low serum zinc levels. Soltan and Jenkins (1983) 
measured plasma zinc concentrations in 48 infertile and 35 control women and
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found no differences between these 2 groups. It was therefore concluded that 
zinc deficiency is not a significant cause of subfertility.  
Finally, Ng et al. (1987) investigated the zinc levels in FF of 33 women 
undergoing IVF in Singapore, and did not observe any correlation between FF 
zinc concentration, follicle volume, the presence of oocytes in the follicle, or the 
eventual fertilization of the oocyte. Therefore these authors conclude that the 
FF zinc content does neither reflect the follicular status nor the status of the 
oocyte. 
 
Reactive oxygen species, antioxidants and fertility 
Antioxidants such as vitamin E (α-tocopherol), vitamin C (ascorbic acid), and 
vitamin A (carotenoids) present in nutrition are important in restoring or 
maintaining the oxidant-antioxidant balance in tissues. As mentioned before, 
folate and zinc present in nutrition are also important for several antioxidant 
functions. These antioxidants can provide protection of cells against oxidative 
and electrophilic stress caused by ROS, leading to damage of DNA or other 
important structures like proteins or cell membranes. Many investigations have 
shown evidence for the role of ROS in the physiology and pathology of both 
male and female reproductive function (de Lamirande and Gagnon, 1994; Riley 
and Behrman, 1991b). Animal studies have shown that antioxidants present in 
nutrition are important to maintain normal semen parameters and to achieve 
pregnancy (Ciereszko and Dabrowski, 1995; Kwiecinski et al., 1989). 
Another system involved in restoring or maintaining the proper pro-oxidant- 
antioxidant balance in human tissues is the glutathione (GSH)/glutathione-
related enzyme system, quantitatively one of the most important protective 
systems in humans. Glutathione is a tripeptide composed of glutamate, 
cysteine and glycine (L-γ-glutamyl-L-cysteinyl-glycine). It is synthesized in 2 
consecutive steps catalysed by γ-glutamylcysteine synthetase and glutathione 
synthetase. The enzyme γ-glutamyltranspeptidase is involved in the break-
down of glutathione, thereby cleaving the γ-bond resulting in glutamate and 
cysteinylglycine (Figure 1). Glutathione and the GSH-related enzymes, 
glutathione S-transferases, are involved in the metabolism and detoxification of 
many cytotoxic and carcinogenic compounds, whereas GSH and glutathione 
peroxidases are pivotal for elimination of ROS (Beckett and Hayes, 1993). 
GSH itself also plays an important role in the protection of cells against
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oxidative and electrophilic stress caused by ROS and radiation (Shan et al., 
1990). 
 
Reactive oxygen species and antioxidants in males 
Human spermatozoa are capable of generating ROS (Aitken et al., 1989a; 
Alvarez et al., 1987; Alvarez and Storey, 1989; D'Agata et al., 1990; Iwasaki 
and Gagnon, 1992), which are involved in regulating epididymal maturation of 
spermatozoa (Cornwall et al., 1988), the rate of hyperactivation (de Lamirande 
and Gagnon, 1993a; de Lamirande and Gagnon, 1993b), as well as the ability 
of the spermatozoa to undergo the acrosome reaction (Burkman, 1990; de 
Lamirande et al., 1993). They also have a physiologic role in mediating the 
attachment of spermatozoa to oocytes (Aitken et al., 1989a; Aitken et al., 
1993). Thus, the presence of ROS seems very important in the process of 
fertilization of oocytes. 
It should be realized that the production of ROS by spermatozoa is a normal 
physiological process. However, the amount of ROS produced has to be 
carefully controlled because an imbalance between generation and scavenging 
of ROS may lead to damage of DNA or other important structures. 
Spermatozoa are particularly susceptible to peroxidative damage, because 
most of their cytoplasm is removed during the final stages of spermatogenesis. 
Therefore, the spermatozoa have almost no cytoplasmic defensive enzymes, 
such as catalase, glutathione peroxidase or glutathione S-transferase, which 
are involved in the protection of most cell types from peroxidative damage 
induced by ROS. Furthermore, the plasma membranes of spermatozoa contain 
large amounts of unsaturated fatty acids, which are particularly vulnerable to 
free-radical attack (Jones and Mann, 1973). Thus, high concentrations of ROS 
are detrimental to sperm.  
Membrane fluidity of spermatozoa is necessary for sperm motility, the 
acrosome reaction, and the ability of the spermatozoa to fuse with the oocyte 
(Aitken et al., 1989b; Aitken et al., 1989a; Sharma and Agarwal, 1996; Zini et 
al., 2000). Lipid peroxidation caused by high concentrations of ROS may lead 
to peroxidation of plasma membrane lipids, resulting in altered membrane 
fluidity, and sperm dysfunction, which may be a cause of male subfertility. This 
is supported by the observations that subfertile men have higher concen-
trations of ROS in seminal plasma, whereas an inverse correlation exists
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between ROS concentration and motility, as well as a normal morphology of 
the spermatozoa (Agarwal et al., 1994; Aitken and Fisher, 1994; Aitken et al., 
1989a; Alkan et al., 1997; D'Agata et al., 1990; Iwasaki and Gagnon, 1992; 
Rao et al., 1989).  
Because of the involvement of GSH in the protection of cells against oxidative 
stress caused by ROS, this tripeptide may also be important in fertility. 
Raijmakers et al. (2003) found that considerable amounts of GSH were present 
in the seminal plasma of both fertile and subfertile men. However, the median 
GSH concentrations were significantly higher in fertile men compared with 
subfertile men. Furthermore, the GSH concentrations in seminal plasma were 
positively correlated with sperm motility, and inversely correlated with sperm 
morphology. These results indicate that the concentrations of GSH in seminal 
plasma play a role in fertility. This was also suggested by Lenzi et al. (1993) 
who investigated the effects of intra-muscular injection of 600 mg GSH for 2 
months. These authors observed a significant increase in sperm motility, in 
particular forward motility, and a significant reduction in the percentage of 
abnormal spermatozoa (Lenzi et al., 1993). Another intervention study 
conducted by Kodama et al. (1997) showed that a combination therapy of 400 
mg GSH, 200 mg vitamin C and 200 mg vitamin E for 2 months significantly 
improved sperm concentration and reduced the level of oxidative DNA damage 
in the spermatozoa. However, Ochsendorf et al. (1998) could not find a 
difference in seminal plasma GSH concentration between azoospermic, 
oligozoospermic-, or normospermic men.  
GSH and cysteine are also present in spermatozoa themselves. Free sulfhydryl 
groups in protamines of sperm chromatin are important in the decondensation 
of the sperm nucleus after fertilization (Rousseaux and Rousseaux-Prevost, 
1995). Garrido et al. (2004) did not find a difference in GSH content in 
spermatozoa between fertile semen donors and infertile men attending an 
infertility centre, while their wives had no demonstrable cause of infertility. 
However, in this study only semen samples with more than 50 million 
spermatozoa were used. These authors also observed that sperm GSH 
concentrations were low in semen samples with less than 5% spermatozoa of 
normal morphology (Garrido et al., 2004). Ochsendorf et al. (1998) also 
investigated GSH content in spermatozoa and found that the mean intracellular 
GSH concentration in oligospermic patients was significantly lower compared
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with that of normal volunteers. Furthermore, these authors investigated the 
relationship between sperm GSH concentration and sperm function evaluated 
by the ability of the spermatozoa to penetrate bovine cervical mucus and 
observed a small but significant positive correlation between sperm GSH 
concentration and penetration of mucus (Ochsendorf et al., 1998). 
 
Reactive oxygen species and antioxidants in females 
The role of ROS at the level of the oocyte and female infertility is not clear. The 
intensive metabolism of granulosa cells and the high numbers of macrophages 
and neutrophilic granulocytes in the follicle wall at ovulation may point at active 
generation of ROS. ROS levels in FF within certain physiologic ranges may be 
necessary for the normal development of the oocyte and subsequent embryo 
growth. However, as in many other systems, high levels may indicate oxidative 
stress.  
ROS are involved in oocyte maturation (Riley and Behrman, 1991b), luteolysis 
(Riley and Behrman, 1991a; Sugino et al., 2000), progesterone production by 
the corpus luteum (Musicki et al., 1994; Sawada and Carlson, 1996; 
Shimamura et al., 1995; Sugino et al., 1993) and ovulation. Inhibition of ROS 
actually hinders ovulation (Miyazaki et al., 1991), Furthermore, Margolin et al. 
(1990) observed that ROS are involved in the loss of sensitivity of granulosa 
cells to gonadotropic hormones and in loss of steroidogenic function, both of 
which are characteristics of follicular atresia. These results suggest that ROS 
may be involved in the atretic regression of the cohort of newly grown follicles 
to leave only one follicle that is destined for ovulation (Margolin et al., 1990). 
One definite consequence of an excess of ROS in the ovary is damage of 
plasma membranes, but what is the effect of this damage on female fertility? 
Several investigators studied the involvement of ROS/oxidative stress in the FF 
and its consequences on several outcome parameters of assisted reproduction 
procedures. Pasqualotto et al. (2004) measured lipid peroxidation (LPO) as a 
marker for oxidative stress, and the total antioxidant capacity (TAC) in pooled 
FF from women undergoing IVF treatment and found that both markers were 
positively correlated with pregnancy rate. These authors therefore concluded 
that high levels of LPO in FF are not impairing oocyte and embryo 
development and quality, and that a certain amount of oxygen is critical for 
oocyte maturation (Pasqualotto et al., 2004). Furthermore, they state that the
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higher TAC levels in these patients can buffer the higher LPO levels. No 
correlations were found between LPO and TAC levels and oocyte maturity, 
embryo quality, fertilization and cleavage (Pasqualotto et al., 2004). 
Similar results were obtained in a study by Attaran et al. (2000) who 
investigated FF levels of ROS and TAC in women undergoing IVF. These 
authors observed that granulosa cells were the primary source of FF ROS, and 
that patients who became pregnant after IVF had significantly higher FF ROS 
levels compared with patients who did not become pregnant, ROS being a 
marker for obligatory minimal metabolic activity within the follicle. Unlike 
Pasqualotto et al. (2004) Attaran et al. (2000) did not observe a difference in 
TAC levels between patients who became pregnant and those who did not. 
Also, results off Bedaiwy et al. (2002) indicated that women with higher FF 
ROS levels were more likely to become pregnant after IVF compared with 
women having lower FF ROS levels. Oyawoye et al. (2003) reported that the 
mean TAC levels in fluid from follicles that yielded successfully fertilized 
oocytes were significantly higher than the mean TAC levels from FF associated 
with oocytes eventually not becoming fertilized. Conversely, the TAC 
concentration in FF eventually yielding oocytes that gave rise to a surviving 
embryo was significantly lower compared with TAC levels in fluid from follicles 
eventually not yielding viable embryos at time of transfer. These authors 
therefore concluded that ROS may have different effects at different stages of 
embryonic development (Oyawoye et al., 2003). Finally, Wiener-Megnazi 
(2004) refined the results and concluded that extreme reductive or oxidative 
states of the FF do not favour the occurrence of pregnancy. 
Some reports deal with the role of ROS and TAC in female fertility, but the 
specific role of GSH in female reproduction is not investigated so far. It is 
known, however, that after fertilization GSH in pig oocytes is very important for 
the reduction of disulphide bonds in the sperm nucleus, and also is involved in 
sperm nucleus decondensation and male pronucleus formation (Yoshida et al., 
1993). Furthermore, GSH in bovine oocytes is also important for male pro-
nucleus formation, and for pronuclear apposition during fertilization (Sutovsky 
and Schatten, 1997). This role of GSH in the oocyte is further endorsed by the 
observation that oocytes matured in the presence of a GSH antagonist were 
not capable of decondensing the sperm nucleus and did not support 
pronucleus apposition after IVF, while these changes could be reversed by the 
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addition of thiols (Sutovsky and Schatten, 1997). Furthermore, supplemen-
tation of components of GSH during in vitro maturation of oocytes resulted in 
improved male pronucleus formation, normal fertilization, and embryo develop-
ment (Jeong and Yang, 2001; Rodriguez-Gonzalez et al., 2003; Sawai et al., 
1997). Also, enhancement of GSH or components of GSH in the oocyte and in 
culture medium of embryos during IVF or ICSI procedures was likely to 
improve fertilization rates and embryo development (Ali et al., 2003; Fukui et 
al., 2000; Kim et al., 1999; Takahashi et al., 1993). 
 
Folate, zinc, antioxidants and apoptosis  
Apoptosis is a programmed and physiological mode of cell death, essential in 
morphogenesis and normal tissue remodelling. In contrast to necrosis, the 
apoptotic process does not elicit an inflammatory response nor does it damage 
adjacent cells.  
Folate is related to apoptosis. Several investigators observed that folate 
deficiency resulted in significant apoptosis in ovarian cells of the Chinese 
hamster (James et al., 1994), human hepatoma Hep G2 cells (Chern et al., 
2001), human T lymphocytes (Courtemanche et al., 2004a; Courtemanche et 
al., 2004b), human trophoblasts (Steegers-Theunissen et al., 2000), and 
human erythrocytes (Koury and Ponka, 2004). Chern et al. (2001) furthermore 
reported that the mechanism whereby folic acid deficiency resulted in 
apoptosis was the severe disruption of methionine metabolism, leading to 
enhanced accumulation of homocysteine. This latter compound was shown to 
be responsible for an increase in oxidative stress through the overproduction of 
hydrogen peroxide. As a result of this oxidative stress situation, a redox-
sensitive transcriptional factor (NK-κB) was found to be hyper-activated, 
resulting in apoptosis through expression of death genes (Chern et al., 2001). 
Other authors observed apoptotic effects of homocysteine on vascular smooth 
muscle cells, while folic acid administration to the cell culture diminished 
apoptosis, probably through reduction of homocysteine concentrations (Buemi 
et al., 2001). 
As mentioned briefly in the section about zinc, this micronutrient also 
possesses anti-apoptotic properties. The inhibitory effects of zinc on apoptosis 
have been postulated to involve 2 mechanisms: early in the apoptotic 
pathways, zinc may inhibit caspases (proteases involved in programmed cell
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death), whereas later in the apoptotic chain of events, zinc may suppress 
calcium and magnesium-dependent endonucleases, which cause apoptotic 
DNA fragmentation (Chai et al., 1999; Chimienti et al., 2003; Perry et al., 1997; 
Truong-Tran et al., 2000). However, excessively high concentrations of zinc 
may be toxic and can induce apoptosis and even necrosis (Chimienti et al., 
2003; Truong-Tran et al., 2000). Further evidence for the involvement of zinc in 
apoptosis is indicated by the observations that zinc depletion can induce 
apoptosis in several cell types whereas zinc supplementation can protect cells 
against diverse pro-apoptotic molecules, preventing programmed cell death 
(Chimienti et al., 2003; Sunderman, Jr., 1995). 
As mentioned above, folic acid and zinc both have antioxidant properties. This 
is still another mechanism whereby these micronutrients can affect apoptosis, 
since oxidative stress is known to influence apoptosis. Buttke and Sandstrom 
state that 'many agents which induce apoptosis are either oxidants or 
stimulators of cellular oxidative metabolism. Conversely, many inhibitors of 
apoptosis have antioxidant activities or enhance cellular antioxidant defences, 
and they discuss several studies supporting this statement (Buttke and 
Sandstrom, 1994). Decreasing the ability of a cell to scavenge or detoxify ROS 
is another way by which oxidative stress can induce apoptosis. Several studies 
have indicated a relationship between intracellular GSH depletion and 
apoptosis. Chiba et al. (1996) observed that intracellular GSH modulated Fas-
mediated apoptosis in malignant and normal human T lymphocytes (Fas is a 
death factor that controls apoptosis). They found that Fas-resistant cells 
contained higher concentrations of GSH, and that pre-treatment of these 
resistant cells with buthionine sulfoximine (an inhibitor of GSH synthesis) or 
depletion of intracellular GSH reversed their resistance to Fas-mediated 
apoptosis (Chiba et al., 1996). Furthermore, Beaver and Waring (1995) 
studying apoptosis in murine thymocytes reported that a reduction in 
intracellular GSH preceded the onset of apoptosis, while pre-treatment of 
thymocytes with GSH before inducing apoptosis resulted in inhibited apoptosis. 
Therefore, they conclude that a decrease in intracellular GSH or an increase in 
GSSG (oxidized glutathione), or perhaps a change in the ratio of GSH to 
GSSG, constitutes a trigger for apoptosis (Beaver and Waring, 1995). Finally, 
Iwata et al. (1997) found that GSH depletion in the culture medium of human 
lymphocytes induced apoptosis because of an increase of ROS in the cultured
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cells, whereas the addition of GSH to the depleted medium protected the 
lymphocytes from apoptosis (Iwata et al., 1997). 
 
Apoptosis in males 
Apoptosis in certain classes of germ cells is a normal feature of 
spermatogenesis in a variety of mammalian species, including the human 
being, and may be important in regulating sperm release (Barroso et al., 2000; 
Hikim et al., 1998). However, little information is available on the biological 
significance of apoptosis in spermatogenesis or its possible role in male fertility 
(Oosterhuis et al., 2000).  
Apoptosis has been related to some forms of male factor subfertility. The 
number of spermatozoa expressing the cell surface protein Fas is low in men 
with normal sperm numbers and higher in men with abnormal sperm 
parameters (Sakkas et al., 1999). The expression of Fas in ejaculated 
spermatozoa may be linked to abnormal apoptosis, as these spermatozoa are 
destined for apoptosis, but still appear in the ejaculate. This can result in 
abnormal spermatozoa in the ejaculate possibly contributing to male 
subfertility.  
Furthermore, intracellular abnormalities such as various nuclear alterations 
including an abnormal chromatin structure, microdeletions in chromosomes, 
aneuploidy and DNA strand breaks are observed in spermatozoa from infertile 
men and possibly induce apoptosis (Barroso et al., 2000). ROS are known to 
cause oxidative damage to DNA in spermatozoa (Hughes et al., 1996; Kodama 
et al., 1997; Twigg et al., 1998a; Twigg et al., 1998b), possibly leading to a 
higher proportion of spermatozoa undergoing apoptosis. This ROS-induced 
apoptosis can be inhibited by various antioxidants (Hockenbery et al., 1993; 
Kane et al., 1993), suggesting a significant role of oxidative stress as well as 
antioxidant activity in inducing or inhibiting apoptosis. As mentioned above, the 
micronutrients folate and zinc, reported to increase sperm count (Wong et al., 
2002), also have antioxidant properties (Joshi et al., 2001; Zago and Oteiza, 
2001). Therefore, these 2 micronutrients also may have an effect on apoptosis.  
 
Apoptosis in females 
Throughout female foetal and postnatal life 99.9% of follicles undergo atresia 
by means of programmed cell death (Tilly et al., 1991; Tilly, 2001). Why so
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many oocytes do not survive to become fertilized by a spermatozoon is not 
understood as yet. Tilly (2001) states that oocyte apoptosis can be considered 
as an utterance to the survival-of-the-fittest theory of evolution, whereby the 
ongoing deletion of inferior oocytes through the apoptotic pathway maximizes 
the chance of reproductive success. Yuan and Giudice (1997) investigated the 
role of apoptosis in different stages of follicular development and observed that 
programmed cell death occurred in human ovaries, and particularly in the 
granulosa cell layer. Furthermore they state that apoptosis commences as 
soon as follicles begin to leave their resting state, since primordial, primary, 
and secondary follicles in the human ovary are not affected by apoptosis, while 
from the preantral stage onwards, the growing follicles show increasing 
amounts of apoptotic granulosa cells (Yuan and Giudice, 1997). Interestingly, 
dominant follicles do not have apoptotic granulosa cells (Yuan and Giudice, 
1997). Similar results were found in the ovaries from rats (Hughes, Jr. and 
Gorospe, 1991; Palumbo and Yeh, 1994). 
Yuan and Giudice also reported that oestrogen-dominant follicles did not 
display any apoptosis, in contrast to androgen-dominant follicles in which 
apoptosis was a characteristic feature. Therefore, these authors state that 
apoptosis in follicles is a function of follicular androgen dominance (Yuan and 
Giudice, 1997). In a review Hsueh et al. (1994) discussed the hormonal control 
of apoptosis in follicular atresia. They stated that gonadotropins and estrogens 
in combination with several ovarian growth factors and regulatory peptides, like 
insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF)/transforming 
growth factor-α (TGFα) and basic fibroblast growth factor (bFGF), are involved 
in the escape from follicular apoptosis, while androgens and atretogenic factors 
like interleukin-6 (IL-6) and GnRH are involved in the induction of apoptosis in 
follicles. 
Apoptosis furthermore seems to be important in the degeneration of corpora 
lutea in the ovary (Shikone et al., 1996; Tilly et al., 1991; Yuan and Giudice, 
1997) and the cyclic shedding of the endometrium in the uterus (Spencer et al., 
1996).  
Another possible role suggested for apoptosis is the prevention of fertilization 
of potentially defective oocytes after ovulation (Fujino et al., 1996). However, 
Van Blerkom and Davis (1998) investigated the extent of apoptosis in newly 
ovulated mouse and human oocytes and found no indication of significant
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apoptosis. Furthermore, these authors showed that penetration and fertilization 
failure of human oocytes were not related to apoptosis. In addition, apoptosis 
of oocytes, if it occurred at all, was patient specific and not related to maternal 
age (Van Blerkom and Davis, 1998). The presence of apoptosis in oocytes 
from specific patients could have consequences regarding their fertility (Van 
Blerkom and Davis, 1998). 
Likewise, İdil et al. investigated the role of granulosa cell apoptosis in the 
aetiology of idiopathic subfertility and found that the apoptotic rate in women 
with unexplained infertility was significantly higher compared with that in 
women with tubal pathology. Therefore, these authors state that granulosa cell 
apoptosis may have a role in the aetiology of unexplained infertility (Idil et al., 
2004). Nakahara et al. (1997a) also investigated the rate of apoptosis per 
patient in relation to different causes of female infertility, and found that the 
amount of apoptosis in mural granulosa cells was significantly higher compared 
with that of cumulus cell masses. In addition, they investigated the difference in 
apoptotic rates between women with tubal infertility, endometriosis, male 
infertility and idiopathic infertility. The results showed no difference in mural 
granulosa cell apoptosis, however, patients with endometriosis showed a 
significantly higher incidence of apoptotic bodies in the cumulus cells 
compared with patients in the other groups (Nakahara et al., 1997a). Other 
authors also suggested involvement of deranged apoptosis in endometriosis 
patients (Garcia-Velasco et al., 2002; Garcia-Velasco and Arici, 2003; 
Nakahara et al., 1998). However, not all authors could demonstrate such a 
connection (Cahill, 1998).  
Finally, Nakahara et al. (1997a) investigated the relationship between 
apoptosis and parameters associated with the IVF program. Results indicated 
that significantly more apoptosis was found in both mural and cumulus 
granulosa cells in patients with less than 6 retrieved oocytes compared with 
patients with more than 6 retrieved oocytes (Nakahara et al., 1997a). Also, the 
apoptotic rates in mural granulosa cells were significantly higher in non-
pregnant compared with pregnant patients, indicating that a higher incidence of 
apoptosis could be indicative of a poor prognosis for IVF (Nakahara et al., 
1997a). Similar results were observed by Oosterhuis et al. (1998) who found 
that women with less than 13% apoptotic granulosa-lutein cells were far more 
likely to become pregnant as compared to women with more than 13%
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apoptotic cells. 
In an additional study investigating apoptosis per follicle, Nakahara et al. 
(1997b) reported that significantly more apoptotic granulosa cells were present 
in follicles containing no oocyte compared with follicles with oocyte, whereas 
follicles from fertilized oocytes contained significantly less apoptotic granulosa 
cells as compared to follicles from non-fertilized oocytes. In addition, follicles 
containing oocytes from which good embryos developed did contain 
significantly less apoptotic granulosa cells compared with follicles with oocytes 
from which morphologically poor embryos developed (Nakahara et al., 1997b). 
These findings also suggest that a higher incidence of apoptosis might be a 
poor prognostic factor for IVF outcome (Nakahara et al., 1997b).  
Finally, Seifer et al. (1996) observed a possible role for apoptosis in women 
with decreased ovarian reserve like in the premature ovarian failure syndrome. 
 
Conclusions 
Many environmental and biochemical factors are involved in male and female 
reproduction. The importance of many of these factors is not yet clearly 
understood. Still numerous couples face unexplained subfertility and can only 
be treated by assisted reproduction technologies. However, these treatments 
do not abolish the cause of subfertility, for which no therapies are available. A 
better understanding of underlying mechanisms in (sub)fertility is important to 
improve diagnosis and treatment. In addition to other possible underlying 
mechanisms of subfertility, the pathways in which nutrition, antioxidants, and 
apoptosis are involved as reviewed in this paper need to be further 
investigated.  
Many investigations in the field of subfertility reviewed here were performed on 
laboratory animals or cell cultures, which is a comprehensive first research 
design. However, it is very important to verify the results in human subjects. 
Also, most investigations actually performed in human beings involve couples 
participating in ART procedures. This is the only way to obtain research 
material in humans. The disadvantage is that all couples experience sub-
fertility, and since subfertility is known to be a combination of female and male 
factors, no information on truly fertile couples is available. It would be a great 
advantage to investigate the same biochemical parameters in fertile couples.
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Abstract  
 
Objective: To determine the frequency of C677T methylenetetrahydrofolate 
reductase (MTHFR) polymorphism in fertile and subfertile males, and the 
MTHFR-dependent response of sperm concentration after folic acid and/or zinc 
sulphate intervention. 
Design: Double-blind, placebo-controlled randomised intervention study. 
Setting: Two outpatient fertility clinics and nine midwifery practices in The 
Netherlands. 
Patients: One hundred thirteen fertile and 77 subfertile males. 
Interventions: Daily capsules of folic acid (5 mg) and/or zinc sulphate (66 mg), 
or placebo for 26 weeks. 
Main outcome measures: Prevalence of C677T MTHFR polymorphism and 
the response of sperm concentration related to MTHFR carriership after 
intervention treatment. 
Results: The C677T methylenetetrahydrofolate reductase genotypes were 
comparable in fertile and subfertile males. Independent of fertility state, sperm 
concentration significantly increased in wild-types after folic acid and zinc 
sulphate treatment only. Heterozygotes and homozygotes did not significantly 
benefit from either treatment. 
Conclusions: C677T methylenetetrahydrofolate reductase polymorphism is 
not a risk factor for male factor subfertility. In contrast to heterozygotes and 
homozygotes for C677T MTHFR polymorphism, sperm concentration in wild-
types significantly improved after folic acid and zinc sulphate intervention. A 
stronger role of other folate genes on spermatogenesis is suggested.
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Introduction 
Gene-environment interactions are involved in the reported decrease of semen 
quality in the last decades (Wong et al. 2000; Auger et al. 1995; Skakkebaek et 
al. 1994). Although nutrition is thought to have an effect on spermatogenesis, 
data on the influence of specific nutrients on spermatogenesis in humans are 
scarce. Recently, our group demonstrated in a randomised controlled trial that 
total normal sperm count significantly increased after intervention with folic acid 
and zinc sulphate in subfertile males (Wong et al. 2002). The beneficial effect 
of both nutrients could be explained by their role in transport ribonucleic acid 
(tRNA) and deoxyribonucleic acid (DNA) synthesis. Moreover, as a cofactor of 
dihydrotestosterone reductase, zinc is involved in testosterone synthesis, and 
thus is important in testicular development, spermatogenesis, and sperm 
motility. There is some evidence that zinc in seminal plasma influences the 
oxygen consumption of spermatozoa, acrosin activity, and stabilization of 
sperm chromatin (Riffo et al. 1992; Kvist et al. 1990). 
Methylenetetrahydrofolate reductase (MTHFR) is one of the key enzymes in 
folate metabolism. The C677T MTHFR polymorphism is common, and its 
prevalence varies among populations. The prevalence of the heterozygous and 
homozygous state is approximately 40% and 10% in Caucasians, respectively 
(Ueland et al. 2001). This polymorphism is associated with an increased 
thermolability and reduced specific activity of MTHFR in vivo, resulting in a 
decreased residual activity of 65% for heterozygous carriers and of 30% for 
homozygous carriers (van der Put et al. 1995; Frosst et al. 1995).  
The methylenetetrahydrofolate reductase-enzyme converts 5,10-methylene-
tetrahydrofolate to the biologically active form 5-methyltetrahydrofolate; 
subsequently, 5-methyltetrahydrofolate donates its methyl group to cobalamin 
to form methylcobalamin and tetrahydrofolate. Methylcobalamin serves as a 
cofactor in the conversion of 5-methyltetrahydrofolate to tetrahydrofolate, in 
which homocysteine is remethylated to the essential amino acid methionine in 
humans. The C677T polymorphism in the MTHFR-gene is accompanied by an 
altered folate metabolism and an impaired homocysteine remethylation, 
resulting in an increased folate need. Individuals with the homozygous (TT) 
genotype have mildly, albeit significantly, elevated plasma homocysteine 
concentrations compared with heterozygotes (CT) and wild-types (CC), 
especially when folate concentrations are low (Malinow et al., 1997). 
Chapter 3 
 
 
50 
Animal in vivo and in vitro studies have shown that zinc deficiency alters the 
absorption and metabolism of dietary folate, because of its function as a 
cofactor for dihydrofolate reductase and γ-glutamyl hydrolase (Ghishan et al. 
1986; Quinn et al. 1990; Favier et al. 1993). Both enzymes are involved in 
folate metabolism. Zinc is not a cofactor of the MTHFR enzyme. However, the 
product of MTHFR, 5-methyltetrahydrofolate, is converted to tetrahydrofolate 
by zinc-dependent methionine synthase (Tamura et al. 1987). 
Information on the effects of the MTHFR genotype on biological parameters is 
scarce. Stern et al. (2000) found that the 677TT genotype is associated with 
decreased DNA methylation compared with the 677CC genotype. This is 
explained by the reduced availability of 5-methyltetrahydrofolate required for S-
adenosylmethionine biosynthesis. Bezold et al. (2001) reported finding a higher 
frequency of the 677TT genotype in infertile males, and suggested that these 
males in particular may benefit from folic acid supplementation. 
As an extension of our previous study (Wong et al. 2002), we determined the 
prevalence of the MTHFR C677T polymorphism in a Caucasian population of 
fertile and subfertile males and evaluated whether this polymorphism interferes 
with the response of folic acid and/or zinc sulphate intervention on sperm 
concentration. 
 
Materials and Methods 
 
Patients 
The present study is based on the previously described double-blind, placebo-
controlled randomised intervention study in which the effect of folic acid and/or 
zinc sulphate intervention on semen parameters was studied in fertile and 
subfertile males (Wong et al. 2002). In summary, fertile men were recruited 
from 9 midwifery practices in the area of Nijmegen in The Netherlands. These 
healthy men, who had no history of fertility problems, had a pregnant partner at 
the moment of enrolment who had conceived spontaneously within 1 year of 
regular, unprotected intercourse. The fertile men had a sperm concentration of 
more than 20 million cells/ml at study entry. Subfertile men were recruited form 
the fertility clinics of the Radboud University Nijmegen Medical Centre and the 
Canisius Wilhelmina hospital in Nijmegen. Subfertility was defined as failure of 
the female partner to conceive after 1 year of regular, unprotected intercourse,
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and the man having a sperm concentration of less than 20 million cells/ml at 
study entry. All the participants gave their written informed consent and were 
assigned to four different intervention groups by computer-generated random 
numbers. The intervention consisted of 26 weeks of a daily dose of folic acid (5 
mg) and placebo, zinc sulphate (66 mg) and placebo, zinc sulphate and folic 
acid (combined), or placebo and placebo. This study was approved by the 
institutional review board and the medical ethical committee of the Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands. 
Methylenetetrahydrofolate reductase polymorphism was determined in both 
fertile and subfertile men, and the frequencies of the three genotypes were 
compared. The wild-type (CC), heterozygous (CT), and homozygous (TT) 
carrier-state of C677T MTHFR was evaluated together with the effect of 
intervention treatment (placebo-placebo, zinc-placebo, folic acid-placebo or 
zinc-folic acid supplementation) on sperm concentration. 
 
Semen samples 
Before and after intervention, one standardized semen sample was obtained 
from every participant for semen analysis according to World Health 
Organization (WHO) guidelines (WHO 1992; Menkveld et al. 2001; Guzick et 
al. 2001). The semen samples were produced by the participants via 
masturbation after an abstinence period of 3-5 days. These samples were 
delivered within 1 hour of production to the fertility laboratory. After liquefaction, 
an aliquot of semen was centrifuged at 1,400 x g (Hettich 16A, 1323 rotor) for 
10 minutes. The supernatant seminal plasma was frozen without preservatives 
and stored at -80°C. The sperm concentration evaluated in this study was 
determined with a Makler counting chamber. 
 
Methylenetetrahydrofolate reductase 
The prevalence of the C677T polymorphism was investigated by polymerase 
chain reaction (PCR) of genomic DNA, followed by restriction enzyme digestion 
with HinfI according to the method of Frosst et al. (1995).  
 
Statistical analyses 
The Chi-square Test for independence was performed to compare the 
frequencies of the MTHFR polymorphism in the fertile and subfertile groups;  
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P < 0.05 was considered statistically significant. The results were analysed for 
statistical significance with the Wilcoxon Signed-Ranks Test for comparing 2 
dependent variables, and the Mann-Whitney U-test for comparing 2 
independent variables. Nonparametric tests were used because of the skewed 
distributions of the determinants. The p values were two-tailed; P < 0.05 was 
considered statistically significant.  
 
Results 
Table I shows the prevalence of the C677T MTHFR polymorphism in fertile and 
subfertile men. The frequency of the MTHFR genotypes in fertile and subfertile 
men was not statistically different (P = 0.35). 
 
Table I The distribution of the MTHFR C677T polymorphism in fertile and 
subfertile men 
 MTHFR C677T genotype, % (n)  
Patients CC CT TT Total 
Fertile men 44.2 (50) 42.5 (48) 13.3 (15) (113) 
Subfertile men 54.2 (42) 36.4 (28) 9.1 (7) (77) 
Total 48.4 (92) 40.0 (76) 11.6 (22) (190) 
Note: CC = wild-type carriers, CT = heterozygous carriers, and TT = homozygous carriers. 
Chi-square Test, P = 0.35 
 
We compared the change in sperm concentration before intervention minus 
after intervention delta, between fertile and subfertile men in the four different 
intervention groups, subdivided according to genotype. This revealed no 
statistically significant differences in delta sperm concentration between fertile 
and subfertile men in any of the four intervention treatment groups for the three 
different MTHFR genotypes (data not shown). This indicated that fertile and 
subfertile men in the three polymorphism groups did not respond differently to 
the intervention treatments. We thus pooled the subfertile and fertile men. 
A statistically significant increase in sperm count was found only in the 
combined folic acid and zinc sulphate intervention group. Also, statistically 
significant increases in sperm concentration were found in wild-types for the 
C677T MTHFR polymorphism only (P = 0.005) (Fig. 1A). No statistically 
significant increase in sperm concentration was found in other intervention 
groups or in the heterozygous (see Fig. 1B) and homozygous (see Fig. 1C)
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carriers.  
To study the effects of the different intervention treatments on sperm 
concentration, we pooled the heterozygous (CT) and homozygous (TT) men 
(see Fig. 1D). We pooled these groups because of the small sample size of the 
TT group (only 10% of the study population, which is in line with the prevalence 
in the Dutch population) and the reduced MTHFR activity in both genotypes. 
No statistically significant difference in sperm concentration was found after 
intervention with any of the treatments in the latter group (see Fig. 1D). 
 
Discussion 
The present study does not provide evidence that C677T MTHFR 
polymorphism is a risk factor for male factor subfertility. The homozygote 
prevalence rate in subfertile and fertile men was not statistically different: 9.1% 
and 13.3%, respectively. Furthermore, we found a statistically significant 
increase in sperm concentration after the combined folic acid and zinc sulphate 
intervention in wild-types for the C677T MTHFR polymorphism, but no such 
increase was found in heterozygous or homozygous carriers having 
compromised enzyme activity.  
Regarding our finding that the prevalence of the three different genotypes for 
the C677T MTHFR polymorphism are comparable between fertile and 
subfertile men, we conclude that it is reasonable to believe that homozygosity 
for the C677T MTHFR polymorphism is not a risk factor for subfertility. 
However, Bezold et al. (2001) found an almost twofold higher prevalence rate 
of C677T MTHFR homozygotes in infertile men compared with fertile men 
(18.8% and 9.5%, respectively) and concluded that homozygosity for the 
C677T MTHFR polymorphism could be a risk factor for male factor infertility. 
However, their report did not provide information on how their study had 
defined male factor infertility (for comparison with our study of male factor 
subfertility), and did not elaborate on the inclusion criteria for the fertile and 
infertile groups. This makes it difficult to compare study results and explain the 
discrepancies. In addition to their findings concerning the significantly higher 
frequency of the homozygous C677T MTHFR polymorphism in infertile men, 
they suggested a beneficial effect of folic acid on sperm concentration.  
Although our data did not reveal the MTHFR polymorphism to be a risk factor 
for male factor subfertility, we did demonstrate that combination treatment with
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Figure 1 Sperm concentration before and after intervention 
 
 
 
 
 
 
 
 
n (x 106/ml) in men with C677T MTHFR polymorphism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: (A) wild-type, CC genotype, (B) heterozygote, CT genotype, (C) homozygote, TT genotype, and 
(D) heterozygote and homozygote genotype. *P=.005, comparing sperm concentration before and after 
folic acid and zinc sulphate intervention in wild-type individuals. White columns = Sperm concentration 
before intervention. Gray columns = Sperm concentration after intervention. 
 
folic acid and zinc sulphate had a statistically significant beneficial effect on 
sperm concentration. However, the effect was observed solely in wild-type 
carriers; intervention treatment in heterozygote and homozygote carriers did 
not show any effect on sperm concentration. We have concluded, therefore, 
that the residual MTHFR activity in homozygote and heterozygote patients 
might be insufficient to improve spermatogenesis compared with wild-type 
individuals. However, other polymorphisms in folate enzymes other than 
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MTHFR also seem to be involved.  
The study by Wong et al. (2002) found a 74% increase in normal sperm count 
specifically in subfertile men but not in fertile men after folic acid and zinc 
sulphate intervention treatment. In our current analysis we pooled fertile and 
subfertile men because wild-type, heterozygous, or homozygous men did not 
respond differently to the intervention treatment regardless of their fertility 
state. However, it remains to be investigated if the observed significant 
increase in sperm concentration in wild-type carriers after folic acid and zinc 
sulphate intervention is due to changes in sperm concentration in fertile men, 
subfertile men, or both. A larger scale, randomised, placebo-controlled study 
should be performed to further investigate sperm concentration and the 
influence of fertility state in wild-type carriers of the MTHFR polymorphism who 
receive folic acid and zinc sulphate.  
There are several factors of concern in studying semen parameters. These 
factors comprise the biology of spermatogenesis itself, methods used to 
assess these parameters, and the analysis of semen parameters in different 
groups of men. It is well-known that semen analyses must be carefully 
interpreted, because data can always be biased by intra-individual biological 
fluctuations in semen variables, limitations and inaccuracies of the methods 
used, and intraobserver and interobserver variability (Tielemans et al. 1997; 
Neuwinger et al. 1990). This bias will in particular impact the semen 
parameters in fertile men, because of their broad ranges. In addition, the use of 
one semen sample to distinguish between fertile and subfertile men may 
introduce some random misclassification. However, this would equally affect 
either group. 
Our results cannot be explained by regression to the mean, because a placebo 
group was included among both fertile and subfertile men. It would have been 
favourable to obtain more semen samples from every participant before and 
after intervention, but this was not feasible in our study, particularly from the 
fertile men. 
Male factor subfertility is a multifactorial disorder. Although heterozygous and 
homozygous carriers of the MTHFR C677T polymorphism do not seem to be 
more susceptible to subfertility, our findings emphasize the importance of 
nutrient-gene interactions. Unlike genetic factors, nutritional factors are 
amendable. Although we found a beneficial effect of the intake of folic acid and
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zinc sulphate supplements on sperm count in 677T MTHFR wild-types, a 
higher percentage of abnormal spermatozoa independent of genotype was 
also found after this intervention treatment (Wong et al. 2002). Therefore, a 
large scale, randomised, placebo-controlled study on the efficacy and safety of 
folic acid and zinc sulphate intervention should be performed to further 
investigate the possible interfering effect of the three different C677T MTHFR 
genotypes and other folate enzymes.  
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Abstract 
 
Background: To investigate the underlying mechanism of increased sperm 
concentration after folic acid and zinc sulphate intervention, we evaluated pre-
and post-intervention endocrine and semen parameters in a double-blind, 
placebo-controlled randomised intervention study. 
Method: A total of 47 fertile and 40 subfertile males participated in a 26-weeks 
intervention study consisting of a daily treatment with folic acid (5 mg/day) and 
zinc sulphate (66 mg/day), or placebo. Pre- and post-intervention semen 
parameters, serum folate, zinc, FSH, testosterone and inhibin B concentrations 
were measured. 
Results: The results indicated that intervention treatment significantly 
increased sperm concentration in subfertile males. Other semen and endocrine 
parameters were not affected by intervention treatment. At baseline, positive 
correlations were found between serum zinc and sperm concentration, motility, 
and inhibin B. Serum zinc and FSH were inversely correlated. As (already) 
well-known from previous research, inhibin B positively correlated with sperm 
concentration, motility, and morphology, and was inversely correlated with 
FSH. The latter was positively correlated with testosterone. In addition, 
testosterone and inhibin B were inversely correlated. Striking was that after 
intervention, the correlations with zinc disappeared. 
Conclusions: We conclude that the increase in sperm concentration after folic 
acid and zinc sulphate intervention is not due to alterations in FSH, 
testosterone or inhibin B concentrations. Although zinc and folate have several 
effects on spermatogenesis, the underlying mechanisms involved are not clear.
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Introduction 
Approximately 15% of all couples in the Western world are involuntarily 
childless, which has a great influence on the quality of life (Wallace, 1995). 
Male factor subfertility plays a role in about 50% of subfertile couples (World 
Health Organization, 1987). In up to 40% the aetiology of male subfertility 
remains unknown (de Kretser, 1997). Additional knowledge on the cause of 
male factor subfertility is crucial for better treatments of couples who are 
involuntarily childless.  
Unlike genetic causes of male factor subfertility, environmental causes of 
subfertility are of particular interest, because of the possibility of curative or 
preventive measures. A significant amendable environmental factor is nutrition. 
Animal studies have demonstrated the importance of effects of nutrition on 
spermatogenesis (Ciereszko & Dabrowski, 1995; Kwiecinski et al., 1989; van 
Pelt & de Rooij, 1991).  
In a first double-blind, placebo-controlled randomised intervention study, in 
which fertile and subfertile males were included, we recently demonstrated a 
74% increase in normal sperm concentration in the subfertile males after folic 
acid and zinc sulphate intervention (Wong et al., 2002). The fertile and 
subfertile males were assigned to four intervention groups, comprising daily 
doses of folic acid (5 mg) and placebo, zinc sulphate (66mg) and placebo, a 
combined dose of folic acid and zinc sulphate, or placebo-placebo throughout 
26 weeks. The significant increase of more than 70% in sperm concentration 
was only observed in subfertile males receiving the combined treatment with 
folic acid and zinc sulphate. In an extended study, we showed that MTHFR 
677CC carriers benefit significantly more from this intervention treatment with 
regard to the sperm concentration than MTHFR CT/TT carriers (Ebisch et al., 
2003). 
Natural folate is important for the synthesis of DNA, transfer RNA-, and 
proteins, and is therefore suggested to be important in spermatogenesis. Zinc 
serves as a cofactor for more than eighty metalloenzymes involved in DNA 
transcription, expression of steroid receptors, and protein synthesis. 
Furthermore, it has been shown that zinc is important in testicular 
development, spermatogenesis and sperm motility, as reviewed by Wong et al. 
(2000). 
The underlying mechanisms involved in the beneficial effects of synthetic folic  
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acid and zinc sulphate on spermatogenesis are not clarified. Therefore, we 
hypothesized that folic acid and zinc sulphate may affect endocrine 
parameters, for example by stimulating the function of the Sertoli cells. These 
cells provide the essential microenvironment for normal germ cell production 
and could therefore be relevant.  
Sertoli cells are the main producers of inhibin B in the human body. The serum 
inhibin B concentration positively correlates with sperm concentration, testicu-
lar volume and the state of the spermatogenetic epithelium (Pierik et al., 1998; 
von Eckardstein et al., 1999). Moreover, inhibin B appears to be a marker of 
advanced stages of spermatogenesis (Anderson & Sharpe, 2000; Andersson, 
2000). Thus, the inhibin B concentration reflects the quality of the Sertoli cell 
function and spermatogenesis and as such can be used as a sensitive marker 
of spermatogenesis in humans. 
From this background, the aims of the present study were to assess the effects 
of folic acid and zinc sulphate intervention on semen parameters and the 
hormonal levels of inhibin B, FSH, and testosterone, and to determine 
associations between baseline and post-intervention folic acid and zinc 
concentrations, and the endocrine and semen parameters.  
 
Materials and Methods  
 
Patients 
This study is part of our previously described randomised trial on the effects of 
folic acid and/or zinc sulphate administration on semen parameters of fertile 
and subfertile males (Wong et al., 2002). Every participant received 2 capsules 
per day, took the capsules after dinner and for 26 weeks. The randomisation 
schedule was: folic acid-placebo, folic acid-zinc sulphate, zinc sulphate-
placebo, or placebo-placebo. The content of the folic acid capsule was 5 mg 
per capsule per day, and for zinc sulphate 66 mg per capsule per day. In the 
current study we evaluated the serum concentrations of folate, zinc, FSH, 
testosterone, and inhibin B, in the available serum specimens, and the semen 
parameters in the fertile and subfertile males, before and after intervention with 
folic acid and zinc sulphate or placebo.  
For the inhibin B determinations a total of 47 serum samples were available 
from the original group of 49 fertile males, of which 23 males had received
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placebo-placebo, and 24 had the combination treatment. From the subfertile 
males 40 serum samples were available from the original group of 49 subjects, 
of which 22 males had received the placebo-placebo, and 18 the combination 
treatment. The data of the other hormones and folate and zinc concentrations 
were available from the original data set.  
The fertile group comprised healthy males without a history of fertility problems 
whose partners were pregnant at the start of the recruitment and who 
conceived spontaneously within 1 year of regular, unprotected intercourse. 
Subfertility was defined as failure of the female partner to conceive after 1 year 
of regular, unprotected intercourse and a sperm concentration between 5 and 
20 x 106 spermatozoa/ml at the first routine semen analysis after referral to the 
fertility clinic. We excluded subfertile males with a sperm concentration of less 
than 5 million spermatozoa/ml semen, thereby excluding males with a severe, 
possibly genetically caused, deranged spermatogenesis, who are not very 
likely to benefit form intervention treatment. The cut-off value of 20 million 
spermatozoa/mL semen was deducted from the WHO guidelines for fertility. 
Also, no further investigations were conducted regarding the fertility of the 
female partners, since it was not our aim to study the outcome measure 
‘pregnancy’. Recruitment of these males was performed as described 
previously by Wong et al. (2002). 
The study was approved by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre, and all participants gave written informed 
consent before participation.  
 
Semen samples 
Before and after intervention one semen sample was obtained from every 
participant for standardised semen analysis according to WHO guidelines 
(World Health Organization, 1992). The semen samples were produced by the 
participants via masturbation after an abstinence period of at least 3 days. 
These samples were delivered at the fertility laboratory within 1 hour after 
production. After liquefaction, the semen parameters volume, sperm concen-
tration, motility, and morphology were determined.  
Sperm concentration was determined with a Makler counting chamber. Motility 
was expressed as the percentage of motile spermatozoa, and morphology was 
determined according to WHO criteria (1992), after incubation of the sample
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with trypsin (10 minutes at room temperature), staining with methylene 
blue/eosin, feathering, and fixation by flame.  
 
Folate and zinc measurements 
Serum folate concentrations were measured using radioassays (Dualcount 
Solid Phase Boil radioassay; Diagnostic Products Corp., Los Angeles, CA, 
USA). Serum zinc was measured using flame atomic absorption spectro-
photometry (Perkin Elmer 4100; Norwalk, CT, USA). 
 
Hormone determinations 
FSH was quantitatively determined in serum (AxSYM; Abbott Laboratories, 
Abbott Park, IL, USA). Serum testosterone was routinely measured by specific 
dextran-coated radioimmunoassay after extraction of serum specimens with 
diethylether and subsequent isolation of the T fraction by Sephadex LH-20 
(Pharmacia) column chromatography, using an antiserum raised in rabbits and 
directed against T-3-(o-carboxymethyl)oxime-BSA (Dony et al., 1985). Inhibin 
B was determined using kits purchased from Serotec Limited, Oxford, UK. The 
intra-assay coefficient of variance (CV) was less than 9%, and the inter-assay 
CV was less than 15%. The lowest detectable inhibin B concentration was 5 
ng/l, based on the mean value of the zero-dose standard plus twice the 
standard deviation. A value of 2.5 ng/l (i.e. half of the value of the undetec-
table range) was assigned to test results below 5 ng/l.  
 
Statistical analyses  
Results are expressed as medians (25th-75th percentile) and were analysed for 
statistical significance using non-parametric tests, because of the skewed 
distribution of the semen parameters and hormone concentrations.  
Results are expressed as medians (25th-75th percentile) and were analysed for 
The Mann-Whitney U-test was used to compare age, folate, zinc, and hormone 
concentrations, and the deltas (post-intervention value minus pre-intervention 
value) between the fertile and subfertile males. To compare endocrine and 
semen parameters in fertile and subfertile males before and after intervention, 
the Wilcoxon Signed-Ranks Test was used. Spearman’s test was used to 
calculate correlation coefficients between the biochemical and semen 
parameters. 
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Furthermore linear regression models were used to analyse the influence of 
folic acid and zinc sulphate on inhibin B, FSH, testosterone and sperm 
concentration. Statistical analyses were performed using SPSS 11.0 for 
Windows software (SPSS Inc, Chicago, IL, USA). 
 
Results 
In Table I the baseline characteristics of the endocrine and semen parameters 
are depicted in the fertile and subfertile groups. The semen parameters were 
by indication significantly different between the groups. Although serum folate 
was not significantly different, serum zinc concentrations were significantly 
higher in fertile males compared with subfertile males (P < 0.05). The median 
FSH concentration was higher in subfertile males compared with fertile males 
(P < 0.05), while the median inhibin B concentration was lower in subfertile 
males than in fertile males (P < 0.05).  
 
Table I Baseline characteristics of subfertile and fertile males 
 Pre-intervention 
 Subfertile males (n = 40) Fertile males (n = 47) 
Age (y) 35.0 (32.3-37.0) 34.0 (31.0-38.0) 
Folate (nmol/l) 18.0  (15.0-22.5) 18.0  (15.0-21.0) 
Zinc (µmol/l) 18.3  (17.3-20.4) 21.1  (18.9-23.4)c 
FSH (IU/l) 5.3  (4.0-10.6) 3.9  (2.7-6.7)c 
Testosterone (nmol/l)  19.6  (14.0-24.4) 19.5  (16.5-23.0) 
Inhibin B (ng/l) 197.0  (154.5-273.0) 255.0  (182.0-338.0)c 
Sperm concentration (106/ml)a 7.0  (3.2-16.8) 75.0  (40.0-120.0)b 
Motility (%)a 20.0  (15.0-40.0) 50.0  (40.0-60.0)b 
Abnormal morphology (%)a 79.0  (70.0-83.0) 63.0  (50.0-70.0)b 
Note: data are given in median (25th-75th percentile). Folate and zinc and the endocrine parameters are 
all measured in serum. a Determination according to WHO (1992). Normal reference values are sperm 
concentration of 20x106/ml, motility > 50%, and morphology < 70% abnormal, b P < 0.001, c P < 0.05  
 
The effects of intervention with folic acid and zinc sulphate treatment 
versus placebo treatment on the serum levels of folate and zinc, the 
hormones of the hypothalamic-pituitary-testis (HPT) axis and on the sperm 
concentrations in both fertile and subfertile males are presented in Table II. 
After intervention with folic acid and zinc sulphate treatment the serum 
folate concentrations increased in both groups (P < 0.001), but the serum 
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zinc concentrations did not significantly increase in fertile and subfertile males 
(P = 0.06 and P = 0.72, respectively). The sperm concentration increased 
significantly in subfertile males, but not in fertile males, P = 0.007 and P = 0.45, 
respectively. After adjusting for the placebo-effect by comparing the delta 
sperm concentration for subfertile males receiving placebo with the delta sperm 
concentration for subfertile males receiving folic acid and zinc sulphate 
intervention, sperm concentration in subfertile males having the combination 
treatment was significantly higher (P = 0.006).  
In order to investigate whether this increase in sperm concentration was due to 
a lower production of prostate or seminal vesicle fluids, we examined the 
change in sperm count (ejaculate volume x spermatozoa concentration). The 
sperm count appeared significantly higher in subfertile males after intervention 
with folic acid and zinc sulphate compared with the baseline sperm count. The 
median baseline sperm count in the subfertile males was 28.8 (8.5-46.2) x 106 
spermatozoa, and after folic acid and zinc sulphate intervention it was 44.4 
(13.6-151.8) x 106 spermatozoa (P = 0.009). From these data we can conclude 
that the observed increase in sperm concentration after the combined 
intervention is due to an effect on spermatogenesis, because intervention 
resulted in a higher production of spermatozoa. 
It is not likely that folate and zinc affected the endocrine parameters, because 
FSH, testosterone, and inhibin B concentrations were not significantly changed 
by the intervention treatment in the fertile and subfertile groups.  
In Table III the correlation coefficients pre-intervention (italics) and post-
intervention (bold) in the pooled group of fertile and subfertile males are shown 
for serum concentrations of folate, zinc, endocrine parameters, and semen 
parameters. Before intervention, significant correlations were observed 
between serum zinc and sperm concentration, motility, FSH, and inhibin B, 
which disappeared after intervention. In addition, at baseline inhibin B was 
significantly correlated with sperm concentration, motility, morphology and the 
endocrine parameters FSH and testosterone. 
The FSH concentration was inversely correlated with testosterone. The three 
semen parameters themselves were also positively correlated with each other. 
The post-intervention correlations were comparable to the pre-intervention 
correlations although the correlation coefficients appeared to be slightly lower. 
However, the correlations between zinc and the semen and endocrine 
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Table II Effects of folic acid and zinc sulphate treatment on serum levels of folate and zinc, endocrine parameters and 
sperm concentration in males 
 
Intervention 
Placebo 
(Subfertile n = 22, Fertile n = 23) 
Zinc and Folic acid 
(Subfertile n = 18, Fertile n = 24) 
 Pre-intervention Post-intervention Delta Pre-intervention Post-intervention Delta 
Subfertile (n = 40)   
Folate (nmol/l) 18.0 (15.0-23.0) 17.0 (12.0-24.0) -1.0 (-3.2 - 1.0) 18.0 (13.0-22.8) 105.0 (86.5-122.5) a 86.0 (69.0 - 100.0) b 
Zinc (µmol/l) 18.8 (18.0-20.0) 20.3 (16.9-22.4) -0.2 (-2.4 - 4.5) 18.2 (16.2-20.5) 19.9 (18.9-22.5) 2.1 (-1.8 - 4.9) 
FSH (IU/l) 5.6 (4.0-9.7) 6.3 (4.9-9.0) -0.4 (-1.2 - 0.8) 5.2 (4.0-11.3) 5.6 (4.0-9.6) 0.2 (-0.6 - 0.9) 
T (nmol/l) 18.3 (14.0-23.1) 19.0 (14.0-24.0) 1.0 (-4.7 - 3.3) 21.0 (13.0-27.8) 18.0 (13.0-24.0) 2.3 (-4.3 - 8.2) 
Inhibin B (ng/l) 183.0 (159.8-300.3) 200.0 (157.8-288.0) -7.5 (-29.8 - 28.0) 204.5 (137.5-256.5) 191.0 (124.8-283.0) 6.5 (-18.0 - 19.0) 
Sperm conc (106/ml) 7.5 (1.5-25.0) 7.0 (3.8-18.3) -2.8 (-7.3 - 5.3)  7.0 (4.0-14.5) 8.0 (5.0-30.0) a 5.0 (1.0 - 17.0) b 
   
Fertile (n = 47) 
Folate (nmol/l) 
 
8.0 (15.0-21.8) 
 
16.0 (13.0-23.0) 
 
-1.0 (-4.0 - 1.0) 
 
18.0 (15.0-21.0) 
 
110.0 (77.0-13.0) a 
 
9.0 (57.0 - 99.0) b 
Zinc (µmol/l) 21.3 (18.9-24.1) 19.6 (18.4-21.9) -1.9 (-5.6 - 3.2) 20.7 (18.2-23.0) 20.5 (18.1-23.1) 0.5 (-3.0 - 4.8) 
FSH (IU/l) 3.7 (2.4-6.5) 3.7 (2.7-6.7)  -0.3 (-1.0 - 0.3) 4.3 (2.7-6.8) 4.5 (3.1-5.9) -0.3 (-1.1 - 1.0) 
T (nmol/l) 20.5 (17.8-24.7) 21.0 (17.0-25.0) -1.0 (-4.1 - 5.0) 18.0 (13.2-21.3) 18.0 (13.3-24.0) 0.2 (-2.9 - 2.3) 
Inhibin B (ng/l) 253.0 (163.0-287.0) 246.0 (187.0-271.0) 18.0 (-17.0 - 63.0) 261.5 (182.8-379.3) 247.0 (174.3-355.8) 7.0 (-13.0 - 26.0) 
Sperm conc (106/ml) 85.0 (45.0-130.0) 80.0 (40.0-110.0) 7.0 (-30.0 - 25.0) 65.5 (34.0-111.3) 77.5 (55.0-95.0) 9.0 (-22.3 - 43.0) 
 
Note: data are medians (25th-75th percentile), deltas are calculated as post-intervention value minus pre-intervention value. a P < 0.01 for 
comparison between pre- and post-intervention values (Wilcoxon Signed-Ranks test), b P < 0.01 for comparison between “delta placebo” and “delta 
zinc and folic acid” (Mann-Whitney U-test).
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Table III Spearman correlation coefficients between serum folate (Fol-ser) and 
zinc concentrations (Zn-ser), semen and serum endocrine parameters, of the 
pooled data of 47 fertile and 40 subfertile males 
 Fol-ser Zn-ser  Sperm conc  Motility  Morph FSH T Inh B 
Fol-ser  -0.11 -0.06 -0.03 -0.02 0.02 -0.13 0.07 
Zn-ser  0.16  0.36 a 0.22 c -0.002  -0.27 b -0.18 0.29 b 
Sperm conc  0.008 0.004  0.52 a 0.52 a -0.50 a -0.09 0.49 a 
Motility  -0.02 0.08 0.62a  0.48 a -0.34 b -0.16 0.29 b 
Morph -0.02 -0.05 0.64a 0.48a  -0.26 c -0.02 0.25 c 
FSH  -0.03 < 0.001 -0.44a -0.29b -0.22c  0.23 c -0.65 a 
T  -0.11 0.11 0.01 0.08 0.07 0.11  -0.26 c 
Inh B  0.08 -0.001 0.30a 0.23c 0.13 -0.66a -0.05  
Note: the r-values in italics indicate correlations observed before intervention and the r-values in 
bold indicate correlations observed after intervention. a p ≤ 0.001, b p ≤ 0.01, c p ≤ 0.05 
 
parameters, between inhibin B and morphology, between FSH and testos-
terone, and between testosterone and inhibin B disappeared. 
Because at baseline the semen parameters correlated with most endocrine 
parameters, we analysed the data by linear regression analysis to adjust for 
these variables and to find valid correlations. To find the independent 
prognostic variables predicting the inhibin B concentration we used the linear 
regression model including the dependent variables: serum zinc concentration, 
sperm concentration, motility and morphology, the FSH and the testosterone 
concentration. We found that the FSH concentration is the only independent 
prognostic factor for the inhibin B concentration in serum (standardized r = -
0.60; P < 0.001). We used the same linear regression model mentioned 
above,but in each case used a different independent variable and found that 
the FSH concentration itself was also predicted by the inhibin B concentration 
(standardized regression coefficient -0.55; P < 0.001). Moreover, the sperm 
concentration was predicted by sperm motility (standardized r = 0.22; P =0.03), 
sperm morphology (standardized r = -0.32; P = 0.002) and inhibin B 
concentration (standardized r = 0.24; P = 0.03). We evaluated the possible 
confounders age and duration of sexual abstinence in regard to the prediction 
of sperm concentration, but found that they in fact are no confounders in our
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study population. Therefore they do not need to be included in the regression 
analysis. Folic acid and zinc sulphate concentrations did not influence inhibin 
B, FSH, testosterone and sperm concentrations.  
After intervention, the results from the linear regression models remained the 
same for the predicting variables of inhibin B and FSH concentrations, but the 
sperm concentration was significantly predicted by sperm motility (standardized 
r = 0.31; P = 0.001), sperm morphology (standardized r = -0.42; P < 0.001), 
and FSH concentration (standardized r = -0.30; P = 0.004). 
 
Discussion 
In this study we confirm our previous data on the beneficial effect of folic acid 
and zinc sulphate intervention on sperm concentration in subfertile males in a 
subset of both study groups. We could not demonstrate an effect of this 
intervention of FSH, testosterone and inhibin B concentrations, reflecting the 
endocrine status of subfertile and fertile males. By interpreting these data we 
have to take into account that only an 18% increase in sperm concentration of 
subfertile males after intervention was now observed.  
Although, this is a true effect, because significance remained after adjusting for 
the placebo-effect, compared with the 74% increase described in the original 
paper by Wong et al. (2002), this increase is much smaller. This may certainly 
have affected the negative findings on the endocrine parameters. Particularly 
the data on inhibin B should be interpreted with caution, because this hormone 
could only be determined in samples of 47 fertile and 40 subfertile males from 
the original study.  
The baseline serum inhibin B concentrations were significantly lower in 
subfertile males compared with fertile males. Only one study also made a 
direct comparison of inhibin B concentrations between fertile and subfertile 
males (Lee et al., 2001), and reported that the mean inhibin B concentration in 
subfertile and fertile males were 163 and 146 ng/l, respectively, and were not 
significantly different. The relatively high values we found may be due to the 
timing of blood collection. The serum inhibin B concentration shows a diurnal 
rhythm in which the levels in the early morning are 30% higher than in the late 
afternoon (Andersson, 2000).  
Another explanation for the different inhibin B levels is the different selection of 
subfertile males. In contrast to the group of Lee et al. (2001), we excluded
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subfertile males with a known cause for infertility and with a sperm 
concentration of less than 5 million spermatozoa/ml semen, thereby excluding 
males with a severe, possibly genetically caused, deranged spermatogenesis 
and concomitant low inhibin B levels. Analytical differences of the 
immunoassay procedures might explain the differences in inhibin B 
concentration as well. Finally, the difference in inhibin B levels could be 
explained by the wide range of sperm concentration with a 10-fold increase 
between the fertile and subfertile groups.  
Furthermore, it remains to be established which specific type of germ cell 
determines inhibin B secretion. It has already been suggested that pachytene 
spermatocytes or early spermatids are the most important determinants of 
circulating inhibin B (Andersson, 2000; Foresta et al., 1999; Pierik et al., 2003). 
Because no significant change in circulating inhibin B concentration was found 
after intervention, it is possible that the effects of the intervention on sperm 
concentration are exerted in later stages of spermatogenesis (e.g., late 
spermatids, spermiogenesis), thereby not influencing circulating inhibin B 
concentrations.  
We demonstrated a significantly positive effect on sperm concentration in 
subfertile males after 26 weeks of folic acid and zinc sulphate treatment. It is 
well-known that natural folate plays an important role in the synthesis of 
purines and pyrimidines for tRNA and DNA, which are both important in 
spermatogenesis. The small study Bentivoglio et al. (1993) showed that oral 
folinic acid supplementation improved sperm concentration and motility in 
infertile males presenting with a high sperm concentration of immature germ 
cells, e.g. spermatids and spermatocytes. In our study we could not 
demonstrate any correlations between serum folate concentrations and semen 
parameters.  
Of interest is the significantly positive correlation between serum zinc 
concentration and sperm concentration. This is supported by findings of others. 
The zinc content in the adult testis is high, and the prostate has an even higher 
concentration of zinc than any other organ in the human body (Mann, 1964; 
Zaichick et al., 1997). Moreover, hypogonadism is a clinical feature of zinc 
deficiency in humans (Prasad, 1985a; Prasad, 1985b; Sandstead et al., 1967) 
and sperm defects have been observed in zinc-deficient rats (Hamdi et al., 
1997). It has also been shown that zinc improved spermatogenesis in animals
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(Hamdi et al., 1997), and increased sperm concentration (Hartoma et al., 1977; 
Stankovic & Mikac-Devic, 1976), motility (Kynaston et al., 1988), and 
morphology in subfertile males (Tikkiwal et al., 1987).  
In this study we observed a significantly higher serum zinc concentration in 
fertile males compared with subfertile males, however, both fertile and 
subfertile males had serum zinc concentrations within the normal ranges. In 
our previous study by Wong et al. (2002) no difference was observed regarding 
serum zinc concentrations between these 2 groups. This could be explained by 
the smaller sample size in the present study.  
Another striking result is the lack of rise in serum zinc concentrations after 
intervention with folic acid and zinc sulphate, also observed in our previous 
study. Possible explanations for this phenomenon are the absence of zinc 
deficiencies, the relatively low dose of zinc used to avoid gastrointestinal side-
effects, or lack of compliance. The latter explanation is not very likely 
considering the marked increase of folate concentration after the combined 
intervention with folic acid and zinc sulphate.  
 
Conclusion 
Despite the absence of an effect of folic acid and zinc sulphate on endocrine 
parameters, we conclude that the correlations between zinc and sperm 
concentration, and the increase in sperm concentration after intervention in 
subfertile males, should stimulate research onto nutrition and environmental 
factors in the pathogenesis and prevention of fertility disorders.  
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Abstract 
 
Background Annexin A5 (anxA5) is abundantly present in seminal plasma, 
however, its endogenous function in seminal plasma is not known. Recently, 
we demonstrated that folic acid and zinc sulphate intervention increased sperm 
count. To explore the involvement of anxA5 in human (sub)fertility, we 
measured anxA5 concentrations in seminal plasma before and after folic acid 
and zinc sulphate intervention in fertile and subfertile males.  
Methods In a double-blind, placebo-controlled randomised intervention study 
with folic acid (5 mg/day) and/or zinc sulphate (66 mg/day) in 86 fertile and 78 
subfertile males, pre- and post-intervention seminal plasma anxA5 
concentrations were determined by sandwich ELISA.  
Results Seminal plasma anxA5 concentrations at baseline were not 
significantly different between fertile and subfertile males, (median) 5.2 mg/l 
(25th –75th percentile: 4.2-7.2), and 5.6 mg/l (4.3-6.7), respectively. The various 
treatments did not affect seminal plasma anxA5 concentrations. 
Conclusions Seminal plasma anxA5 concentration is not associated with male 
factor subfertility and the observed increase in sperm count after folic acid and 
zinc sulphate treatment cannot be explained by a change in the seminal 
plasma anxA5 concentration. Further studies are needed to elucidate the 
mechanisms responsible for the beneficial effect of this intervention treatment 
on sperm count.  
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Introduction 
Subfertility is a common disorder with a prevalence of about 15% in all couples 
in the Western world (Mosher and Pratt, 1990; Templeton et al., 1990; Wallace, 
1995). In about half the number of cases a male factor is identified, defined as 
male factor subfertility. In most cases, subfertility is regarded as idiopathic, 
however, gene-environment interactions are suggested to be involved (Wong 
et al., 2003). The environmental causes are particularly of interest, because 
they are better amendable to curative and/or preventive measures than genetic 
factors. A significant but largely neglected environmental factor is nutrition. It is 
well-known that nutrition plays an important role in reproduction (Steegers-
Theunissen, 1995). The vitamin folate is known to contribute to the prevention 
of neural tube defects when taken periconceptionally (Steegers-Theunissen, 
1995; Wald et al., 1991). Folate plays an important role in the synthesis of 
transport ribonucleic acid (tRNA) and deoxyribonucleic acid (DNA) and 
methylation of proteins.  
Zinc is an essential nutritional compound, serving as a cofactor for more than 
80 metalloenzymes, and also as a cofactor in the synthesis of macromolecules 
such as DNA and tRNA. It has been shown that zinc is essential in testicular 
development (Hamdi et al., 1971). Also, seminal plasma zinc concentrations 
influence the oxygen consumption of spermatozoa (Eliasson et al., 1971; 
Huacuja et al., 1973), nuclear chromatin condensation (Kvist, 1980), acrosome 
reaction (Riffo et al., 1992), and acrosin activity (Stevens et al., 1982). 
Furthermore, the synthesis of testosterone in the Leydig cells and the 
conversion of testosterone to 5α-dihydrotestosterone by the 5α-reductase 
enzyme is dependent on zinc supply (Netter et al., 1981).  
Recently, we conducted an intervention study supplying both folic acid and zinc 
sulphate to fertile and subfertile men, and found that after 26 weeks of 
intervention treatment, subfertile men had a 74% increase in normal sperm 
count (Wong et al., 2002). Despite the knowledge that zinc and folate are 
essential for the synthesis of genetic material, the precise underlying 
mechanism by which these micronutrients affect spermatogenesis is not clear.  
Annexin A5 is a member of the protein family of annexins which contains more 
than ten members. These proteins (especially anxA5) are characterized by 
their high affinity for negatively charged phospholipids present in cell 
membranes (Andree et al., 1990). Annexin A5 is primarily known because of its
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world-wide use to detect apoptosis in vitro and also experimentally in vivo 
(Hofstra et al., 2000; Martin et al., 1995). Due to the affinity to negatively 
charged phospholipids, anxA5 is a potent inhibitor of blood coagulation and 
inflammation (van Heerde et al., 1995). It is also known that anxA5 is 
abundantly present in seminal plasma (Christmas et al., 1991). Because our 
research group has not yet identified the underlying mechanism of the 
beneficial effect of folic acid and zinc sulphate on spermatogenesis, and 
because of the observation that anxA5 is abundantly present in seminal 
plasma, we explored the possibility that endogenous anxA5 is directly involved 
in male factor subfertility. Furthermore, we evaluated the effect of intervention 
treatment with folic acid and zinc sulphate on anxA5 concentrations in seminal 
plasma.  
 
Materials and methods 
From the double-blind, placebo-controlled randomised intervention study 
designed to study the effect of folic acid and zinc sulphate on semen 
parameters (Wong et al., 2002; Ebisch et al., 2003), samples before and after 
intervention from 86 fertile and 78 subfertile males were available for the 
determination of endogenous anxA5 concentrations. 
In the referred study, fertile males were recruited from 9 midwifery practices in 
the surrounding areas of Nijmegen, The Netherlands. These healthy men, 
without a history of fertility problems at the moment of enrolment, had a 
pregnant partner who conceived spontaneously within 1 year of regular, 
unprotected intercourse.  
Subfertile males were recruited from the fertility clinics of the Radboud 
University Nijmegen Medical Centre and the Canisius Wilhelmina Hospital in 
Nijmegen. Subfertility was defined as failure of the female partner to conceive 
after 1 year of regular, unprotected intercourse and a sperm concentration 
between 5 and 20 million spermatozoa per mL on the first routine semen 
analysis after referral to the fertility clinic. The females of these subfertile males 
were not further evaluated, because the main focus was on the effect of folic 
acid and zinc sulphate treatment on semen parameters in subfertile males. The 
fertile and subfertile males were included after having given their written 
informed consent and assigned to the four intervention groups by computer-
generated random numbers. The interventions consisted of a daily dose of folic
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acid (5 mg) and placebo, zinc sulphate (66 mg) and placebo, or a combined 
dose of folic acid and zinc sulphate, or placebo-placebo throughout 26 weeks. 
Before and after intervention one standardized semen sample was obtained 
from every participant for semen analysis according to World Health 
Organization (WHO) guidelines (WHO, 1992). The semen samples were 
produced by the participants via masturbation after an abstinence period of at 
least 3-5 days. These samples were delivered within 1 hour after production to 
the fertility laboratory. In this hour the participants were advised to keep the 
sample at room temperature. After liquefaction, an aliquot of semen was 
centrifuged at 1,400 x g (Hettich 16A, 1323 rotor) for 10 minutes. The 
supernatant seminal plasma was frozen without preservatives and stored at –
80 °C until assayed. Sperm concentration was determined with a Makler 
counting chamber.  
The Medical Ethical Committee and the Institutional Review Board of the 
Radboud University Nijmegen Medical Centre approved of this trial. 
 
Annexin A5 
The anxA5 concentration was investigated by sandwich enzyme-linked 
immunosorbent assay (ELISA) (ZYMUTEST anxA5, Hyphen BioMed, Andrésy, 
France) as described by van Heerde et al. (2003). The antibodies used in this 
test are affinity purified rabbit polyclonal antibodies specific for human anxA5 
(F(ab’)2 fragments) and an horse radish peroxidase coupled affinity purified 
rabbit polyclonal antibody against anxA5. The substrate used is ortho-
phenylene diamine (OPD) in presence of hydrogen peroxide. After colour 
development adsorption is measured in a micro ELISA plate reader at 492 nm 
(Easy reader, SLT Labinstruments Austria).  
 
Quantitative real time annexin A5 RT-PCR 
The seminal plasma anxA5 concentration may originate from different sites of 
synthesis, e.g. from testis, prostate or seminal vesicles. To determine whether 
the prostate or the testis is the main producer of anxA5, anxA5 mRNA was 
measured and the anxA5 antigen was stained in human prostate and testis 
sections. Complementary DNA was synthesized by using 1 µg RNA of prostate 
tissue and testis (Clontech, Palo Alto). Testis messenger RNA (mRNA) was 
isolated out of whole normal testes pooled from 45 Caucasians (age 14-64) 
Chapter 5 
 
 
78 
who deceased suddenly. Prostate mRNA was isolated from 47 Caucasians 
(age 14-57) who also deceased suddenly. The mRNA was mixed with 625 µM 
dNTPs, 5 mg/l random hexamer primer DTT, RNAsin (20 U) and M-MLV RT 
(200 U) in a total volume of 15 µl to obtain cDNA. The mixture was incubated 
for 10 minutes at 20°C, followed by 45 minutes at 42°C and 10 minutes at 
95°C. Primer-probe combinations for the anxA5 cDNA were designed using 
PRIMER-EXPRESS software. De forward primer CCACAGTCTGGTCCTGCT-
TC, the reverse primer AGTCACAGTGCCTCTGAGAACCT, and the minor 
groove binding probe CTGACCTGAGTAGTCGC were mixed with 50 ng cDNA, 
1.25 U AmpliTaq Gold DNA polymerase with 250 µmol/l dNTPs. 1 X Taqman 
buffer A in a total volume of 50 µl. Samples were heated at 95°C for 10 
minutes and amplified for 45 cycles of 15 sec at 95°C and 60 sec at 60°C 
(ABI/Prism 7700 Sequence detector, Applied Biosystems). The expression of 
porphobilinogendeaminase (PBGD), a low copy number housekeeping gene, 
was measured in duplicate onto each sample to normalize for PCR and cDNA 
input variations (Mensink et al., 1998). The anxA5 mRNA concentrations were 
measured in duplicate and analysed with Taqman software. The results were 
expressed as delta cycle threshold (δCt) in which δCt = Ct (PBGD) minus Ct 
(anxA5). The relative difference in expression is calculated by 2-δδCt.  
 
Immunohistochemistry 
Post mortem human paraffin-embedded prostate and testis tissue sections 
were stained with a polyclonal antibody directed against human anxA5. The 
sections were macroscopically and microscopically checked by the pathologist 
as being normal prostate and testis tissues. The sections were routinely 
processed to remove the paraffin and to rehydrate the tissues. Next, the 
sections were blocked with human serum albumin (0.1%) containing 50mM 
tris-buffered salt buffer, pH 7.4 (TBS/HSA) to which 20% normal swine serum 
was added. After 30 minutes the sections were washed in TBS and incubated 
for another 2 hours with a polyclonal antibody against human anxA5 (1000 X 
diluted in TBS/HSA)(Hyphen Biomed, Andrésy, France). The sections were 
washed again and incubated for 90 minutes with a biotin-conjugated swine 
anti-rabbit polyclonal antibody (1000-fold diluted in TBS/HSA)(Dako, Glostrup, 
Denmark). Finally, after washing the sections were incubated with alkaline 
phosphatase-conjugated streptavidin-biotin complex (DakoCytomation,
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Glostrup, Denmark) for 1 hour. After extensive washing the sections were 
stained by using the alkaline-phosphatase substrate kit containing 2mM 
levamisole (Sigma, St Louis, MI) to block the endogenous alkaline 
phosphatase activity, according to the manufacturers procedure (Vector, 
Burlingame, CA, USA). The presence of anxA5 is notified by a red colour. The 
nucleus was counterstained blue with Mayer’s Haematoxylin (Merck, 
Darmstadt, Germany).  
 
Statistical analyses 
The results were analysed for statistical significance using non-parametric 
tests, because of the skewed distributions of the determinants. Concentrations 
of endogenous anxA5 are given as median and 25th –75th percentile. Baseline 
seminal plasma anxA5 concentrations were compared between fertile and 
subfertile males using the Mann-Whitney U-test. The effect of the four 
interventions in fertile and subfertile males was investigated by comparison 
between the baseline and post-intervention seminal plasma anxA5 
concentration by the Wilcoxon Signed-Ranks test. We corrected for a possible 
placebo-effect by comparing the delta anxA5 concentration for males receiving 
placebo with the delta anxA5 concentration for males receiving the folic acid, 
zinc sulphate, or combined intervention treatment. The p values were two-
tailed and p ≤ 0.05 was considered statistically significant. Statistical analyses 
were performed using SPSS 10.0 for Windows software (SPSS Inc, Chicago, 
IL, USA). 
 
Results 
 
Annexin A5 concentration in seminal plasma  
Although anxA5 could be determined in seminal plasma, it did not show an 
association with male fertility. The median (25th-75th percentile) baseline 
seminal plasma anxA5 concentrations was 5.2 mg/l (4.2-7.2) in fertile (Table I) 
and 5.6 mg/l (4.3-6.7) in subfertile males (P = 0.96, Table II).  
 
Effect of intervention on seminal plasma annexin A5 concentration 
Tables I and II show the effects of all interventions on seminal plasma anxA5 
concentration in both fertile and subfertile males, respectively. We observed no
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Table I The effect of interventions on seminal plasma anxA5 concentrations 
(mg/l) in fertile males 
 N 
Pre-intervention  
anxA5 (mg/l) 
Post-intervention  
anxA5 (mg/l) 
Delta AnxA5 
(mg/l) 
All subjects (baseline) 86 5.2 (4.2-7.2) -- -- 
Intervention: 
 Placebo 
 
21 
 
5.2 (4.0-5.9) 
 
5.2 (4.2-6.9) 
 
-0.5 (-1.1-1.6) 
 Folic acid 20 5.6 (4.3-7.6) 5.4 (3.7-7.2) -0.3 (-2.1-1.6) 
 Zinc sulphate 22 5.4 (4.3-8.1) 5.5 (3.2-6.9) -0.7 (-2.1-0.8) 
 Folic acid and zinc sulphate 23 4.9 (3.6-7.1) 3.4 (1.8-6.6) -1.3 (-2.3-1.0) 
Note: data are the median (25th-75th percentile). Deltas are calculated as post-intervention – pre-
intervention value. AnxA5 = annexin A5 
 
Table II The effect of interventions on seminal plasma anxA5 concentrations 
(mg/l) in subfertile males 
 N 
Pre-intervention  
anxA5 (mg/l) 
Post-intervention  
anxA5 (mg/l) 
Delta AnxA5 
(mg/l) 
All subjects (baseline) 78 5.6 (4.3-6.7) -- -- 
Intervention 
 Placebo 
 
23 
 
5.7 (4.3-7.6) 
 
5.5 (2.6-8.9) 
 
-0.5 (-2.6-2.9) 
 Folic acid 16 5.4 (3.8-6.6) 5.2 (3.0-6.4) -0.01 (-1.7-1.2) 
 Zinc sulphate 18 5.2 (4.4-6.7) 4.9 (3.5-6.9) -1.1 (-2.0-1.6) 
 Folic acid and zinc sulphate 21 5.6 (2.5-6.1) 3.7 (2.1-5.7) -0.4 (-1.6-0.9) 
Note: data are the median (25th-75th percentile). Deltas are calculated as post-intervention – pre-
intervention value. AnxA5 = annexin A5 
 
effect of the combination treatment with folic acid and zinc sulphate on anxA5 
concentration in both fertile and subfertile males (from 4.9 mg/l (3.6-7.1) to 3.4 
mg/l (1.8-6.6) in fertile males and from 5.6 mg/l (2.5-6.1) to 3.7 mg/l (2.1-5.7) in 
subfertile males). All the other intervention types (placebo, folic acid, and zinc 
sulphate intervention) also did not significantly affect the anxA5 concentrations, 
neither in fertile, nor in subfertile males. 
 
Annexin A5 site of synthesis  
To get some global insight in the synthesis of anxA5, the anxA5 mRNA 
concentrations and immunohistochemical localization of anxA5 protein were 
determined. Annexin A5 mRNA concentrations appeared to be approximately 
twice as high in the prostate (δCt 5.0) as compared to the testis (δCt 3.8).
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Figure 1 
a. Seminiferous tubules of the testis (x40)  
Immunohistochemical 
staining with a polyclonal 
antibody directed against 
anxA5 counterstained by 
Haematoxylin. Annexin A5 is 
stained red whereas the 
nucleus is blue. In the testis a 
gradual staining of anxA5 
was observed. The highest 
intensity is nearby the 
spermatocytes. The sperma-
togonia are not stained.  
b. Prostate (x20)  
In the prostate mainly the 
glandular epithelium is stain-
ed. 
 
 
 
 
 
 
 
 
Furthermore, as shown in Figure 1, immunohistochemical staining of anxA5 
revealed strong staining in the prostate and some staining in the testis. In the 
prostate mainly the glandular epithelium is stained. In the testis a gradual 
staining of anxA5 was observed. The highest intensity is nearby the 
spermatocytes. The spermatogonia are not stained.  
 
Discussion 
This study was performed to explore if anxA5 is associated with male factor 
subfertility and to find an underlying mechanism for the intriguing observation 
that folic acid and zinc sulphate intervention increases the sperm count in sub- 
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fertile males (Wong et al., 2002; Ebisch et al., 2003). Remarkable was the 
finding that the endogenous seminal plasma anxA5 concentrations are at least 
1000-fold higher compared with the concentrations of anxA5 in blood plasma of 
healthy volunteers, in which anxA5 concentrations as low as 5 ng/ml are found 
(van Heerde et al., 2003; Flaherty et al., 1990).  
The baseline seminal plasma anxA5 concentration, however, was not 
significantly different between fertile and subfertile males. This strongly 
suggests that it is not very likely that anxA5 is associated with sperm 
concentration. Therefore, anxA5 is probably not involved in male factor 
subfertility.  
Our data suggest that anxA5 is not produced by the spermatozoa themselves, 
since the immunohistochemical results indicate that the spermatocytes 
themselves are not stained. Furthermore, the real time mRNA analysis shows 
that the prostate is the most important organ in the production of anxA5 in 
seminal plasma.  
Only one other study could be found in which the authors investigated the 
concentration of anxA5 in seminal plasma. These authors obtained semen 
samples from normal or vasectomised patients and found anxA5 
concentrations of approximately 20 mg/l (Christmas et al., 1991). It is 
remarkable that these authors found an almost 4 times higher anxA5 
concentration in seminal plasma compared with our findings. A possible 
explanation for this difference in anxA5 concentration is the method used to 
measure these concentrations. Christmas et al. (1991) pooled all there seminal 
plasma, purified the annexins present in the seminal plasma using an affinity 
column coated with phospholipids to which the annexins bind, and thereafter 
used SDS-PAGE and immunoblot analysis to determine if anxA5 was present 
in seminal plasma. The concentrations of anxA5 in seminal plasma were 
estimated by comparing the immunostaining intensity of immunoreactive bands 
with known standards of placental anxA5. In comparison to our ELISA 
procedure the method used by Christmas et al. (1991) is only semi-quantitative 
which may explain the higher yields of anxA5 from seminal plasma. Christmas 
et al. (1991) further state that the annexins in seminal plasma are actively 
secreted by the prostate, it being the main producer of seminal plasma anxA5, 
which is in agreement with our findings. They exclude the epididymis as a 
possible source of annexin because the seminal plasma annexin
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concentrations are not changed by vasectomy. This is consistent with our 
finding that the anxA5 concentrations were not significantly different between 
fertile and subfertile males at baseline.  
The question remains what the possible link can be between increases in 
sperm count in subfertile males after folic acid and zinc sulphate intervention 
and the seminal plasma anxA5 concentration. An interesting hypothesis is the 
effect of both nutrients on the control of apoptosis. Spontaneous death of 
certain classes of germ cells has been shown to be a constant feature of 
normal spermatogenesis in a variety of mammalian species, including man 
(Barroso et al., 2000; Hikim et al., 1998). Scarce information is available on the 
biological significance of apoptosis in spermatogenesis or its possible role in 
male fertility (Oosterhuis et al., 2000). Since it is known that endogenous 
anxA5 binds to apoptotic cells in vivo, possibly the seminal plasma anxA5 
concentration reflects the degree of apoptosis of spermatozoa and other cell 
types involved in spermatogenesis and seminal fluid production. 
Another possible link between seminal plasma anxA5 concentration and sperm 
concentration is related to the function of anxA5 as an inhibitor of inflammation. 
It is well-known that subfertile men have higher leukocyte numbers in their 
semen compared with their fertile counterparts, the frequency of leukocyto-
spermia (> 106 white blood cells/ml semen) being between 10-20% among 
infertile males (Wolff, 1995). Sperm damage by white blood cells can amongst 
others be mediated by proteases and cytokines, released during inflammation 
reactions. Since anxA5 inhibits inflammation it could have a protective effect in 
these situations, keeping sperm counts up.  
In conclusion, the results presented in this paper do not support that anxA5 is 
associated with male factor subfertility. Intervention with folic acid and zinc 
sulphate does not affect seminal plasma anxA5 concentration. Therefore, it is 
not very likely that the observed increase in sperm count after intervention can 
be attributed to a possible decrease in apoptosis rate of cells involved in 
spermatogenesis or protection to inflammation by endogenous seminal plasma 
anxA5 concentration. Further research is needed to clarify the underlying 
mechanisms responsible for the observed increase in sperm count after folic 
acid and zinc sulphate intervention. 
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Abstract 
 
Background: Fertilization in subfertile couples often is successfully achieved 
by artificial reproduction techniques. Nevertheless, this is not a causal 
treatment of the subfertility. From this background we outline the importance of 
the plasminogen activator (PA)-system and vascular endothelial growth factor 
(VEGF) in subfertility. 
Method: A literature search was performed using MEDLINE, Science Direct 
and bibliographies of published works. 
Results: The PA-system in the male is involved in the passage of 
spermatozoa precursor cells over the blood-testis-barrier, the epididymal 
maturation of spermatozoa, the modifications of the sperm surface for 
capacitation, the acrosome reaction and zona pellucida attachment, and finally 
the facilitation of spermatozoa to move into the Fallopian tubes. In the female, 
the PA-system plays a role during ovulation in the release of the oocyte from 
the follicle, the facilitation of oocyte movement into the Fallopian tubes, and the 
extracellular matrix degradation, important for angiogenesis in the ovary. 
The function of VEGF during fertilization is largely unknown. It has been 
suggested that VEGF is important for the fluid and proteins in semen and fluid 
secretion in the female genital tract, thereby influencing sperm motility and 
survival. The latter could be due to an effect of VEGF on testicular 
microvasculature through which an adequate microenvironment for spermato-
genesis is provided. In the female, VEGF is involved in the regulation of the 
cyclic ovarian angiogenesis, the development and/or selection of follicles, the 
accumulation of follicular fluid, and corpus luteum angiogenesis. 
Conclusions: The role of the PA-system and VEGF in reproduction most likely 
is of great interest. However, much of the data are derived from experimental 
animal studies. So far, information on the importance of these systems in 
humans is scarcely investigated. Therefore, further research is required to 
elucidate the role of the PA-system and VEGF in the pathogenesis and 
prevention of male and female subfertility. Eventually, this will contribute to the 
improvement of the diagnosis of subfertility and may possibly lead to targeted 
therapeutic management of subfertility.  
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Introduction 
Subfertility is a disorder occurring in approximately 10-17% of all couples, 
either as primary or secondary subfertility at some time during reproductive life 
(Philippov et al., 1998; Snick et al., 1997). Subfertility is defined as the failure to 
conceive after 1 year of regular, unprotected intercourse with the same partner. 
Various causes and frequencies of subfertility are summarized in Table I.  
 
Table I Causes and frequencies of human subfertility (Modified from Cahill and 
Wardle, 2002)  
CAUSE FREQUENCY (%) 
Male factor subfertility 
 Sperm defects or dysfunction 
 
30 
Female factor subfertility 
 Ovulation failure (amenorrhoea or oligomenorrhoea) 
 Tubal infections 
 Endometriosis  
 Cervical mucus defects or dysfunction 
 Uterine abnormalities  
 
25 
20 
5 
3 
(< 1) 
Unexplained subfertility 25 
Coital failure or infrequency 5 
Note: total exceeds 100% as 15% of couples have more than one cause of subfertility 
 
Zargar et al. (1997) reported that in 22% the cause was predominantly 
originating from the male, and in 58% mainly of female origin. In 5% fertility 
abnormalities were found in both partners, while in the remaining 15% no clear 
cause of subfertility was identified.  
Several methods are used to assess (sub)fertility in men and women. The 
WHO designed guidelines giving cut-off values for abnormal sperm 
parameters, including sperm concentration, motility and morphology, which can 
be used to estimate fertility in men. According to these guidelines, a sperm 
concentration of less than 20 million cells per millilitre, a progressive motility of 
less than 50% and a proportion of less than 30% cells with normal morphology 
in the ejaculate is regarded as abnormal semen (WHO, 1992). Another more 
holistic approach to evaluate spermatozoa morphology is by using the strict 
Tygerberg criteria (Menkveld et al., 1990; Menkveld et al., 2001). Also, the 
evaluation of endocrine parameters like follicle stimulating hormone (FSH),
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luteinizing hormone (LH), testosterone and inhibin B concentrations can 
contribute to the characterization of male fertility (Figure 1). Furthermore, in 
men with sperm concentrations below 5 million per millilitre, karyotyping and 
search for microdeletions of the Y-chromosome are often performed.  
In women with regular cycles a basal body temperature curve chart is used to 
assess the menstrual cycle for ovulation disorders. Furthermore, in women with 
oligo-amenorrhea serum concentrations of FSH, LH, 17β-estradiol, proges-
terone, testosterone, sex hormone binding globulin (SHBG), prolactin, and 
thyroid stimulating hormone (TSH) are assessed to detect the origin of an-
ovulation (Figure 1). Evaluation for possible tubal damage is performed by 
using Chlamydia serology. More specifically, a hysterosalpingogram (HSG) can 
be made to assess the uterine cavity and the tubal patency. Laparoscopy can 
be performed to assess tubal patency, pelvic adhesions and endometriosis. 
Since both male and female factors determine the chance of conception, the 
Sims-Hühner test is also performed, because it takes into account the 
interaction of both partners. This assay tests the quality of the cervical mucus, 
assesses the occurrence of coital problems, the buffer capacity of the semen, 
and the motility of sperm in the cervical mucus.  
Subfertile couples can have difficulties coping with their involuntary 
childlessness (Whiteford and Gonzalez, 1995), and therefore are often eager to 
conceive by artificial reproduction techniques (ART). In most cases these 
treatments, however, do not treat the underlying cause of the subfertility. This 
is because subfertility often is a multifactorial condition in which many and 
mostly unknown genetic and environmental factors are involved. 
It is hypothesized that derangements in matrix degradation by the plasminogen 
activator system and vascularization induced by the vascular endothelial 
growth factor (VEGF) are causally involved in subfertility (Figure 1). In this 
paper we will review the evidence in literature for the involvement of these 2 
systems in reproduction. Figure 2 displays the plasminogen activator system 
involving molecules like tissue-type plasminogen and urokinase-type 
plasminogen activators, together with plasminogen activator inhibitors, which 
are involved in the process of matrix degradation and fibrinolysis. For sperm 
progenitor cells to be able to pass the tight junctions between the Sertoli cells, 
and for the oocyte to undergo ovulation, matrix degradation has to occur. 
Finally, the micro-environment in which the germ cells develop affects the
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Figure 1 The Hypothalamus-Pituitary-Gonadal axis in men and women  
 
 
 
 
Abbreviations : A, antrum; Act, Activin; AF, antral follicle; BM, basement membrane; E2, estradiol; Est, 
early spermatid; FolS, Follistatin; FSH, follicle stimulating hormone; GnRH, Gonadotropin releasing 
hormone; Grc, Granulosa cells; Inh B, inhibin B; L, Leydig cells; LH, luteinizing hormone; Lst, late 
spermatids; PreAF, preantral follicle; PreOF, preovulatory follicle; ProdF, primordial follicle; Prog, 
progesterone; PrSc, primary spermatocytes; S, Sertoli cells; ScSc, secondary spermatocytes; Sg, 
spermatogonium; Sz, spermatozoa; T, testosterone; Thc, theca cells. 
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reproductive capacity of these cells. Essential for the micro-environment is the 
blood flow for the provision of nutrients and growth factors and the removal of 
(toxic) metabolites. A significant factor involved in vascularization is the 
vascular endothelial growth factor. Interestingly, vascular endothelial growth 
factor induces the expression of tissue- and urokinase plasminogen activators 
and plasminogen inhibitor type 1 (Mandriota et al., 1995; Pepper et al., 1991), 
indicating that both systems interact (Figure 2). 
We are aware that fertilization is a complex process and that the 2 systems 
outlined in this review are only part of the puzzle. Research into these specific 
fields, however, will lead to more insight into the pathogenesis, treatment, and 
prevention of subfertility in men.   
 
Figure 2 Regulation and control of extracellular proteolysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ECM, extracellular matrix; MMP, matrix metalloproteases; 
PAI, plasminogen activator inhibitor; PN-1, protease nexin-1; Pro-uPA, 
enzymatically inactive form of urokinase plasminogen activator; tPA, 
tissue-type plasminogen activator; uPA, urokinase-type plasminogen 
activator; uPAR, urokinase plasminogen activator receptor. 
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Materials and Methods  
A thorough literature search was performed on MEDLINE, Science Direct, and 
via bibliographies of published works. The literature reviewed consisted of 
papers in English published between 1950 and 2005, discussing both animal 
and human studies. The following words combined in different ways were used 
as search terms: fertilization, subfertility, tissue-type plasminogen activator 
(tPA), urokinase-type plasminogen activator (uPA), plasminogen activator 
inhibitor type 1 (PAI-1) and vascular endothelial growth factor (VEGF). 
 
The Plasminogen Activator (PA)-system  
The PA-system (Figure 2), mostly known for its role in fibrinolysis, tumour 
invasion and metastasis, is involved in the activation of the inactive proenzyme 
plasminogen into the active serine proteinase, plasmin. Plasmin is capable of 
readily degrading extracellular matrix (ECM) proteins. The inactive 
plasminogen is abundantly present in blood and in most other body fluids 
(Saksela and Rifkin, 1988). The PA-system is present in a variety of different 
cell types and body fluids (Dano et al., 1985). The combination of plasminogen 
and plasminogen activators serves as an almost unlimited supply of proteolytic 
capacity. 
The PA-system involves 2 plasminogen activators, the urokinase-type 
plasminogen activator (uPA) and the tissue-type plasminogen activator (tPA). 
The homology between these 2 PAs at the amino acid level is only 40% 
(Degen et al., 1986), however, both enzymes are highly similar in their basic 
structures. Both uPA and tPA are secreted as single-chain polypeptides. The 
single-chain form of uPA is an inactive proenzyme, while the two-chain form is 
the active enzyme (Eaton et al., 1984; Wun et al., 1982). The two-chain form of 
tPA also is the active enzyme, although conflicting results as to the enzyme 
activity of the single-chain form of tPA have been reported (Andreasen et al., 
1984; Rijken et al., 1982). 
Because PAs occur in a variety of different cell types in the organism, it is likely  
that PAs are involved in several biological processes. Furthermore, the 
different distribution of uPA and tPA in the organism makes it feasible that 
these 2 activators have different biological functions, uPA being implicated in 
processes of cell migration and tissue remodelling, while tPA is thought to be 
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involved in thrombolysis (see for reviews: Dano et al., 1985; Schmitt et al., 
1997). 
PA-activity is effectively controlled by specific inhibitors produced by a number 
of cell types. These inhibitors belong to the serine proteinase inhibitor (serpin) 
gene superfamily and involve plasminogen activator inhibitor type-1 (PAI-1), 
plasminogen activator inhibitor type-2 (PAI-2), type-3 (PAI-3 or protease C 
inactivator) and protease nexin I (PN I). Furthermore, an uPA receptor (uPAR) 
exists, which is a membrane-anchored binding protein for (pro-)uPA, concen-
trating uPA-activity at the cellular surface (Vassalli et al., 1985).  
Degradation of the ECM resulting from plasminogen activation is important in 
cell migration, necessary for morphogenesis, tissue repair and remodelling, 
neovascularization and invasion of (malignant) cells.  
 
The PA-system in the male reproductive system 
Germinal cell development is a continuous cyclic process of the seminiferous 
epithelium. The interaction between Sertoli cells and germ cells is important for 
normal spermatogenesis. The Sertoli cells form junctional complexes that 
constitute the blood testis barrier (BTB). During spermatogenesis, preleptotene 
and leptotene spermatocytes must cross this BTB, moving from the basal 
compartment of the seminiferous epithelium to the adluminal compartment for 
further development into spermatids. This necessary passage across the BTB 
indicates that the interactions between the Sertoli cells themselves and 
between Sertoli cells and germ cells are dynamic and require a rapid rate of 
tissue remodelling (Griswold, 1995). Protease activities, including that of the 
PA-system, seem to be important for several aspects of the passage of 
spermatocytes across the BTB and release of mature spermatozoa into the 
lumen of the seminiferous tubule (Zhang et al., 1997b).  
Sertoli cells are generally considered the main source of tPA in rodent testis 
(Lacroix et al., 1977). The secretion of tPA is controlled by different hormones 
(Liu et al., 1995; Tolli et al., 1995), by cell-cell interactions between Sertoli and 
Leydig cells (Liu et al., 1996a; Tolli et al., 1995), and by the interaction with 
neighbouring preleptotene primary spermatocytes (Vihko et al., 1984). The 
same control mechanisms are operational for tPA production in monkey testis 
(Zhang et al., 1997b). Furthermore, rat, mouse and monkey testes are all 
capable of producing PAI-1 (Lacroix et al., 1977; Vihko et al., 1986; Zhang et
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al., 1997b), and germinal cells are the cells producing the highest intracellular 
levels of PAI-1 mRNA (Zhou and Liu, 1996), however Sertoli cells in these 
species are also capable of producing PAI-1 mRNA (Magueresse-Battistoni et 
al., 1998; Liu et al., 1993; Liu et al., 1995). Treatment with FSH decreased PAI-
1 mRNA and expression (Zhang et al., 1997a; Magueresse-Battistoni et al., 
1998). 
It was shown in rat testis that under basal conditions uPA was secreted by 
Sertoli cells (Hettle et al., 1986; Vihko et al., 1986). In contrast to the 
unchanged uPA mRNA concentration (Vihko et al., 1989), treatment with FSH 
increased tPA mRNA levels (Nargolwalla et al., 1990). Other authors, however, 
reported a decrease in uPA production in response to FSH treatment, and 
considering the complex regulation of uPA and tPA production by rat Sertoli 
cells in response to the same hormonal stimulus, they hypothesized that the 2 
PAs have different functions (Tolli et al., 1995).  
It has been suggested that uPA is involved in the extensive tissue remodelling 
taking place during the stages VII-VIII of spermatogenesis, mostly because 
uPA mRNA levels are highest at these stages (Vihko et al., 1989). The tissue 
remodelling includes the release of preleptotene spermatocytes from basement 
membranes (Hettle et al., 1986), spermiation (Le Blond and Clermont, 1952), 
and the detachment of residual bodies from the mature spermatids (Morales et 
al., 1986). On the contrary, tPA mRNA levels were highest at stages IX-XII 
(Penttila et al., 1994), and therefore tPA has been suggested to release the 
tight junctions between neighbouring Sertoli cells during stages X-XII, when 
zygotene spermatocytes migrate to the adluminal compartment of the 
seminiferous tubules (Ailenberg and Fritz, 1989).  
Conversely, PAI-1 of Sertoli cells, secreted in the adluminal compartment of 
the seminiferous tubules, can limit the net protease activity during passage of 
preleptotene spermatocytes across the BTB, thereby preventing damage to the 
Sertoli cell barrier. Furthermore, secreted PAI-1 can prevent the premature 
release of  the new elongated spermatids at spermiation (Magueresse-
Battistoni et al., 1998). 
The PA-system is not only active in the testis. Urokinase PA is present in the 
stereociliated epithelial cells, in the lumen of the vas deferens of mice (Huarte 
et al., 1987; Larsson et al., 1984), in the seminal vesicles and to a lesser extent 
in the epididymis of mice (Huarte et al., 1987) and monkeys (Zhang et al.,
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1997a). In addition, evidence for the presence of tPA mRNA in monkey 
epididymis was presented (Zhang et al., 1997a). Most spermatozoa are stored 
in the cauda epididymis and vas deferens awaiting ejaculation. Proteases like 
uPA and tPA in the epididymal and vas deferens luminal fluid may play an 
important role in epididymal maturation, involving the loss or alteration of 
sperm surface molecules (Eddy et al., 1985; Tulsiani et al., 1995). These 
alterations are necessary for sperm maturation, motility and fertilizing ability of 
the spermatozoa. Furthermore, ejaculated spermatozoa express uPA activity 
on their cell surface, particularly around the head region (Huarte et al., 1987). 
However, spermatozoa stored in the vas deferens, or spontaneously drained 
from dissected vas deferens possess almost no uPA immunoreactivity. This 
suggests that the secretion of uPA by the male accessory organs may be 
stimulated by ejaculation, followed by the binding of uPA to the cell surface of 
the spermatozoa, possibly via its specific plasma membrane receptor (Huarte 
et al., 1987).  
It has been suggested that a trypsin-like enzyme is involved in the limited 
proteolysis necessary for sperm surface modifications occurring during 
capacitation (Talbot and Chacon, 1981), and in the stimulation of the acrosome 
reaction (Pillai and Meizel, 1991). Huarte et al. (1987) observed a proteolytic 
cascade around the head region of the ejaculated spermatozoa, which was 
triggered by uPA. Therefore, uPA could very well be the aforementioned 
trypsin-like enzyme involved in sperm surface modification. Another possible 
function of the uPA mediated proteolysis is the facilitation of spermatozoa 
movement towards the ampulla of the Fallopian tubes by preventing adhesion 
of spermatozoa to fibrin deposits on the tubal mucosa. In the ampulla of the 
Fallopian tubes the actual fertilization takes place. To establish this fertilization, 
spermatozoa have to attach to the zona pellucida of the oocyte. In this regard, 
trypsin enzyme inhibitors were shown to prevent binding of mouse 
spermatozoa to the zona pellucida, probably by their action on a sperm-derived 
protease (Saling, 1981). These data suggest that spermatozoa-bound uPA 
may participate in the proteolytic events that accompany capacitation and 
fertilization.  
Other investigators also have shown the presence of both uPA and tPA in 
ejaculated spermatozoa and seminal plasma of various species, including 
humans (Smokovitis et al., 1987). The observed tPA was demonstrated to be
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synthesized in the prostate gland (Reese et al., 1988). Smokovitis et al. (1992) 
observed a species difference in the presence of tPA and/or uPA on the outer 
acrosomal membrane and plasma membrane of the spermatozoa. Tissue PA 
and uPA, present on different locations of sperm membranes, may have 
distinct roles in regulating sperm functions. Tissue PA and uPA located on the 
outer acrosomal membrane of human spermatozoa may participate in the 
attachment too, and penetration of the spermatozoon to the zona pellucida, 
whereas the PAs located on the plasma membrane might be involved in 
spermatozoa maturation, capacitation, binding to the zona pellucida, and 
acrosome reaction (Smokovitis et al., 1992). 
In addition, PAI-1 is also found outside the testis. High concentrations of PAI-1 
mRNA were expressed in the caput of the epididymal epithelial cells of adult 
monkeys, while in the initial and caudal regions of the epididymis PAI-1 mRNA 
levels were much lower (Zhang et al., 1997a). The authors hypothesize that 
PAI-1 is important in some aspects of sperm maturation and since PAI-1 
concentrations are higher in the caput of the epididymis, they hypothesize that 
the caput is more important in sperm maturation than the other regions. 
However, the precise mechanism of action is unclear. 
Furthermore, PAI-1 antigens are located on the surface of the sperm head, 
midpiece and tail of human spermatozoa, which indicates that human 
spermatozoa are capable of binding PAI-1 (Liu et al., 1996b). Smokovitis et al. 
also demonstrated PAI-1 on both plasma and outer acrosomal membranes of 
human spermatozoa (Smokovitis et al., 1992). Since both uPA and tPA can 
also be found on spermatozoa, PAI-1 may function as a counterbalancing 
factor, thereby coordinating the proteolysis induced by the 2 activating factors. 
 
The PA-system in the female reproductive system 
It is known from animal experiments that around ovulation, tPA and uPA are 
produced by rat granulosa cells that line the interior of the follicle, and by rat 
thecal cells in the interstitium of preovulatory follicles (Liu et al., 1987; Ny et al., 
1985). Mouse granulosa cells, however, do not produce tPA but rather secrete 
uPA (Canipari et al., 1987). This indicates that similar ovarian cell types from 
these closely related species produce different PAs which could have similar 
functions. 
Synthesis of tPA and uPA in the granulosa and thecal cells is under 
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gonadotropin control (Canipari et al., 1987; O'Connell et al., 1987). In the rat 
ovary, the regulation of the 2 PAs by gonadotropins differs between granulosa 
and theca cells. Hormonal stimulation of the rat ovary results in an increased 
uPA and tPA activity in both granulosa and theca cells. However, only tPA 
mRNA was up-regulated in both cell types, while uPA mRNA was up-regulated 
in the thecal cells and down-regulated in granulosa cells (Macchione et al., 
2000). This discrepancy in uPA activity and mRNA levels in granulosa cells 
was explained by a shift from the soluble form of uPA in the FF to the cell-
surface of the granulosa cell where it binds to a specific uPA-receptor. 
Furthermore, the down-regulation of uPA mRNA indicates that the increase in 
uPA activity is not the result of newly formed uPA molecules by these cells 
themselves. The redistribution of the uPA molecule from the fluid phase to the 
cell membrane as a result of binding to its specific receptor, while tPA is active 
in the fluid phase, strongly suggests that these 2 PAs may have different 
functions in ovulation (Macchione et al., 2000). 
Because of the redistribution of uPA to the cell-surface of granulosa cells, this 
factor seems to be involved in the degradation of the ECM between mural 
granulosa cells, important for the escape of the cumulus-oocyte complex 
(COC) from the follicle. Tissue PA, in solution in the FF, is more likely to be 
involved in the degradation of the core protein of proteoglycans present in the 
FF, responsible for the high viscosity of the FF. Around the time of ovulation 
the FF liquefies, thereby facilitating the release of the COC from the inside of 
the follicle. Another possible role for tPA is the prevention of blood clotting 
during rupture and subsequent bleeding of the highly vascularized theca cell 
layers of the follicle during ovulation, thereby preventing entrapment of the 
COC inside the follicle (Canipari and Strickland, 1985).  
Proof for the involvement of tPA in ovulation was found by Tsafriri et al. (1989). 
These authors observed a significant decrease in ovulation rate after a single 
intrabursal injection of tPA antibodies in the rat ovary at the time of human 
chorionic gonadotropin (hCG) injection. Ovulation was, however, not 
completely inhibited. Morphologic evaluation revealed that there were no 
pathologic changes in the ovary after the injection, and several follicles with 
oocytes entrapped within their antrum were observed (Tsafriri et al., 1989). No 
significant decrease in ovulation rate was detected if the tPA antibodies were 
injected 4 hours after hCG injection. Therefore, the authors conclude that tPA
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is involved in the early stages of ovulation (Tsafriri et al., 1989).  
Not only granulosa and theca cells express PA activity, also COCs and 
denuded oocytes are reported to synthesize PAs. Liu et al. (1986) 
demonstrated that the COCs and denuded oocytes collected from preantral 
follicles of hypophysectomized immature rats contained tPA. This tPA was 
present in the cytoplasm of the primary oocytes. The tPA enzyme activity in 
COCs was stimulated by FSH, and even uPA activity was observed after FSH 
stimulation. The tPA enzyme activity in denuded oocytes, however, was not 
enhanced by treatment with FSH. Thus, these authors suggest that cumulus 
cells may stimulate tPA activity at the oocyte level (Liu et al., 1986). 
Furthermore, Liu and Hsueh (1987) found that after hCG treatment, tPA activity 
in the COCs responded similarly as found after FSH treatment, but denuded 
oocytes showed an increase in tPA activity after treatment with hCG. Liu and 
Hsueh not only reported that the intracellular content of tPA was increased 
after gonadotropin treatment, but also that the secretion of tPA by the COC 
was upregulated during the preovulatory period. The oocyte content of tPA 
even continued to increase after ovulation, but the secretion of tPA by the COC 
decreased after ovulation (Liu and Hsueh, 1987). The precise function of tPA in 
the primary oocyte/COC is not yet clear. Tissue PA concentrations secreted by 
the COC could facilitate liquefying of the FF, thereby enabling ovulation in a 
way similar to tPA produced by granulosa and theca cells. In addition, tPA from 
the oocyte could prevent entrapment of the released oocyte in fibrin deposits 
present in the oviducts, or could be involved in the breakdown of the communi-
cation between cumulus cells (CC), and between CC and the oocyte. 
In the preovulatory period, the CCs which normally are tightly packed around 
the oocyte, start to lose contact with each other and with the oocyte. However, 
the COC does not disintegrate, because a mucoelastic ECM is formed keeping 
the different cell types together. Because of loosening of the tightly packed 
CCs, and formation of the ECM the volume of the COC significantly increases, 
hence this process is referred to as cumulus expansion. This CC-matrix is 
important, for instance in oocyte release from the follicle and pickup of the 
oocyte by the tubal fimbriae, and also this matrix provides an appropriate 
microenvironment for successful fertilization. After ovulation, the CC and matrix 
are gradually shed from the COC, thereby reducing the chance of oocyte 
fertilization. This shedding of CCs is probably designed to promote fertilization
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of freshly ovulated oocytes and to prevent fertilization of aged oocytes. During 
the shedding of the CC the aforementioned matrix is degraded, and it is 
hypothesized that components of the PA-system are involved in this 
proteolysis. D’Allessandris et al. (2001) showed that uPA production in CCs of 
mice differs from uPA production of mural granulosa cells during the 
preovulatory period. Urokinase PA production in CCs does not significantly 
increase during this period, when ECM deposition of the COC occurs. They 
concluded that the decreased uPA production by CCs compared with the mural 
granulosa cells is due to a paracrine control of the oocyte on the response of 
surrounding cumulus cells to gonadotropin stimuli. However, this inhibitory 
action of the oocyte does not last, and uPA synthesis by cumulus cells abruptly 
rises after full expansion of the CC-matrix. This rise in uPA synthesis is 
reflected in concomitant matrix degradation and cumulus dispersion, resulting 
in a less fertilizable oocyte. 
In this review we presented on outline of the production of PAs by granulosa 
and theca cells, the COC and the oocyte itself, but also other cells of the ovary 
synthesize PAs. Ovarian surface epithelial cells produce uPA, thereby 
contributing to ECM degradation resulting in ovulation (Colgin and Murdoch, 
1997). Also, endothelial cells in the ovary express uPA in a transient fashion. In 
the ovary, unvascularized preantral follicles only can mature into Graafian 
follicles if they develop their own capillary sheath, indicating that angiogenesis 
is necessary. To form new blood vessels, endothelial cells must be released 
from the basement membrane, which is achieved by targeted proteolysis. Also, 
the subsequent migration of endothelial cells to form new blood vessels 
requires proteolysis of the ECM. The observation that endothelial cells in the 
ovary express uPA provides support for a role of this enzyme in controlling the 
angiogenesis-associated proteolysis (Bacharach et al., 1992). 
Finally, some gene function studies were conducted to investigate the role of 
the PA-system in reproduction. Carmeliet et al. (1994) found that both single 
and double-knock-out (uPA and tPA) male and female mice were able to 
reproduce. However, double-knock-out mice were significantly less fertile 
compared with control mice, indicated by their significantly less frequent litters 
and smaller litter size. Whether this decrease in ability to reproduce was 
related to the poor general health of these double-knock-out mice, or to more 
specific fertility reducing consequences related to their uPA or tPA
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deficiency was not clear. 
Leonardsson et al. (1995) quantified the effects of PA deficiencies on ovulation. 
They found that ovulation efficiency was not different between wild-type mice 
and mice that were heterozygous or homozygous for mutations in the tPA or 
uPA gene. However, they found a reduced ovulation efficiency in mice with a 
combined deficiency of tPA and uPA, thereby suggesting that the PA-system is 
involved in ovulation, although, there is no unique requirement for either uPA or 
tPA. The data suggest that there is a redundancy in plasminogen activator 
activity regulating ovulation, and that one of the PAs (uPA, tPA) can 
functionally compensate for the loss of the other (Leonardsson et al., 1995). It 
is obvious however, that the PA-system is not the only system involved in ECM 
degradation during ovulation, because in the absence of PAs ovulation still 
occurs, although with a reduced efficiency. This indicates that other proteolytic 
active proteases like matrix metalloproteins (MMPs) contribute to ovulation (for 
review on MMPs and ovulation see: Ny et al., 1993).  
Not only uPA and tPA, but also PAI-1 is expressed in the female reproductive 
tract. In the mouse ovary, PAI-1 is expressed throughout the periovulatory 
period, however in much lower concentrations compared with uPA and tPA 
(Leonardsson et al., 1995). Therefore these authors conclude that it is possible 
that other protease inhibitors can reduce plasminogen activation in the mouse 
ovary. PAI-1 levels were slightly induced around the time of ovulation, induced 
by hCG treatment (Leonardsson et al., 1995). Hägglund et al. (1996) observed 
similar results in mouse ovaries, and they also defined the cells expressing 
PAI-1 mRNA as being thecal-interstitial cells of postovulatory follicles. These 
authors recognize the importance of other protease inhibitors suggested by 
Leonardsson et al. since they observed high expression of the protease nexin-
1 by granulosa cells and cumulus cells in the entire periovulatory period 
(Hägglund et al, 1996). Furthermore, Leonardsson et al. (1995) found that 
there was no difference in ovulation efficiency between wild-type control mice 
and mice with heterozygous or homozygous mutations in PAI-1 genes. In the 
rat ovary a different expression of PAI-1 is observed, compared with the 
expression in the mouse. The intensity of PAI-1 increased with follicular 
development, reaching peak levels in the preovulatory period (Li et al., 1997). 
The distribution of PAI-1 was uniformly distributed between granulosa and 
theca interna cell compartments, but the PAI-1 transcript levels were highest in
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granulosa cells. These authors hypothesize that PAI-1 is important in 
preventing premature rupture of the ovulatory follicle until the expected time of 
ovulation when PAI-1 expression and activity are down-regulated (Li et al., 
1997). Since changes in the PAI-1 expression followed a similar temporal 
pattern as tPA Li et al. (1997) suggest that the synchrony in the synthesis of 
these proteins may be important in focussing the tPA action primarily to the site 
of follicle rupture as well as keeping the functional proteolytic activity low.  
After ovulation the corpus luteum begins to form. Also, in this process PAI-1 
expression is found. In the monkey PAI-1 mRNA is equally expressed 
throughout the luteal tissues, with the highest PAI-1 expression found in 10-
day-old corpus luteum, decreasing to 50% on day 13 (Liu et al., 1997). A 
similar pattern was observed for uPA in the corpus luteum and therefore these 
authors conclude that proteolysis mediated by uPA and regulated by PAI-1 
could play a role in luteal maintenance, while tPA may participate in luteal 
regression, since this protein increased at the time of luteal regression (Liu et 
al., 1997). Other authors investigating the expression of PAI-1 in the corpus 
luteum of rats found that during corpus luteum formation PAI-1 mRNA was 
expressed inside the collapsed postovulatory follicle in a subpopulation of cells 
localized at the innermost layers of the proliferating granulosa cells (Bacharach 
et al., 1992). Again, a physical proximity was observed between PAI-1 and a 
plasminogen activator being uPA in rats. Urokinase PA was mainly detected in 
capillary sprouts within the developing corpus luteum, indicating that uPA is 
important in the neovascularization of this structure, while PAI-1 was mainly 
found in cells in the proximity of capillaries. Therefore, these authors conclude 
that PAI-1 may protect these cells from degradation by uPA bound to the 
surface of nearby cells (Bacharach et al., 1992). 
Finally, Jones et al. (1989) observed that follicular fluid (FF) from human 
preovulatory follicles contained a relative abundance of PAI-1 in relation to tPA 
and uPA, resulting in low levels of uncomplexed free and thus active 
plasminogen activators in FF. They further state that granulosa cells may be 
the primary producers of FF PAI-1 (Jones et al., 1989). 
 
Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor is a protein with anti-apoptotic, mitogenic 
and permeability-increasing activities. VEGF mRNA is produced by non-
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malignant and malignant cells in response to hypoxia and inflammation. VEGF 
is a member of a family of growth factors comprising VEGFA, -B, -C, -D, and -
E, placental growth factors and platelet derived growth factors. Alternative 
splicing of VEGF A pre-mRNA leads to production of a number of variants 
consisting of 121, 145, 165, 183, 189, and 206 amino acid residues. As 
mentioned before, VEGF has been shown to inhibit apoptosis in several cell 
types including endothelial cells (Spyridopoulos et al., 1997), multiple myeloma 
cells (Le Gouill et al., 2004), smooth muscle cells (Yamanaka et al., 2005), 
human podocytes (Foster et al., 2005), endometrial stroma cells (Berkkanoglu 
et al., 2004), and haematopoietic stem cells (Gerber et al., 2002). The 
mechanisms involved in this survival function of VEGF includes the up-
regulation of members of the anti-apoptotic Bcl-2 protein family (Gerber et al., 
1998; Le Gouill et al., 2004; Nor et al., 1999), and the decrease of Fas ligand 
expression (a mediator of apoptosis) (Berkkanoglu et al., 2004). 
Furthermore, it is reported that the expression of VEGF is increased by 
homocysteine and other thiol-containing reductive compounds, due to 
activation of VEGF transcription (Roybal et al., 2004). Therefore, folate 
deficiencies resulting in hyperhomocysteinemia could hypothetically result in 
increased VEGF expression. Some authors found that reactive oxygen species 
(ROS) are dose- and time-dependent inducers of VEGF gene and protein 
expression in vascular smooth muscle cells, human retinal pigment epithelial 
cells, human melanoma cells and glioblastoma cells (Bassus et al., 2001; 
Kuroki et al., 1996). Interesting to note is that the antioxidant N-acetylcholine 
(NAC) can suppress VEGF induction (Chua et al., 1998; Redondo et al., 2000).  
Finally, VEGF is known to induce the expression of uPA, tPA, uPAR, and PAI-1 
in cultured bovine microvascular endothelial cells in a dose dependent manner 
(Mandriota et al., 1995; Pepper et al., 1991). These results suggest that the 
PA-system is important in the ECM degradation and endothelial cell migration 
during angiogenesis, induced by VEGF (Mandriota et al., 1995; Pepper et al., 
1991). The induction of PAI-1 by VEGF is necessary to maintain a proper 
balance between proteolytic PA-activity and inhibition, necessary for normal 
capillary morphogenesis (Pepper and Montesano, 1990). 
 
VEGF in the male reproductive system 
Brown et al. (1995) showed that VEGF is present in seminal plasma in very
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high concentrations, even exceeding the concentrations of VEGF measured so 
far in malignant effusions (Yeo et al., 1993). They also demonstrated that 
VEGF mRNA and protein were strongly expressed in both prostate and 
seminal vesicle epithelium. This was supported by the observation that post- 
vasectomy ejaculates still contained high concentrations of VEGF. These 
results indicate that prostate and/or seminal vesicles, but not testes or 
epididymis, are the major sources of VEGF in seminal plasma (Brown et al., 
1995). However, it was also shown that VEGF is synthesized and secreted by 
Leydig and Sertoli cells, and not by germ cells (Ergun et al., 1997).  
Since VEGF is produced in very high quantities by prostate and seminal 
vesicles, an important role for this growth factor in fertility is emphasized. 
However, the function of VEGF in the male genital tract is yet unclear. Brown et 
al. (1995) suggested several possible functions for VEGF in reproduction. 
VEGF, as a regulator of microvascular permeability, could play an important 
role in determining the fluid and protein composition of semen. Furthermore, 
they suggest that VEGF present in semen could alter microvascular 
permeability and may influence fluid secretion in the female genital tract when 
deposited there during coitus. This effect of VEGF on the amount and 
composition of fluids from both the male and female genital tract may be of 
influence on fertility by affecting sperm motility or survival. The stimulatory 
effect of VEGF on endothelial cell growth and angiogenesis could play a role in 
early angiogenic events that are critical for the implantation of the blastocyst in 
the endometrium. Another possible function of VEGF in the male genital tract 
was provided by Ergün et al. (1997) who stated that VEGF, produced by Sertoli 
and Leydig cells, has a paracrine effect on testicular microvasculature, 
providing an adequate microenvironment in seminiferous, tubular, and inter-
stitial compartments of the testes. These authors also reported the presence of 
VEGF receptors on Sertoli and Leydig cells, and suggested that VEGF may 
have an autocrine regulatory effect on the activity of both cell types. The 
function of this autocrine effect until now is still unclear. 
Obermair et al. (1999) showed that seminal plasma VEGF concentrations 
correlated with pregnancy rates in patients undergoing in vitro fertilization (IVF) 
or intracytoplasmic sperm injection (ICSI) procedures. However, VEGF 
concentrations in seminal plasma were not associated with male infertility, 
semen parameters or oocyte fertilization rate. Also, expression of VEGF 
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receptors on spermatozoa was demonstrated, suggesting that seminal plasma 
VEGF may target the spermatozoa themselves. Furthermore, Obermair et al. 
(1999) propose a possible effect of seminal plasma VEGF in the female genital 
tract, however, sexual intercourse is often discouraged during an IVF proce-
dure.  
Overexpression of VEGF121 in mice resulted in markedly reduced fertility or 
even infertility. The testes of these mice were macroscopically atrophic, 
showing partial or complete sperm maturation arrest, with disorganization of 
germ cells in the seminiferous tubules (Huminiecki et al., 2001). A loss of 
adhesion between differentiating spermatocytes and Sertoli cells was 
observed. Also, in the epididymis large quantities of immature precursors and 
apoptotic spermatocytes were present (Huminiecki et al., 2001). Similar 
observations were made by Korpelainen et al. (1998), who found that 
overexpression of VEGF165 resulted in male infertility and no offspring was 
produced by these transgenic mice. The infertility in these male mice is 
probably due to effects of VEGF on both the testis and the epididymis. The rete 
testis was remarkably dilated and the capillary density was increased. Also, a 
sperm maturation arrest at the elongated phase of the spermatids was 
observed. Furthermore, enlarged and swollen epididymes were observed.  
The presence of VEGF receptors on the spermatozoa themselves (on mid-
pachytene spermatocytes and round spermatids) suggests that VEGF may act 
directly on spermatogenic cells. The expression of VEGF receptors on round 
spermatids is of particular interest since the observed spermatogenic arrest 
occurs at this point (Korpelainen et al., 1998). Korpelainen et al. also suggest 
that the observed infertility could result from an effect of VEGF on Leydig cells, 
which also express the VEGF receptor. The Leydig cells are the main source of 
testosterone, necessary for normal spermatogenesis. Furthermore, a rise in 
testicular temperature due to increased capillary density and size, resulting 
from the vascular effects of VEGF overexpression in testis, could also 
contribute to the infertile phenotype (Korpelainen et al., 1998).  
 
VEGF in the female reproductive system 
The female reproductive organs contain some of the few tissues that exhibit 
periodic growth and regression. Thus, it is not surprising that female 
reproductive tissues belong to the few tissues in which angiogenesis takes
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place as a regular physiological process. 
For the cyclic growth and regression of ovarian, endometrial and placental 
structures, programmed angiogenesis is necessary. In the ovary, this growth 
and regression is regulated by cyclic and pulsatile secretion of gonadotropins, 
which leads to ovulation and steroidogenesis within the ovary. Therefore, it is 
suggested that the angiogenic waves involved in the cyclic growth within the 
female reproductive system are likely to be coordinated by gonadotropins 
and/or locally produced steroids (Geva and Jaffe, 2000). This suggestion is 
supported by in vivo and in vitro studies, which show that FSH, LH and hCG 
modulate the expression of VEGF mRNA and protein levels (Christenson and 
Stouffer, 1997; Laitinen et al., 1997). 
Several studies have indicated that VEGF is involved in the physiological 
regulation of ovarian angiogenesis (Fujimoto et al., 1998; Otani et al., 1999; 
Ravindranath et al., 1992). VEGF is expressed and secreted by the human 
ovary in strong association with the cyclic angiogenesis and permeability 
patterns observed in the ovary. This suggests a role for VEGF in these 2 
processes, both of which are critical for ovarian folliculogenesis and normal 
reproductive function.  
Among the four VEGF isoforms, the VEGF121 and VEGF165 transcripts are 
predominantly expressed in human ovaries (Fujimoto et al., 1998; Otani et al., 
1999). In situ hybridisation studies in female rats showed that VEGF mRNA is 
expressed in the ovary along with follicular growth and maturation (Shweiki et 
al., 1993). In preantral and small antral follicles, VEGF mRNA is expressed in 
the interstitial tissue and theca layers. Later in the development of the follicles, 
the cumulus cells engulfing the oocyte are the first cells to express VEGF inner 
to the theca cell layer. The granulosa cells express high levels of VEGF mRNA 
only at the immediate preovulatory stage. Finally, shortly after ovulation, when 
the formation of the corpus luteum begins, the main site of VEGF mRNA 
expression is the granulosa-lutein cell (Shweiki et al., 1993).  
In human ovaries, VEGF expression was found to be related to follicular 
maturation. Otani et al. (1999) observed by immunohistochemistry that  
granulosa cells in primordial follicles did not express VEGF, while the 
corresponding oocytes did express this growth factor. In the small antral 
follicle, VEGF mRNA expression was observed in granulosa cells facing the 
follicular antrum in the oocytes themselves, but not in theca cells (Otani et al.,
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1999). Only theca cells in medium sized follicles expressed VEGF, and in this 
stage the VEGF expression was higher than in granulosa cells. Like in the rat, 
human preovulatory follicles express high levels of VEGF in both granulosa 
and theca cells and the intensity of immune staining for VEGF gradually 
increased as the follicles matured (Otani et al., 1999). Also, the granulosa and 
theca lutein cells in the human corpus luteum expressed VEGF in the early, 
mid- and late-luteal phase. The VEGF expression was highest in the mid-luteal 
phase (Otani et al., 1999). 
VEGF expressed by theca and granulosa cells of the follicle probably acts 
primarily on the nearby endothelial cells (Shweiki et al., 1993), thereby 
stimulating vascular endothelial proliferation in the theca cell layer (Otani et al., 
1999). VEGF also can increase vascular permeability, leading to accumulation 
of antral fluid, thereby regulating gonadotropin accumulation in the different 
follicles. Therefore, highly vascularized theca cell layers are probably critical for 
gonadotropin-dependent follicle growth. Thus, the follicle with the highest 
vascularized theca cell layer probably receives most gonadotropins, resulting in 
more pronounced growth. This indicates that VEGF might play a role in the 
selection of the dominant follicle. Furthermore, it is known that VEGF induces 
uPA, tPA and PAI-1 mRNA and activity (Olofsson et al., 1998; Pepper et al., 
1991), components that are involved in ovulation as described above. Finally, 
an essential role for VEGF in corpus luteum angiogenesis was demonstrated 
(Ferrara et al., 1998).  
Several authors investigated the possibility of predicting artificial reproduction 
outcome by measuring VEGF concentrations in FF. Friedman et al. (1998) and 
Asimakopoulos et al. (2005) observed that elevated VEGF concentrations in 
FF were associated with poor conception rates in artificial reproduction 
technique (ART) cycles. Women with elevated VEGF concentrations in FF had 
fewer oocytes retrieved at the ART procedure, lower peak serum estradiol 
concentrations, and reduced pregnancy rates (Friedman et al., 1998). These 
findings could imply that VEGF in the FF may be a marker of ovarian 
senescence or decreased ovarian reserve. This is in accordance with Lee et al. 
(1997) who reported that VEGF concentrations in FF correlated with age of 
women. Ocal et al. (2004) also observed that VEGF levels in FF were 
associated with poor conception rates in IVF. Elevated VEGF concentrations in 
FF were associated with fewer follicles, fewer oocytes retrieved, fewer mature
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oocytes, and fewer embryos, consistent with ovarian aging. However, no 
correlation was observed between VEGF and chronological age of the women 
in this study (Ocal et al., 2004). In addition, it was found that fertilized oocytes 
developing into high quality embryos originated from follicles containing low 
levels of VEGF (Tozer et al., 2004). 
In contrast with these findings, Kim et al. (2004) could not verify the 
relationship between the VEGF concentration in FF and age or pregnancy 
outcome. Also, no correlation was found between VEGF concentration in FF 
and the cause of infertility (Kim et al., 2004). Similarly, Attar et al. (2003) also 
could not find a correlation between VEGF concentration in FF and age of the 
women, number of oocytes retrieved, number of mature follicles, oocyte 
number, fertilization rate, or IVF success rates. 
A possible side effect of ART cycles is the ovarian hyperstimulation syndrome 
(OHSS) due to exaggerated gonadotropin induced follicular stimulation. The 
OHSS is characterized by hyperpermeability of ovarian capillaries and several 
studies have implicated VEGF to be involved in the pathogenesis of OHSS 
(Geva and Jaffe, 2000; Ludwig et al., 1999; Meldrum, 2002). Women at risk of 
developing OHSS in an artificial reproduction program are treated by either 
discontinuation of the cycle or by withholding gonadotropin and delaying hCG 
administration. It is thought that coasting diminishes the functional granulosa 
cell cohort through increased granulosa cell apoptosis. Tozer et al. (2004) 
investigated the effect of withholding gonadotropins during controlled ovarian 
stimulation on FF VEGF concentration and observed a significantly lower FF 
VEGF concentration in the coasted group of women compared with the control 
group, possibly reflecting the diminished capacity of the remaining granulosa 
cells to produce VEGF. 
Finally, VEGF seems to be involved in the aetiology of endometriosis (for 
review, see McLaren, 2000). Elevated concentrations of VEGF were found in 
FF of women with endometriosis compared with patients with Fallopian tube 
pathology (Attar et al., 2003). Furthermore, the expression of VEGF in 
endometriotic lesions appeared to be associated with the extent of their 
neovascularization, and the imbalance in VEGF expression in the endometrium 
could play a role in the development of endometriosis (Tan et al., 2002). 
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Conclusions 
Subfertility is a problem which numerous couples have to face. Despite the 
available assisted reproduction techniques, such as IVF or ICSI, most 
subfertile couples remain involuntarily childless. This is at least in part because 
the causes of the subfertility are not tackled.  
It is known that subfertility mostly is a multifactorial condition in which many 
factors of genetic, endocrine, environmental and life style origin are involved. 
The importance of these factors and their interplay is not clearly understood. 
To improve diagnosis and treatment of subfertility, a better understanding of 
several processes involved in reproduction like ovulation, spermatogenesis, 
fertilization and embryo implantation is required.  
In order to further investigate the underlying mechanisms of subfertility, this 
review emphasises the importance of the PA-system and VEGF in 
reproduction. Further investigations in this field may lead to targeted therapies 
for subfertility. In males the PA-system is involved in tissue remodelling events 
in the seminiferous tubules, epididymal maturation of spermatozoa, and events 
important for fertilization like the acrosome reaction and attachment to the 
oocyte. In females, the PA-system components are involved in angiogenesis in 
the ovary and ovulation, and movement of both oocyte and spermatozoa in the 
Fallopian tubes. The function of VEGF in the male reproductive tract is still 
largely unknown, but VEGF seems to be involved in influencing the testicular 
microvasculature and the composition of seminal plasma. In the female 
reproductive tract VEGF is likely implicated in the cyclic ovarian angiogenesis, 
follicle development and selection, the accumulation of FF, and corpus luteum 
angiogenesis. Also, VEGF can influence the composition of fluid secretions in 
the female genital tract, influencing the motility and survival of sperm present in 
the female genital tract after sexual intercourse. 
Most investigations discussed in this review involve experimental animal 
studies and the data clearly show that these systems are relevant. Therefore, it 
is justified to extend these results in humans. To obtain materials, blood, 
semen, spermatozoa, FF, or tissue, in order to study the involvement of the 
PA-system and VEGF in human fertility, te ART procedures are an important 
tool.
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Abstract 
 
Background: Thiols are scavengers of reactive oxygen species (ROS). We 
aim to investigate associations between thiols in various fluids in (sub)fertile 
couples and fertility outcome parameters.  
Methods: In 156 couples undergoing assisted reproduction techniques we 
measured the concentrations of glutathione (GSH), cysteine (Cys), homo-
cysteine (Hcy), and cysteinylglycine (CGS) and fertility outcome parameters in 
the ejaculate, purified spermatozoa and follicular fluid (FF).  
Results: All thiols were detectable in most ejaculates, spermatozoa and FFs, 
of which Cys concentrations were highest. Thiol concentrations in the ejaculate 
were similar in fertile and subfertile men. However, Hcy in FF was higher in 
women with endometriosis compared with women in the idiopathic subfertile 
group (P = 0.04). The GSH, Cys, Hcy and CGS concentrations in spermatozoa 
of subfertile men were significantly higher compared with men in the idiopathic 
subfertile group and fertile men (P < 0.001). Most notably, Hcy concentrations 
in both the ejaculate and FF were negatively associated with embryo quality on 
culture day 3 in the IVF/ICSI procedure.  
Conclusions: Spermatozoa of subfertile men contain significantly higher thiol 
concentrations as compared to those of fertile men. The detrimental effect on 
embryo quality of a high Hcy concentration in the ejaculate and in FF is 
intriguing and may suggest that Hcy is inversely associated with fertility 
outcome.
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Introduction 
Subfertility is a prevalent disorder occurring in approximately 10% of all 
couples during reproductive life. In about 30% of these couples, no cause for 
the subfertility can be found (Snick et al., 1997).  
In humans the thiol glutathione (GSH) (L-γ-glutamyl-L-cysteinyl-glycine) 
functions as the most important endogenous antioxidant involved in 
maintaining the pro-oxidant-antioxidant balance in human tissues. Other 
endogenous thiols are cysteine (Cys), homocysteine (Hcy) and cysteinylglycine 
(CGS). Cys is a precursor amino acid of GSH and both are taken up by food or 
are formed as a metabolic product of Hcy. CGS is composed of cysteine and 
glycine and is a main intermediate in the transport or synthesis of GSH (Figure 
1).  
 
Figure 1 Schematic summery of the glutathione metabolism 
 
 
Schematic summary of glutathione metabolism. Glutathione is a tripeptide (L-γ-glutamyl-L-cysteinyl-
glycine) synthesized from glutamate, cysteine and glycine in 2 consecutive steps catalyzed by γ-
glutamylcysteine synthetase and glutathione synthetase. The enzyme γ-glutamyltranspeptidase is 
involved in the breakdown of glutathione, thereby cleaving the γ-bond resulting in glutamate and 
cysteinylglycine. Abbreviations: GSH, glutathione (reduced glutathione); GSSG, glutathione disulphide 
(oxidized glutathione). 
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GSH is also involved in the metabolism and detoxification of cytotoxic and 
carcinogenic compounds, and in the elimination of reactive oxygen species 
(ROS) (Shan et al., 1990).  
Thiols and ROS are implicated in human reproduction. In humans, 
spermatozoa generate ROS which are known to affect hyperactivation of 
spermatozoa, the acrosome reaction, and the attachment of spermatozoa to 
oocytes thereby contributing to the fertilization of oocytes (de Lamirande et al., 
1993; de Lamirande and Gagnon, 1993a; 1993b; Aitken et al., 1989a). Thiols 
are scavenging ROS and are therefore suggested to be important in sperm 
function and fertilization as well. The DNA in the spermatozoa head is intensely 
compacted as a result of disulphide bridges between oxidized Cys residues in 
protamine molecules important during the maturation of spermatozoa in the 
epididymis. The oxidation of thiols is also important for the stabilization of the 
tail structure, sperm motility, and the protection of sperm DNA against physical 
or chemical damage. After fertilization of the oocyte, the compacted sperm 
nucleus is decondensed to form the male pronucleus (PN). The deconden-
sation depends on the presence of a small amount of free Cys capable of 
initiating a thiol-disulphide exchange (Rousseaux and Rousseaux-Prevost, 
1995). Besides the beneficial effects of ROS, an excess of ROS is detrimental 
to spermatozoa and leads to damage of the DNA and plasma membrane 
through lipid peroxidation. Because spermatozoa have discarded most of their 
cytoplasm during the final stages of spermatogenesis, the availability of 
cytoplasmic defensive enzymes is limited, and therefore, these cells in particu-
lar are susceptible to ROS. Increased lipid peroxidation of spermatozoal 
plasma membranes may lead to altered membrane fluidity, which can render 
sperm dysfunction through impaired metabolism, acrosome reaction reactivity 
and ability of the spermatozoa to fuse with the oocyte (Cummins et al., 1994). 
This may result in abnormal sperm concentrations, loss of motility and 
abnormal morphology of the spermatozoa, leading to loss of fertility (Agarwal et 
al., 1994; Aitken et al., 1989b; Aitken et al., 1991; Sharma and Agarwal, 1996).  
Little is known about the role of ROS and thiols at the level of the oocyte and 
female fertility. At the time of ovulation, the intense metabolism of granulosa 
cells and the high numbers of macrophages and neutrophilic granulocytes in 
the follicle wall may point at an active generation of ROS. Physiologic ranges of 
ROS are involved in oocyte maturation, luteolysis, progesterone production by
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the corpus luteum, atretic regression of the cohort of newly grown follicles to 
leave only one follicle destined for ovulation and the ovulation itself (Riley and 
Behrman, 1991b; Miyazaki et al., 1991; Margolin et al., 1990; Sawada and 
Carlson, 1996). In similarity with males, one consequence of an excess of ROS 
in the ovary may be plasma membrane damage of the oocytes. The 
significance of such damage for female fertility, however, is unknown. It has 
been shown that follicular fluid (FF) contains free-radical scavengers to keep 
the ROS level in balance and to protect the oocyte and embryo (Jozwik et al., 
1999; Pasqualotto et al., 2004). It is suggested from animal studies that the 
concentration of GSH in the oocyte is important to reduce the disulphide bonds 
during sperm nucleus decondensation and enable PN formation, decapitation, 
formation of the zygotic centrosome, and pronuclear apposition (Sutovsky and 
Schatten, 1997). This is endorsed by the observation that GSH antagonists 
disturbed the maturation of oocytes by compromising the decondensation of 
the sperm nucleus and thus preventing PN apposition. Furthermore, supple-
mentation of Cys or GSH during in vitro maturation of oocytes resulted in 
improved male PN formation, normal fertilization, and embryo development 
(Jeong and Yang, 2001; Rodriguez-Gonzalez et al., 2003; Sawai et al., 1997). 
Also, enhancement of GSH or GSH-building blocks in the oocyte and in culture 
medium of embryos during IVF or ICSI procedures seems to improve 
fertilization rates and embryo development (Ali et al., 2003; Fukui et al., 2000; 
Kim et al., 1999; Takahashi et al., 1993). On the contrary, it is also known that 
high levels of ROS in the culture medium of embryos results in low blastocyst 
and low cleavage rates and high embryonic fragmentation (Bedaiwy et al., 
2004). However, excessive scavenging of ROS by thiols has a negative effect 
on IVF, in particular fertilization, indicating that physiological levels of ROS are 
essential for normal fertilization (Ali et al., 2003; Bedaiwy et al., 2004; Kim et 
al., 1999). 
Given the effects of ROS and thiols on physiological and pathological 
processes involved in fertility as described above, our goal was to 
systematically investigate the role of thiols in human fertility. Therefore, the 
aims of the present study were: (i) to measure the levels of GSH, Cys, Hcy, 
and CGS in the ejaculate, purified spermatozoa and FF at the day of oocyte 
retrieval of couples undergoing assisted reproduction techniques (ART); and 
(ii) to determine associations between thiol concentrations in semen,  
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spermatozoa and FF, and the fertility outcome parameters proportion of 
fertilized oocytes, proportion of cleaved embryos, mean embryo quality and 
pregnancy.  
 
Materials and Methods 
 
Patient selection 
From April 2002 until May 2003 all patients visiting the fertility clinic of the 
Radboud University Nijmegen Medical Centre were considered for 
participation. The selection criteria for participation comprised the following 
diagnostic categories: (i) idiopathic subfertility, absence of abnormalities in both 
man and woman regarding semen and endocrine analyses, menstrual cycle, 
Chlamydia serology and hysterosalpingogram, but no spontaneous conception 
within 1 year of unprotected intercourse; (ii) female factor subfertility consisting 
of endometriosis or Fallopian tube pathology (any condition leading to an 
impediment of oocyte pick-up or transport); or (iii) male factor subfertility (MFS) 
defined by the presence of at least one of the sperm anomalies oligozoo-, 
asthenozoo-, and/or teratozoospermia. Couples with both a male and a female 
factor explaining their subfertility and patients first visiting other hospitals for 
fertility treatment were excluded from the study. The group of fertile men was 
defined as the male partners without abnormal semen parameters of the 
women suffering from Fallopian tube pathology or endometriosis. The group of 
fertile women without tube and menstrual cycle abnormalities comprised the 
partners of the men with MFS. 
All materials collected were anonymized. The patients were notified about the 
study by brochures available in the waiting room of the IVF treatment unit. 
Information was given on the background and objectives of the study, inclusion 
criteria, study periods and other relevant procedures. It was acknowledged that 
the decision whether or not to participate in the study would neither interfere 
nor have consequences for the IVF or ICSI treatment.  
The materials have been collected in accordance with the guidelines of the 
ethical and institutional board of the Radboud University Nijmegen Medical 
Centre. 
A total of 156 couples were enrolled in the study and information concerning 
age, type of treatment (IVF or ICSI), 17β-estradiol (E2) concentration in serum
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of the women and FSH dose (Puregon, Organon, Oss, The Netherlands) 
administered for ovarian stimulation treatment was made available from the 
medical records. 
 
Ejaculate collection 
Participants provided the ejaculates in polypropylene containers produced via 
masturbation at home or in the hospital after an abstinence period of 3-5 days. 
After liquefaction for 20 minutes, the total volume was measured and the main 
part of the sample was prepared for IVF or ICSI. Two hundred microlitres of the 
remaining ejaculate was obtained for semen analysis and preservation. Semen 
analysis was performed according to the guidelines of the World Health 
Organization (Guzick et al., 2001; World Health Organization, 1992). Thus, 
sperm concentration was determined using a Makler counting chamber, 
designed in a 10-by-10 compartments frame format. Motility was expressed as 
the proportion of motile spermatozoa, and morphology was determined after 
incubation of the sample with trypsin (10 minutes at room temperature), 
staining with methylene blue/eosin, feathering, and fixation by flame. The 
sample was frozen without preservatives and stored at –80 °C until assay for 
the thiol concentrations.  
 
Spermatozoa collection 
The ejaculate provided for the IVF or ICSI procedure (minus the 200 microlitre 
obtained for this study) was purified by means of centrifugation on 80% Pure 
Sperm reagent (Nidacon International AB, Sweden). After isolation, the 
concentration and motility of spermatozoa was determined according to the 
WHO guidelines. In the following step, the spermatozoa were diluted with 
culture medium (Human Tubal Fluid, Cambrex company, Belgium) to the 
concentrations required for the IVF or ICSI procedures. Residual concentrated 
sperm was collected, frozen without preservatives and stored at –80 °C until 
assay for the thiol concentrations.  
 
Follicular fluid collection 
After oocyte retrieval for the IVF or ICSI procedure a sample of the follicular 
fluid (diluted with 10 IU/ml heparin and phosphate buffer, pH 7.4) was 
centrifuged for 10 minutes at 2000 g to separate red blood cells, leukocytes
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and granulosa cells from the follicular fluid. The follicular fluid was frozen 
without preservatives and stored at –80 °C until assay for the thiol concen-
trations, 17β-E2, progesterone and total protein content.  
 
Fertility outcome parameters 
The number of follicles and the number of follicles > 15 mm were determined 
using ultrasound 2 days before the follicles were punctured. One day after the 
IVF or ICSI procedure, fertilization was determined by counting the number of 
pronuclei in the oocyte. The proportion of fertilized oocytes was calculated by 
dividing the number of oocytes with two pronuclei by the total number of 
oocytes retrieved (IVF), or by the total number of oocytes injected (ICSI).  
On the following 2 days, the embryos were examined once a day for 
development. The proportion of cleaved embryos was calculated following 
division of the number of cleaved embryos on day 3 by the total number of 
oocytes retrieved (IVF), or the total number of oocytes injected (ICSI). 
Furthermore, embryo quality was established by judgement of fragmentation 
and cleavage activity of the embryos after 3 days of culturing, and was denoted 
as low, moderate, reasonable or high.  
An hCG-based pregnancy test was performed in first-morning voided urine 
from the woman on day 15 after the embryo transfer. The result of this test was 
communicated by phone to the personnel of the fertility clinic. 
 
17β-Estradiol and progesterone in FF 
The concentrations of 17β-E2 and progesterone in FF were measured by a 
specific procedure described previously (Thomas et al., 1977). Fifty microlitres 
of a FF specimen was extracted twice with diethylether, and after drying, the 
residue containing 17β-E2 and progesterone was further purified by chromato-
graphy on Sephadex LH-20 columns. The steroids were quantified by specific 
radioimmunoassays. 
 
Total protein content in FF 
The FFs were assayed for protein concentration using the Pierce BCA protein 
assay reagent kit (Pierce, Rockford, IL). Absorptions were read at 540 nm in an 
automatic microtiter plate reader (Multiskan Ascent, Labsystems). The protein 
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content of the FF was determined as a biomarker for the maturity of the follicle 
(Spitzer et al., 1996).  
 
Thiol assays 
For the analysis of the thiol contents of the spermatozoa, these cells first had to 
be lysed. This was accomplished by freezing in liquid nitrogen and subsequent 
thawing for five times. Subsequently, the thiol assay was similar for the 
spermatozoa, the ejaculate and the FF. The samples were diluted six times 
with 12% (v/v) perchloric acid and centrifuged for 5 minutes at 10 000 g. Next, 
10 µl 10% (w/v) Tris (2-carboxyethyl) phospine (Fluka Chemie AG, Bornem, 
The Netherlands) was added to 100 µl of each sample. After reduction for 30 
minutes at room temperature, samples were neutralized by adding 76 µl, 2 
mol/l NaOH. Subsequently, 100 µl of the neutralized sample was derivatized 
with 7-fluorobenzofurazane-4-sulfonic acid (SBDF; Fluka Chemie AG) for 1 h at 
60 °C by adding 60 µl of derivatization buffer containing 50 µl borate buffer 
(125 mmol/l K2B4O7·4H2O and 4 mmol/l EDTA, pH 9.5), 5 µl SBDF (4 mg/ml 
borate buffer) and 5 µl NaOH (1.55 mol/l) (Raijmakers et al., 2001). Of each 
derivatized sample, 20 µl was injected and thiols were eluted with an isocratic 
eluent (2.0% methanol in 0.1 mol/l acetic acid, pH 5.0) at flow rates of 350 
µl/minutes for 5 minutes, 600 µl/minutes for another 5 minutes and 300 
µl/minutes for 15 minutes. Thiols were separated by high-performance liquid 
chromatography (HPLC) with fluorescent detection using an autosampler 
(Model Marathon, Spark, Holland), solvent delivery system (High Precision 
Pump model 480; Gynkotek, Munich, Germany), and fluorescent detector 
(Intelligent Spectrofluorometric Detector model 821-FP; Jasco, H.I. Ambacht, 
The Netherlands) operating at an excitation wavelength of 385 nm and an 
emission wavelength of 515 nm. The separating column (Inertsil ODS-2; 100 x 
3 mm, 5-µm particle size) and guard column (R2; 10 x 2 mm) were from 
Chrompack (Middelburg, The Netherlands). Data obtained were analysed with 
the Chromeleon chromatography data system (Gynkotek, Munich, Germany). 
Concentrations of thiols were determined using calibration curves for all thiols, 
which were run in parallel with the samples. These calibration curves were 
prepared by diluting stock solutions with 0.9% sodium chloride/4mmol/l EDTA 
that were stored in small aliquots at –30 °C. All samples were analysed in
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duplicate. 
 
Statistical analyses 
The fertility outcome parameters were normally distributed and the results are 
expressed as means and standard deviation (SD). The proportion of fertilized 
oocytes, cleaved embryos and mean embryo quality in the IVF and ICSI 
groups were compared using the independent sample t-test. The number of 
clinical pregnancies occurring in IVF and ICSI groups was compared using the 
Chi-square test.  
Thiol concentrations in the ejaculate were normally distributed and the results 
are expressed as means and SD. Thiol concentrations in spermatozoa and FF 
were skewed; therefore natural logarithmic transformations were performed 
and data are expressed as geometrical means and 25th-75th percentiles. The 
thiol concentrations between groups were compared using one-way analysis of 
variance (ANOVA) and further analysed using post hoc Bonferroni compari-
sons. 
In the pooled group of men, Pearson correlations were calculated between thiol 
concentrations in the ejaculate and the logarithmic transformed characteristics 
of the study population age, sperm concentration, motility percentage and 
percentage abnormal cells. In the pooled group of women, Pearson 
correlations were calculated between the logarithmic transformed thiol-protein 
ratios in FF and the study population characteristics described in Table II. 
Linear regression analyses were performed in the pooled group of men or 
women to find associations between the fertility outcome parameters, being the 
proportion of oocytes fertilized and the proportion of cleaved embryos on 
culture day 3 as the independent variables and GSH, Cys, Hcy and CGS 
concentrations in the ejaculate, in spermatozoa and in FF as the independent 
variables. Also, logistic regression analyses were carried out in the pooled 
group of men or women to find associations between the dependent variables 
embryo quality on culture day 3 (expressed as low-moderate, or reasonable-
high) and achievement of pregnancy (yes or no) and the independent 
continous variables such as GSH, Cys, Hcy and CGS concentrations in 
ejaculate purified spermatozoa and FF. Potential confounders were included in 
the linear or logistic regression models, and the factors that substantially 
affected the association between the dependent variable and the thiol variable
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(causing a change in the regression coefficient of more than 10%) were 
maintained in the final models.  
A P-value of ≤ 0.05 was considered statistically significant. Statistical analyses 
were performed using SPSS 12.0 for Windows software (SPSS Inc, Chicago, 
IL, USA). 
 
Results 
A total of 156 couples undergoing ART were evaluated in this study of which 
67.9% received IVF treatment and 32.1% underwent an ICSI procedure. Most 
idiopathic subfertile couples and almost all couples experiencing female factor 
subfertility underwent IVF treatment, 84.6% and 96.2%, respectively. Most 
couples experiencing MFS however, received ICSI treatment (e.g. 76.9%). 
The basic characteristics of the male study group are summarized in Table I. 
Patient's age and volume of the ejaculate were comparable between the 
groups. As expected, the sperm concentration and motility in the ejaculate and 
purified samples, and morphology in the ejaculate were different in the MFS 
group compared with fertile men and men in the idiopathic subfertile group.  
The basic characteristics of the female study group are summarized in Table II. 
The only difference between the four diagnostic subgroups was age. Women 
with endometriosis were slightly younger as compared to women in the 
idiopathic subfertile group. 
The outcome parameters in the IVF, ICSI, and total group of couples are 
presented in Table III. The proportion of fertilized oocytes and the proportion of 
cleaved embryos were significantly higher in the ICSI group, compared with the 
IVF group, P = 0.04 and P = 0.01, respectively. However, the mean embryo 
quality and the number of clinical pregnancies are comparable between the two 
treatment groups. 
The concentrations of the thiols measured in the ejaculate and spermatozoa 
are presented in Table IV and V, respectively. All thiols could be determined in 
both specimens. However, because measurement of the ejaculate samples 
gave considerable problems by congesting the separating column of the HPLC 
apparatus, only 77 of the total number of 156 samples could be evaluated. Of 
the thiols measured, Cys was present in the highest concentrations in the total 
ejaculate samples. The concentrations of the four different thiols in ejaculate 
were comparable between the three diagnostic subgroups. Furthermore, thiol
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concentrations in the ejaculate were much higher than the concentrations in 
spermatozoa (results not shown). 
 
Table I Characteristics of men undergoing an IVF/ICSI procedure 
Characteristics Fertile (n = 52) IS (n = 52) MFS (n = 52) 
Age (years) 35.0 (32.0-37.7) 35.7 (34.0-38.0) 34.7 (32.0-37.7) 
Volume ejaculate (ml) 2.8 (2.1-3.5) 2.9 (2.2-4.4) 3.3 (2.5-4.8) 
Ejaculate Sperm conc (x106/ml)  
 Motility (%) 
 Abnormal cells (%) 
66.1 (45.5-100.0) 
56.2 (50.0-65.0) 
78.7 (72.0-87.0) 
55.6 (31.3-100.0) 
54.0 (50.0-63.8) 
81.1 (75.0-87.8) 
3.8 (1.2-14.5) 
18.9 (10.0-30.0) 
93.0 (89.0-97.0) 
Purified sperm (x106/ml) 
 Sperm conc (x106/ml)
 Motility (%) 
 
19.9 (10.0-53.7) 
75.8 (70.0-90.0) 
 
11.9 (5.0-30.0) 
67.9 (60.0-85.0) 
 
2.2 (0.7-5.0) 
29.8 (20.0-50.0) 
Note: values are given as geometrical mean and (25th –75th percentile). IS = idiopathic subfertility, MFS 
= male factor subfertility. 
 
Table II Characteristics of women undergoing an IVF/ICSI procedure 
Characteristics Fertile (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
Age (years) 32.8 (30.3-36.0) 34.3 (32.0-36.0) 33.2 (31.0-38.0) 31.5 (29.0-35.3) 
Puregon dose (IU) 179 (150-250) 173 (150-200) 182 (150-300) 170 (144-263) 
E2 in blood (pmol/l) 5114 (3725-7575) 5499 (3925-8350) 5545 (5025-7025) 5603 (4050-8500) 
E2 in FF (nmol/l) 871 (660-1350) 924 (683-1300) 971 (763-1400) 849 (540-1425) 
Prog in FF (µmol/l) 24.7 (19.0-36.8) 27.3 (22.5-35.8) 22.2 (16.0-32.3) 23.5 (19.0-33.0) 
Protein in FF (µg/l) 38.2 (34.0-43.5) 39.1 (35.8-45.8) 38.7 (33.6-47.2) 38.9 (32.7-49.1) 
Follicles (n) 12.0 (9.0-20.8) 14.1 (10.0-21.0) 13.3 (10.8-17.0) 14.4 (13.0-20.3) 
Follicles> 15mm (n) 6.2 (5.0-10.0) 6.5 (5.0-10.0) 7.1 (6.0-9.0) 6.9 (4.8-11.3) 
Oocytes (n) 8.5 (6.0-13.0) 9.2 (7.0-13.8) 8.6 (6.0-13.0) 8.2 (5.8-13.0) 
Note: values are given as geometric mean and (25th –75th percentile). E2 = 17β-estradiol, EM = 
endometriosis, FF = follicular fluid, FTP = Fallopian tube pathology, IS = idiopathic subfertility, Prog = 
progesterone. 
 
Table III Outcome parameters of IVF and ICSI procedures 
 IVF group (n = 106) ICSI group (n = 50) Total group (n = 156) 
Fertilization rate (%) 55.9 (26.6) 65.1 (25.7)a 58.9 (26.6) 
Cleavage rate (%) 65.9 (27.5) 76.2 (19.7)a 69.2 (25.7) 
Mean embryo quality 2.2 (0.7) 2.0 (0.8) 2.1 (0.8) 
No. of pregnancies (%) 33 (31.1) 17 (34.0) 50 (32.1) 
Note: values are given as mean (SD). a: P < 0.05 
† Embryo quality is scored on a scale of 0 to 3; 0 = low, 1 = moderate, 2 = reasonable and 3 = good 
embryo quality. 
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Table IV Thiol concentrations in ejaculate of men undergoing an IVF/ICSI 
procedure 
Thiol concentrations (µmol/l) Fertile (n = 28) IS (n = 26) MFS (n = 23) 
Glutathione 7.7 (2.4) 7.2 (2.9) 6.2 (2.9) 
Cysteine 36.9 (17.2) 32.5 (13.4) 31.0 (14.9) 
Homocysteine 5.9 (3.1) 5.8 (3.4) 4.2 (3.0) 
Cysteinylglycine 7.9 (3.4) 7.9 (3.5) 7.9 (2.9) 
Note: values are given as mean and (SD). IS = idiopathic subfertility, MFS = male factor subfertility. 
  
Table V Thiol concentrations in spermatozoa of men undergoing an IVF/ICSI 
procedure 
Thiol concentrations  
(pmol/million cells) Fertile (n = 52) IS (n = 52) MFS (n = 52) 
Glutathione 0.90 (0.42-2.25) 1.60 (0.42-4.00) 7.29 (3.10-20.0)a,b 
Cysteine 60.8 (34.1-103.0) 106.5 (32.8-257.2) 426.1 (172.1-946.9)a,b,c 
Homocysteine 12.4 (6.35-20.0) 20.9 (8.83-44.3) 58.8 (26.3-155.0)a,b 
Cysteinylglycine 8.9 (3.72-15.5) 17.3 (5.7-40.5) 86.1 (39.0-222.3)a,b,c 
Note: values are given as geometrical mean and (25th-75th percentile). Post hoc Bonferroni comparisons 
a: between the fertile and male factor subfertility (MFS) group, P < 0.001; b: between the idiopathic 
subfertile (IS) and MFS group, P < 0.001; c: between the fertile and IS, P ≤0.05. 
 
The GSH concentrations in spermatozoa were below the detection limit in 122 
out of 156 samples tested. These 122 samples were allocated a value of 0.01 
µmol/l (half of the lowest detectable value for GSH in spermatozoa). Thiols 
measured in the purified spermatozoa samples were eventually expressed as 
pmol thiol/million spermatozoa to compare the thiol concentrations between the 
different diagnostic subgroups. Again the concentrations of Cys were much 
higher compared with the other thiols measured. All thiol concentrations in 
spermatozoa differed between the three diagnostic subgroups (ANOVA, P < 
0.001). Post hoc Bonferroni comparisons revealed that spermatozoa of men in 
the MFS group contained significantly higher GSH (mean difference 2.0 pmol 
(95% CI 1.37-2.62); P < 0.001), Cys (mean difference 1.95 pmol (95% CI 1.39-
2.50); P < 0.001), Hcy (mean difference 1.56 pmol (95% CI 0.99-2.12); P < 
0.001), and CGS (mean difference 2.27 pmol (95% CI 1.69-2.85); P < 0.001) 
per million spermatozoa as compared to those in fertile men. Similarly, 
spermatozoa of men in the MFS group contained significantly higher GSH 
(mean difference 1.51 pmol (95% CI 0.89-2.14); P < 0.001), Cys (mean
Chapter 7 
 
 
126 
difference 1.39 pmol (95% CI 0.83-1.95); P < 0.001), Hcy (mean difference 
1.04 pmol (95% CI 0.48-1.60); P < 0.001), and CGS (mean difference 1.60 
pmol (95% CI 1.02-2.18); P < 0.001) per million spermatozoa as compared to 
these thiol concentrations in spermatozoa of men in the idiopathic subfertile 
group. Furthermore, post hoc Bonferroni comparisons revealed that Cys 
concentrations in spermatozoa of men in the idiopathic subfertile group were 
significantly higher compared with those in fertile men (mean difference 0.56 
pmol per million spermatozoa (95% CI 0.001-1.12); P = 0.049). Also, CGS 
concentrations in spermatozoa of men in the idiopathic subfertile group were 
significantly higher compared with those in fertile men (mean difference 0.67 
pmol per million spermatozoa (95% CI 0.09-1.25); Bonferroni P < 0.02). 
The concentrations of the thiols in FFs are presented in Table VI. All thiols 
were detectable in the FF samples. The Hcy concentrations in the FF were 
below the detection limit in 43 out of 156 samples tested. These 43 samples 
were allocated a value of 0.1 µmol/l (half of the lowest detectable value for Hcy 
in FF). Thiols measured in FF were eventually expressed as µmol thiol/mg 
protein to adjust for the maturity of the follicle. In similarity to the ejaculate 
samples, Cys was present in the highest concentrations as compared to the 
other thiols measured. In the women, FF Hcy concentrations differed between 
the diagnostic subgroups (ANOVA, P = 0.02). The Hcy concentrations in the 
FF of endometriosis patients were significantly higher compared with those in 
women in the idiopathic subfertile group (mean difference 0.71 µmol/mg protein 
(95% CI 0.02-1.39); Bonferroni, P = 0.04). 
 
Table VI Thiol concentrations in follicular fluids of women undergoing an 
IVF/ICSI procedure 
Thiol concentrations 
(µmol/mg protein) Fertile (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
GSH 0.31 (0.24-0.43) 0.29 (0.24-0.43) 0.25 (0.18-0.44) 0.28 (0.23-0.47) 
Cys 1.40 (1.0-2.0) 1.32 (1.0-1.9) 1.14 (1.0-1.4) 1.37 (1.0-2.1) 
Hcy 14.7 (9.9-26.7) 9.2 (2.6-27.1) 9.8 (2.9-23.2) 18.8 (14.4-44.4)a 
CGS 0.21 (0.16-0.26) 0.20 (0.14-0.25) 0.17 (0.13-0.22) 0.22 (0.17-0.31) 
Note: values are given as geometrical mean and (25th and 75th percentile). a: P = 0.02 
CGS = cysteinylglycine, Cys = cysteine, EM = endometriosis, FTP = Fallopian tube pathology, GSH = 
glutathione, Hcy = homocysteine, IS = idiopathic subfertility. 
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Furthermore, we calculated correlations between the thiol levels in the 
ejaculate versus the various basic characteristics. No significant correlations 
were observed for GSH, Hcy or CGS in the ejaculate, however, Cys in the 
ejaculate was inversely correlated with the proportion of abnormal 
spermatozoa (r = -0.29; P = 0.01). Likewise, in women correlations were 
calculated between the thiol-protein ratios in the FF and the fertility (outcome) 
parameters. The GSH-protein concentrations were positively correlated with 
the number of retrieved oocytes (r = 0.17; P = 0.03), and an inverse correlation 
was determined between the Cys-protein concentrations and progesterone 
levels in FF (r = -0.30; P ≤ 0.001). No other significant correlations were 
observed. Linear and logistic regression analyses were performed to 
investigate whether the thiol concentrations in the ejaculate and spermatozoa 
were associated with the proportion of fertilized oocytes, the proportion of 
cleaved embryos, embryo quality or pregnancy. A significant association was 
observed between the Hcy concentration in the ejaculate and embryo quality 
on culture day 3, expressed as reasonable/high or moderate/low quality (OR = 
0.83, 95% CI 0.70-0.98). None of the other characteristics confounded this 
association. 
For the female parameters similar regression analyses were performed, and 
again Hcy concentrations in FF and embryo quality on culture day 3 were 
significantly associated (OR = 0.58, 95% CI 0.35-0.97) without confounding by 
other characteristics. 
Finally, we combined the male and female data in one logistic regression 
model to assess the association between embryo quality on culture day 3 and 
Hcy concentrations. Included in the analyses were Hcy in the ejaculate, Hcy in 
spermatozoa, Hcy in FF and as confounders spermatozoa concentration and 
proportion motile spermatozoa in the purified spermatozoa sample, proportion 
motile spermatozoa in the ejaculate, and the number of oocytes retrieved. 
These regression analyses yielded an adjusted OR of 0.81 (95% CI 0.65-1.00; 
P = 0.05) for Hcy concentrations in the ejaculate and an adjusted OR of 0.42 
(95% CI 0.18-0.94; P = 0.04) for Hcy concentrations in the FF in relation to the 
embryo quality on culture day 3 after IVF or ICSI procedures. 
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Discussion  
This study demonstrates that women with endometriosis have higher FF Hcy 
concentrations compared with women in the idiopathic subfertile group. 
Furthermore, thiol concentrations in the ejaculate were higher as compared to 
those in spermatozoa indicating the important antioxidant function of the 
seminal plasma for the protection of spermatozoa. The thiol concentrations 
were significantly higher in purified spermatozoa of men with MFS as 
compared to fertile men and men in the idiopathic subfertile group. Unique and 
most interesting is that for the first time an association has been found between 
embryo quality in an IVF/ICSI procedure and Hcy concentrations in the total 
ejaculate and FF of the couple. It reveals that a 1 µmol/l decrease of the Hcy 
concentrations in the ejaculate was associated with a 1.2 fold higher chance of 
achieving a reasonable/high quality embryo in an IVF or ICSI procedure. 
Similarly, a 1 µmol/l decrease of the Hcy concentration in FF was associated 
with a significant 2.4 fold higher chance of a reasonable/high quality embryo in 
an IVF or ICSI procedure. These findings are supported by in vitro studies in 
which exposure of chicken embryos to Hcy concentrations varying from 
physiologic to toxic amounts leads to developmental defects, such as neural 
tube defects and cardiac abnormalities, growth retardation and lethality (Boot 
et al., 2004a; Rosenquist et al., 1996).  
So far not much is known about specific individual thiol concentrations in 
ejaculate, spermatozoa and FF. More literature is available on the total non-
enzymatic antioxidant capacity (TAC) of seminal plasma and spermatozoa. 
Most authors report significantly lower TAC levels in seminal plasma of 
subfertile men as compared to fertile men (Lewis et al., 1995; Lewis et al., 
1997; Smith et al., 1996). More specifically, Raijmakers et al., (2003) reported 
significantly higher seminal plasma GSH concentrations in fertile men 
compared with subfertile men. In accordance with this finding, Alkan et al. 
(1997) observed lower levels of sulphydryl groups in seminal plasma of 
subfertile patients compared with fertile men. In contrast we could not observe 
any difference in total ejaculate thiol concentrations between fertile and 
subfertile men in our study group, which was comparable to the results of 
Lewis et al. (1997) and Ochsendorf et al. (1998).  
Furthermore, other authors observed positive correlations between TAC or 
GSH levels in seminal plasma and sperm motility, whereas inverse correlations
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were found between TAC or GSH levels and sperm morphology (Raijmakers et 
al., 2003; Smith et al., 1996). The latter observations are in accordance with 
the negative association between Cys concentrations in the ejaculate and the 
proportion of abnormal spermatozoa, as reported in this study. However, none 
of the other thiols were related to sperm morphology in our study group. 
Measurement of thiols in spermatozoa by other research groups yielded 
conflicting results. Garrido et al. (2004) observed that the GSH concentrations 
in spermatozoa from fertile and idiopathic subfertile men were comparable, 
which is similar to our findings. However, these authors did observe 
significantly lower GSH concentrations in spermatozoa of samples with less 
than 5% normal morphology, whereas our results indicate that spermatozoa of 
men in the MFS group contain significantly higher concentrations of GSH. Also, 
Ochsendorf et al. (1998) found that spermatozoa of oligozoospermic patients 
contained much lower GSH concentrations than those of normozoospermic 
men. Similar to our results, Lewis et al. (1997) observed significantly higher 
thiol concentrations in spermatozoa of asthenozoospermic men. According to 
their explanation, this may be due to the contribution of ROS produced by 
spermatozoa in this group leading to the up-regulation of thiol synthesis in 
order to protect the spermatozoa from oxidative damage. These authors 
speculate that the high thiol concentrations caused the reduced motility in 
these spermatozoa, because of a decrease in disulphide bonding during sperm 
maturation in the epididymis. The different data could be explained therefore by 
differences in the cause and amount of triggering of the (anti)oxidant system.  
So far, thiol concentrations in FF and the association with fertility parameters 
have not been studied before. More data, however, are available on the 
relationship between TAC and fertility. Although Pasqualotte et al. (2004) 
observed a positive association between TAC and pregnancy rate, in FF the 
TAC was not associated with oocyte maturity, fertilization, cleavage and 
embryo quality. Therefore, they concluded that a certain amount of oxidative 
stress is necessary for the establishment of pregnancy. In contrast, Oyawoye 
et al. (2003) reported that the mean TAC level in FF from follicles yielding 
oocytes that were successfully fertilized, was significantly higher than the TAC 
levels from FF associated with oocytes that were not fertilized. Furthermore, 
they observed that the TAC level of FF from follicles whose oocytes gave rise 
to an embryo that survived until the moment of transfer was significantly lower
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compared with the FF TAC level resulting in non-viable embryos. Therefore, 
these authors conclude that ROS may have different effects at different stages 
of embryonic development, and that the role of ROS prior to ovulation differs 
from that in relation to fertilization and embryo viability. Similar to our results, 
Attaran et al. (2000) did not find an association between TAC levels in FF and 
pregnancy rates. However, they observed a positive correlation between the 
ROS levels in FF and pregnancy rate, which is supported by others (Bedaiwy 
et al., 2002).  
Direct comparisons of the results of other studies is often difficult, because of 
the differences in the methods used for the processing and analysis of semen. 
Most researchers use the guidelines of the WHO to classify the diagnostic 
subgroups and semen samples. Others, such as Garrido et al. (2004) also 
used Tygerberg strict criteria for sperm morphology. In addition centrifugation, 
the use of Percoll gradients or swim-up techniques for the purification of 
spermatozoa are often applied. The methods used to measure (anti)oxidants or 
(anti)oxidant activity vary significantly in the various studies cited. In most 
studies TAC was measured by using enhanced chemoluminescence assays; 
total sulfhydryl groups were measured after 5,5'-dithiobis (2-nitrobenzoic acid) 
derivation and subsequent spectrophotometry or lipid peroxidation tests were 
performed by using thiobarbituric acid tests. The only authors specifically 
measuring GSH also used 5,5'-dithiobis (2-nitrobenzoic acid) derivation and 
subsequent spectrophotometry (Ochsendorf et al., 1998) or biochemical 
reactions and spectrophotometry methods (Garrido et al., 2004). Only 
Raijmakers et al. (2003) used the same HPLC method we used. However, they 
measured GSH in seminal plasma after centrifugation of the total ejaculate, in 
which spermatozoa and other cell materials were removed.  
The only study focused on the association between embryo quality and 
antioxidants in an IVF or ICSI setting published so far was performed by 
Paszkowski and Clarke (1996). They found that incubation of poor quality 
embryos was associated with a decline in TAC in the preimplantation embryo 
culture medium, which was significantly larger than that observed in good and 
fair embryos. These authors therefore stated that impaired embryo 
development may be associated with an increased generation of ROS by the 
embryo. No studies were done so far investigating the role of thiols in the 
ejaculate or FF, in association with the subsequent embryo quality after an IVF
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or ICSI procedure.  
The findings of the higher FF Hcy concentrations in women with endometriosis 
and the inverse association between FF Hcy levels and embryo quality are 
supported by previous prospective and retrospective studies. These clinical 
trials demonstrate a decreased oocyte and embryo quality in women with 
endometriosis, which is suggested to be due to an altered intrafollicular milieu 
in endometriosis. We found a biochemical difference in the FF Hcy level that 
can be due to environmental factors, such as nutrition and lifestyle, and genetic 
variations in for example folate genes. If the detrimental effects of endo-
metriosis are non-genetic in origin, modulation of the process of folliculo-
genesis may become feasible to treat the disease and cure the infertility 
(Garrido et al., 2002).  
Some limitations of the present study have to be addressed. The separation of 
spermatozoa from seminal plasma in IVF or ICSI procedures, the washing, 
centrifugation, vortexing and also freeze-thawing may have generated ROS in 
the spermatozoa sample in contrast to the ejaculate. As a consequence, GSH 
concentrations in the spermatozoa samples may have decreased. Thus, it is 
very likely that the thiol concentrations measured underestimate the in vivo 
antioxidant capacity of the spermatozoa (Gadea et al., 2004). This may also 
explain the many samples with an undetectable GSH concentration in our 
study. However, because all samples were treated exactly in the same 
manner, we believe that the differences observed between fertile and subfertile 
men are real. Next, it is also possible that due to some leukocyte contamination 
of the ejaculate samples, the ROS production was increased and counteracted 
by thiols that consequently decreased in particular in the subfertile population 
(Aitken et al., 1992). Because the thiol concentrations in the ejaculate were 
comparable between fertile and subfertile men in our study and higher than the 
concentrations in subfertile men reported by others, we do not believe that the 
presence of leukocytes was a factor of significance. With regard to the purified 
spermatozoa samples, similar problems with contaminating leukocytes could 
arise. We believe the purification of spermatozoa with the Pure Sperm gradient 
had discarded almost all present leukocytes; however, we did not verify the 
efficiency of this purification. Therefore, it is possible that purified spermatozoa 
samples of subfertile men in particular still contained some leukocytes. This 
would result in higher ROS concentrations in these samples leading to a
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depletion of thiols. Because our results show that spermatozoa of subfertile 
men contain significantly higher thiol concentrations, we do not believe that 
contamination with leukocytes has interfered with our results.  
Furthermore, the FF samples collected were pooled samples from different 
follicles. Therefore, it may be incorrect to directly correlate the FF thiol 
concentrations with the development of a specific embryo. However, we could 
not change the method of FF collection because we had to adhere to the 
regular IVF and ICSI protocols.  
Finally, because we examined several variables and their associations with 
fertility outcome parameters, multiple testing could be an issue in our study. 
Because all the thiols measured were higher in the spermatozoa of subfertile 
men, and both the Hcy concentrations in ejaculates as well as in the FFs were 
negatively associated with embryo quality, in concordance with the toxicity of 
Hcy reported in the literature, we believe that the results obtained in this study 
do not merely reflect chance. 
The strengths of our study is the relatively large number of couples undergoing 
an IVF or ICSI procedure that were investigated. Furthermore, our study group 
is homogeneous and subfertile, and fertile men or women are very comparable 
because we applied strict selection criteria. We only included couples who 
were unable to achieve a spontaneous conception within 1 year of regular, 
unprotected intercourse. Women with menstrual disorders were excluded, as 
were couples with both a male and a female factor explaining their subfertility 
or patients with multiple causes for subfertility within one individual. 
In conclusion, thiol concentrations in spermatozoa of subfertile men are 
significantly higher compared with the concentrations in spermatozoa of fertile 
men. These high thiol concentrations may result in a diminished motility, 
because of decreased disulphide bonding during sperm maturation in the 
epididymis and perhaps may also lead to excessive scavenging of ROS to 
levels below those physiologically necessary for normal sperm function. 
However, we did not measure in parallel the ROS levels and therefore further 
research is necessary to verify this explanation. Intriguing are the high Hcy 
concentrations in the ejaculate and FF which are associated with moderate/low 
embryo quality, and the corresponding higher FF Hcy concentration in women 
with endometriosis, known to suffer from low embryo quality. This strongly 
suggests a predictive value for embryo quality in artificial reproduction of the
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Hcy concentration in these biological fluids. 
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Abstract 
 
Objective: To correlate components of the plasminogen activator (PA)-system 
with fertility outcome parameters in participants of an IVF/ICSI procedure. 
Design: Case-control study. 
Setting: Outpatient clinic for IVF/ICSI treatment at the Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands.  
Participants: 156 couples undergoing an IVF/ICSI procedure . 
Interventions: None  
Main Outcome Measures: Urokinase-type plasminogen activator (uPA), 
tissue-type plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-
1) and tPA-PAI-1 complex concentrations in the ejaculate, spermatozoa and 
follicular fluid (FF). 
Results: Concentrations of tPA were higher in spermatozoa of the male factor 
subfertility group (geometrical mean 77.1 pg/million spermatozoa, 25th-75th 
percentile (31.8-211.2) compared with fertile (1.91 (0.74-5.79) and idiopathic 
subfertile men (3.14 (0.97-9.97), P < 0.001). Furthermore, the concentration of 
tPA in the spermatozoa is significantly associated with pregnancy (OR 0.995, P 
= 0.03). Likewise, a trend was shown for higher tPA concentrations in FF of 
women with Fallopian tube pathology (geometrical mean 18.5 pg tPA/mg 
protein, 25th-75th percentile (11.4-25.7) or endometriosis (18.8 (11.4-27.1) 
compared with fertile (14.3 (10.3-17.6) and idiopathic subfertile women (13.9 
(9.5-17.8), P = 0.07. Also, tPA in FF is associated with the proportion of 
cleaved embryos (regression coefficient 0.16, P < 0.001). The concentrations 
of uPA, PAI-1 and tPA-PAI-1 complex were comparable between the 
diagnostic subgroups in both men and women.  
Conclusions: The tPA concentrations in spermatozoa and in follicular fluid 
tend to be higher in human subfertility and seem to be associated with some 
fertility outcome parameters.  
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Introduction 
Subfertility is a prevalent disorder occurring in approximately 10-17% of all 
couples during reproductive life (Snick et al., 1997). In many of these couples 
no cause for the subfertility can be found.  
The components of the plasminogen activator (PA)-system are involved in the 
activation of the inactive proenzyme plasminogen into the active serine 
proteinase, plasmin. Plasmin degrades extracellular matrix (ECM) proteins. 
The PA-system involves 2 plasminogen activators, the urokinase-type 
plasminogen activator (uPA) and the tissue-type plasminogen activator (tPA). 
Urokinase PA and tPA activities are effectively controlled by specific inhibitors 
like plasminogen activator inhibitor 1 (PAI-1) (Andreasen et al., 1997; Dano et 
al., 1985; Schmitt et al., 1997). The components of the PA-system occur in a 
variety of different cell types and are involved in several biological processes. 
Degradation of the ECM resulting from plasminogen activation is important in 
cell migration, necessary for morphogenesis, tissue repair, neovascularization 
or invasion of malignant cells. One of the interesting areas in which the PA-
system appears to play an important role is reproduction. 
In the male, uPA and tPA are produced by Sertoli cells (Hettle et al., 1986; 
Lacroix et al., 1977; Vihko et al., 1986). Proteolysis mediated by these 2 
components is suggested to be involved in the release of preleptotene 
spermatocytes from the basement membranes (Hettle et al., 1986), passage of 
spermatocytes across the blood testis barrier (Zhang et al., 1997b), 
spermiation (LeBlond and Clermont, 1952), and the detachment of residual 
bodies from the mature spermatids (Morales et al., 1986). The PA-system 
seems also involved in the release of mature spermatozoa into the lumen of 
the tubules (Zhang et al., 1997b). It has been reported that in the epididymis 
the PA components play a role in the alteration of sperm surface molecules 
(Eddy et al., 1985; Tulsiani et al., 1995). These alterations are necessary for 
sperm maturation and motility, and the fertilizing ability of the spermatozoa. 
The PA-system is also involved in sperm surface modifications involved in 
capacitation (Talbot and Chacon, 1981; Talbot and Franklin, 1978), stimulation 
of the acrosome reaction (Dravland et al., 1984; Pillai and Meizel, 1991), and 
attachment to, and penetration of the spermatozoon into the zona pellucida 
(Smokovitis et al., 1992). In the female, a variety of ovarian tissues (granulosa, 
theca (Beers et al., 1975; Canipari and Strickland, 1985; Liu et al., 1987; Ny et
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al., 1985), cumulus, oocyte (Liu et al., 1986) and ovarian surface epithelial cells 
(Colgin and Murdoch, 1997)) are known to produce PA components, which are 
under gonadotropin control (Canipari et al., 1987; Canipari and Strickland, 
1985; O'Connell et al., 1987). Of its many functions, these components are 
involved in angiogenesis-associated proteolysis, such as the transition of the 
unvascularized preantral follicles into mature Graafian follicles (Bacharach et 
al., 1992) and in the regulation of follicular fluid (FF) viscosity, prevention of 
blood clotting during rupture of the follicular wall, thereby preventing 
entrapment of the cumulus-oocyte complex inside the follicle (Canipari and 
Strickland, 1985). Also, the PA-system plays a part in the changing interactions 
between oocyte and cumulus cells important for cumulus expansion, oocyte 
pick-up, fertilization and eventually the ageing of the oocyte (D'Alessandris et 
al., 2001).  
Thus, the PA-system is involved in a variety of reproductive processes in both 
males and females. With the possibilities of the assisted reproductive 
techniques our aim was to gain more insight into the role of the PA-system by: 
(i) measuring uPA, tPA and PAI-1 concentrations in human FF at the day of 
oocyte retrieval, ejaculate and spermatozoa of couples undergoing an IVF or 
ICSI treatment; and (ii) exploring associations between FF and semen PA 
component concentrations and various fertility parameters and the pregnancy 
rate, respectively. 
 
Materials and methods 
 
Patient selection 
From April 2002 until May 2003 all patient couples visiting the fertility clinic of 
the Radboud University Nijmegen Medical Centre were considered for 
participation. The selection criteria for participation comprised the following 
diagnostic categories: (i) idiopathic subfertility, absence of abnormalities in both 
man and woman regarding semen and endocrine analyses, menstrual cycle, 
Chlamydia serology and hysterosalpingogram, but no spontaneous conception 
within 1 year of unprotected intercourse; (ii) female factor subfertility (FFS) 
consisting of endometriosis or Fallopian tube pathology (any condition leading 
to an impediment of oocyte pick-up and transport); or (iii) male factor subfertility
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(MFS) defined by the presence of at least one of the sperm anomalies 
oligozoo-, asthenozoo-, and/or teratozoospermia. Couples with both a male 
and a female factor explaining their subfertility and patients first visiting other 
hospitals for fertility treatment were excluded from the study. Fertile men were 
the partner of a women with Fallopian tube pathology or endometriosis, without 
abnormalities in semen parameters. Fertile women comprised partners of the 
men with MFS, without tube and menstrual cycle abnormalities. 
All material collected was made anonymous in accordance with the guidelines 
of the ethical and institutional board of the Radboud University Nijmegen 
Medical Centre. The patients were notified about the study by brochures 
available in the waiting room of the IVF treatment unit. The materials have 
been collected in accordance with the guidelines of the ethical and institutional 
board of the Radboud University Nijmegen Medical Centre. A total of 156 
couples were enrolled in the study.  
 
Ejaculate and spermatozoa collection 
Participants provided semen samples produced via masturbation, after an 
abstinence period of 3-5 days. The main part of the sample was prepared for 
IVF or ICSI. Two hundred microlitres of the remaining semen sample was 
obtained for semen analysis performed according to the guidelines of the 
World Health Organization (Guzick et al., 2001; World Health Organization, 
1992). The sample was frozen without preservatives and stored at –80 °C until 
assay for uPA, tPA and PAI-1 concentrations.  
The ejaculate provided for the IVF or ICSI procedure (minus the 200 microlitre 
obtained for study purposes) was purified and after isolation the concentration 
and motility of spermatozoa was determined according to the guidelines of the 
WHO and the cells were diluted with culture medium (Human Tubal Fluid, 
Cambrex Company, Belgium). Residual concentrated sperm was collected, 
frozen without preservatives and stored at –80 °C until assay for uPA, tPA, 
PAI-1, and tPA-PAI-1 complex concentrations. 
 
Follicular fluid collection 
After oocyte retrieval for the IVF or ICSI procedure, a sample of the follicular 
fluid (diluted with 10 IU/ml heparin and phosphate buffer, pH 7.4) was
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centrifuged for 10 minutes at 2000 g to separate cells from the fluid. The FF 
was frozen without preservatives and stored at –80 °C until assay for uPA, tPA, 
PAI-1, 17β-estradiol (E2), progesterone and protein concentrations. 
  
Fertility outcome parameters 
The number of follicles grown and the number of follicles > 15 mm were 
determined using ultrasound 2 days before the follicles were punctured. One 
day after the IVF or ICSI procedure, fertilization was determined by counting 
the number of pronuclei in the oocyte. The percentage of fertilized oocytes was 
calculated by dividing the number of oocytes with two pronuclei by the total 
number of oocytes retrieved (IVF), or by the total number of oocytes injected 
(ICSI).  
On the following 2 days, the embryos were examined once a day for 
development. On day 3 the proportion of cleaved embryos (vs. arrested at 2 
pronuclei) was calculated by dividing the number of cleaved embryos by the 
total number of oocytes retrieved (IVF), or the total number of oocytes injected 
(ICSI). Furthermore, embryo quality was established by judgement of 
fragmentation and cleavage activity of the embryos after 3 days of culturing, 
and was denoted as low, moderate, reasonable or high.  
An hCG-based pregnancy test was performed in first-morning voided urine 
from the woman on day 15 after the embryo transfer.  
 
17β-Estradiol, progesterone and protein concentrations in FF 
The concentrations of 17β-E2 and progesterone in FF were measured by 
specific radioimmunoassays described previously by Thomas et al. (1977). The 
protein content of the FF was determined as a biomarker for the maturity of the 
follicle (Spitzer et al., 1996) using the Pierce BCA protein assay reagent kit 
(Pierce, Rockford, IL).  
 
uPA, tPA, PAI-1 and tPA-PAI-1 complex concentrations 
For the measurement of uPA, tPA and PAI-1 in follicular fluid, ejaculate and 
spermatozoa samples, and for the measurement of tPA-PAI-1 complexes in a 
subset of spermatozoa samples we used ELISAs developed by our department 
for components of the plasminogen activation system (Grebenchtchikov et al.,
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1997). To increase the sensitivity of the assays, the colour detection was 
replaced by a fluorometric detection using the biotin-streptavidin-labelled β-
Galactosidase detection as previously described by Manders et al. (2004). The 
spermatozoa samples were frozen in liquid nitrogen and subsequently thawed 
for five times to lyse the spermatozoa before the ELISA was performed. All 
samples were analysed in duplicate.  
 
Statistical analyses 
The fertility outcome parameters were normally distributed and the results are 
expressed as means and standard deviation (SD). The proportion of fertilized 
oocytes, cleaved embryos and mean embryo quality between the different 
diagnostic subgroups were compared using the one-way analysis of variance 
(ANOVA). The number of clinical pregnancies occurring in the different 
subgroups was compared using the Chi-square test.  
Because of the skewed distributions of the PA-component variables measured 
in this study, natural logarithmic transformations were performed and data were 
subsequently expressed as geometrical means and (25th-75th percentiles). The 
uPA, tPA and PAI-1 concentrations between the groups were compared using 
ANOVA. The tPA and tPA-PAI-1 complex concentrations within the different 
subgroups of men were compared using the Paired-Samples T Test. Further 
analyses were carried out by post hoc Bonferroni comparisons. 
In the pooled group of men, Pearson correlations were calculated between the 
concentrations of the PA-system components in the ejaculate and the 
logarithmic transformed semen characteristics of the study. In the pooled group 
of women, Pearson correlations were calculated between the logarithmic 
transformed PA-system component-protein ratios in FF and the study popu-
lation characteristics described in Table II. 
Linear regression analyses were performed in the pooled group of men or 
women to find associations between the dependent fertility outcome 
parameters and the continuous independent uPA, tPA and PAI-1 concen-
trations in the ejaculate, in spermatozoa and in FF. Also, logistic regression 
analyses were carried out in the pooled group of men or women to find 
associations between the dependent variables embryo quality on culture day 3, 
expressed as low-moderate or reasonable-high, achievement of pregnancy
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(yes or no), and uPA, tPA and PAI-1 concentrations in ejaculate, purified 
spermatozoa and FF as the independent continuous variables. Potential 
confounders were included in the linear and logistic regression models; factors 
that substantially affected the association between the dependent variable and 
the PA-system components (causing a change in the regression coefficient of 
more than 10%) were maintained in the final models.  
A P-value of ≤ 0.05 was considered statistically significant. Statistical analyses 
were performed using SPSS 12.0 for Windows software (SPSS Inc, Chicago, 
IL, USA). 
 
Results 
 
Basic characteristics 
The basic characteristics in men and women are summarized in Table I and II, 
respectively. As expected, sperm concentrations and the proportion motility 
were substantially lower in the MFS group as compared to the fertile and 
idiopathic subfertile men. Furthermore, the MFS group displayed a substan-
tially higher proportion of abnormal spermatozoa in the ejaculate compared 
with fertile and idiopathic subfertile men. Women with endometriosis were 
slightly younger as compared to idiopathic subfertile women. In Table III the 
fertility outcome parameters for the different diagnostic subgroups are summa-
rized. All the fertility outcome parameters were comparable between the 
different subgroups.  
 
Table I Characteristics of the male study population  
Characteristics Fertile (n = 52)  IS (n = 52) MFS (n = 52) 
Age (years) 35.0 (32.0-37.7) 35.7 (34.0-38.0) 34.7 (32.0-37.7) 
Volume ejaculate (mL) 2.8 (2.1-3.5) 2.9 (2.2-4.4) 3.3 (2.5-4.8) 
Sperm conc. (x106/ml)  66.1 (45.5-100.0) 55.6 (31.3-100.0) 3.8 (1.2-14.5) 
Motility (%)  56.3 (50.0-65.0) 54.0 (50.0-63.8) 18.9 (10.0-30.0) 
Abnormal cells (%)  78.7 (72.0-87.0) 81.1 (75.0-87.8) 93.0 (89.0-97.0) 
Note: values are given as geometric mean and (25th –75th percentile). IS = idiopathic subfertility, MFS = 
male factor subfertility.  
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Table II Characteristics of the female study population  
Characteristics Fertile (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
Age women (years) 32.8 (30.3-36.0) 34.3 (32.0-36.0) 33.2 (31.0-38.0) 31.5 (29.0-35.3) 
Puregon dose (IU) 179 (150-250) 173 (150-200) 182 (150-300) 170 (144-263) 
E2 in blood (pmol/l) 5114 (3725-7575) 5499 (3925-8350) 5545 (5025-7025) 5603 (4050-8500) 
E2 in FF (nmol/l) 871 (660-1350) 924 (683-1300) 971 (763-1400) 849 (540-1425) 
Prog in FF (µmol/l) 24.7 (19.0-36.8) 27.3 (22.5-35.8) 22.2 (16.0-32.3) 23.5 (19.0-33.0) 
Protein in FF (µg/l) 38.2 (34.0-43.5) 39.1 (35.8-45.8) 38.7 (33.6-47.2) 38.9 (32.7-49.1) 
Follicles (n) 12.0 (9.0-20.8) 14.1 (10.0-21.0) 13.3 (10.8-17.0) 14.4 (13.0-20.3) 
Follicles > 15mm (n) 6.2 (5.0-10.0) 6.5 (5.0-10.0) 7.1 (6.0-9.0) 6.9 (4.8-11.3) 
Oocytes (n) 8.5 (6.0-13.0) 9.2 (7.0-13.8) 8.6 (6.0-13.0) 8.2 (5.8-13.0) 
Note: values are given as geometric mean and (25th –75th percentile). E2 = 17β-estradiol, EM = 
endometriosis, FF = follicular fluid, FTP = Fallopian tube pathology, IS = idiopathic subfertility. 
 
Table III Fertility outcome parameters 
 MFS (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
Fertilization rate (%) 57.5 (28.8) 56.9 (24.5) 60.3 (27.3) 63.9 (25.9) 
Cleavage rate (%) 67.1 (26.3) 67.4 (26.9) 75.5 (20.9) 71.0 (26.5) 
Mean embryo quality 2.06 (0.82) 2.19 (0.72) 2.08 (0.72) 2.08 (0.72) 
No. of pregnancies (%) 15 (30.6) 17 (35.4) 5 (19.2) 13 (52.0) 
Note: values are given as mean and (SD) unless otherwise indicated. EM = endometriosis, FTP = 
Fallopian tube pathology, IS = idiopathic subfertility, MFS = male factor subfertility.  
†
 Embryo quality is scored on a scale of 0 to 3; 0 = low, 1 = moderate, 2 = reasonable and 3 = good 
embryo quality.  
 
uPA, tPA, PAI-1 and tPA-PAI-1-complex concentrations in ejaculate and 
spermatozoa 
The ejaculate showed a much higher tPA concentration compared with the 
uPA and PAI-1 concentrations (Table IV). The concentrations of these three 
PA components in ejaculate were not significantly different between fertile 
men, idiopathic subfertile men or men with MFS. No PA components could be 
detected in the collected suspension of purified spermatozoa, but after freeze-
thawing for five times tPA could be detected in small amounts, while uPA and 
PAI-1 remained below the lower level of detection in spermatozoa.  
The spermatozoa of men with MFS contained significantly higher concen-
trations of tPA compared with fertile and idiopathic subfertile men, geometrical 
mean: 162.7 pg/ml (25th-75th percentile (105.0-321.0), 38.0 pg/ml (25.5-99.9) 
and 37.2 pg/ml (23.9-97.5), respectively, P < 0.001). Because men with MFS 
had much lower sperm concentrations, we corrected for the number
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of spermatozoa in the purified semen sample resulting in an increased 
difference between subfertile and fertile men. Subfertile and fertile men showed 
concentrations of approximately 70 pg tPA/million spermatozoa and 2 pg 
tPA/million spermatozoa (P < 0.001) (mean difference 3.70, (95% CI 2.92-
4.48); Bonferroni, P < 0.001), respectively. In idiopathic subfertile men the 
concentration was around 3 pg tPA/million spermatozoa (P < 0.001) (mean 
difference 3.20, (95% CI 2.42-3.98); Bonferroni P < 0.001).  
Because the ELISA we used for the determination of tPA in the spermatozoa 
does not differentiate between active tPA and inactive tPA-PAI-1 complexes, it 
is possible that the tPA measured is an inactive complexed form. To 
investigate this further we measured the tPA-PAI-1 complexes with a specific 
ELISA. The tPA-PAI-1 complex concentrations were comparable in fertile and 
idiopathic subfertile men, however, spermatozoa of men with MFS contained 
significantly more tPA-PAI-1 complex (Table V) Furthermore, spermatozoa of 
subfertile men contained significantly higher total tPA concentrations as 
compared to the tPA-PAI-1 complex concentrations. 
 
Table IV Plasminogen activation component concentrations in men  
 Fertile (n = 52) IS (n = 52) MFS (n = 52) 
Total ejaculate 
(ng/ml) 
uPA  
tPA 
PAI-1  
24.0 (18.0-30.0) 
178.6 (100.4-254.6) 
3.99 (3.14-4.74) 
25.6 (21.7-30.3) 
203.9 (110.8-312.0) 
4.14 (3.13-5.51) 
22.6 (19.3-27.8) 
169.4 (95.4-262.9) 
3.60 (2.31-5.23) 
Spermatozoa 
(pg/million cells) 
uPA  
tPA  
PAI-1  
 n.d. 
1.91 (0.74-5.79) 
 n.d. 
n.d 
3.14 (0.97-9.97) 
 n.d. 
n.d. 
77.1 (31.8-211.2)a 
n.d. 
Note: values are given as geometric mean and (25th and 75th percentile). a P < 0.001 in Oneway 
ANOVA. IS = idiopathic subfertility, MFS = male factor subfertility, n.d. = non detectable (below 
detection limit).  
 
Table V Tissue-type PA and tPA-PAI-1 complex concentrations in 
spermatozoa  
PA-components Fertile (n = 11)  IS (n = 10) MFS (n = 9) 
pg tPA/million cells 2.12 (1.30-3.00) 3.39 (2.41-5.18) 70.5 (56.2-85.1)a 
tPA-PAI-1 complex (pg/ml) 56.1 (49.0-78.0) 58.9 (41.3-89.5) 61.9 (45.5-78.5)b 
pg tPA-PAI-1 complex/million cells 2.09 (0.98-3.67) 3.07 (1.92-4.65) 24.8 (15.5-46.8)a,b 
Note: values are given as geometric mean and (25th and 75th percentile). a P < 0.001 in Oneway 
ANOVA, for comparison between the three diagnostic subgroups. b P = 0.003 in Paired-Samples T Test, 
for comparison between tPA and tPA-PAI-1 complex concentrations within the three diagnostic 
subgroups. IS = idiopathic subfertility, MFS = male factor subfertility. 
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uPA, tPA, and PAI-1 concentrations in FF 
In the FF, PAI-1 concentrations are much higher than the uPA and tPA 
concentrations (Table VI). Although, the uPA and PAI-1 concentrations were 
not significantly different between the four diagnostic subgroups, a trend was 
shown for higher tPA concentrations in FF of women with Fallopian tube 
pathology or endometriosis (one-way ANOVA, P = 0.07).  
 
Table VI Plasminogen activation component concentrations in follicular fluid  
PA-components Fertile (n = 52)  IS (n = 52) FTP (n = 26) EM (n = 26) 
pg uPA/mg protein 
ng PAI-1/mg protein 
pg tPA/mg protein 
6.48 (5.04-6.89) 
7.19 (5.69-10.1) 
14.3 (10.3-17.6)  
6.74 (4.77-8.86) 
7.78 (5.90-10.7) 
13.9 (9.5-17.8) 
5.96 (4.88-6.98) 
6.70 (4.94-8.98) 
18.5 (11.4-25.7) 
8.03 (4.97-9.70) 
6.94 (5.02-8.71) 
18.8 (11.4-27.1) 
Note: values are given as median and (25th and 75th percentile). EM = endometriosis, FTP = Fallopian 
tube pathology, IS = idiopathic subfertility. 
 
Correlations between the PA-system components and basic 
characteristics 
No significant correlations were observed between uPA and tPA in the 
ejaculate and age, spermatozoa concentration, motility percentage and 
percentage abnormal cells. However, PAI-1 in the ejaculate was correlated 
with age (r = 0.21; P = 0.01) and with sperm concentration (r = 0.19; P = 0.02). 
The uPA concentration in FF was inversely correlated with age, number of 
follicles grown, number of follicles larger than 15 mm, number of collected 
oocytes and the concentration of progesterone in FF (Table VII). The PAI-1 
concentration was inversely correlated with the Puregon dose received, 
positively correlated with the number of follicles grown, and the number of 
collected oocytes. Finally, tPA was inversely correlated with age, number of 
collected oocytes, and the concentration of progesterone in FF.  
 
Associations between the PA-system components and outcome 
parameters 
None of the components of the PA-system were significantly associated with 
oocyte fertilization, cleavage or embryo quality, investigated with linear and 
logistic regression analyses. However, tPA concentration in the spermatozoa 
was significantly associated with pregnancy. Confounders included in the 
logistic regression model were the three semen parameters, age, the propor-  
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Table VII Pearson correlation coefficients between the natural logarithms of the 
components of the PA-system in FF and basic characteristics of the pooled 
data of 156 women 
 uPA (pg/mg protein) tPA (pg/mg protein) PAI-1 (ng/mg protein) 
Age (years) -0.20 (0.01) -0.34 (< 0.001) -0.05 (0.52) 
Puregon dose (IU) 0.04 (0.65) -0.15 (0.06) -0.21 (0.01) 
E2 in serum (pmol/l) -0.13 (0.10) -0.01 (0.88) 0.01 (0.91) 
E2 in FF (nmol/l) -0.13 (0.12) -0.15 (0.07) -0.11 (0.16) 
Prog in FF (µmol/l) -0.40 (< 0.001) -0.56 (< 0.001) 0.10 (0.21) 
Follicles (n) -0.18 (0.02) 0.01 (0.90) 0.24 (0.003) 
Follicles > 15mm (n) -0.16 (0.04) 0.001 (0.99) 0.13 (0.12) 
Oocytes (n) -0.29 (< 0.001) -0.16 (0.05) 0.26 (0.001) 
Note: data are given as r-value (P-value). E2 = 17ß-estradiol; FF = follicular fluid. 
 
tion of fertilized oocytes, the proportion of cleaved embryos, mean embryo 
quality and the artificial reproduction method IVF or ICSI. The OR for tPA was 
0.995 with a 95% confidence interval (0.991-1.000) (P = 0.03). Because tPA is 
a continuous variable in the logistic regression analyses, the height of the OR 
is dependent on the dimension of tPA and can be illustrated as follows: A mean 
decrease in the spermatozoa tPA concentration of around 125 pg/ml (the 
difference between the fertile and subfertile group) results in a nearly 2-fold 
increased probability to achieve pregnancy after an IVF or ICSI procedure, 
calculated using the formula OR = eβ x 0.125 with β = -4.621. 
Also, for the female parameters tPA seemed to be important. The concen-
tration of tPA in the FF was significantly associated with the proportion of 
cleaved embryos on day 3. Confounders included in this linear regression 
model were the proportion of fertilized oocytes and the progesterone 
concentration in FF. The adjusted regression coefficient for tPA and proportion 
of embryo cleavage was 0.16 (P < 0.001). The tPA concentration in FF, 
however, was not significantly associated with the probability to become 
pregnant after an IVF or ICSI procedure. 
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Discussion 
 
Male study population We demonstrate that the mean tPA concentration in 
spermatozoa of men with MFS and undergoing an IVF or ICSI procedure is 
significantly higher than in fertile and idiopathic subfertile men. Moreover, 
spermatozoa of subfertile men possessed higher concentrations of tPA-PAI-1 
complexes compared with the other 2 groups thereby suggesting increased 
complex formation in response to the overload of tPA. As the tPA 
concentrations measured in fertile and idiopathic subfertile men were 
predominantly in the inactive complex form, spermatozoa of men in the MFS 
group contained some inactive tPA-PAI-1 complexes, but most of the tPA 
measured was in the free and therefore active form. Even more interesting, 
fertile men with lower tPA concentration in spermatozoa have about a 2-fold 
increased chance of pregnancy after an IVF or ICSI procedure.  
Our observations are supported by those of others. Maier et al. observed signi- 
ficantly higher tPA concentrations in spermatozoa of patients with oligo-
asthenoteratozoospermia (OAT-syndrome) than in normozoospermic men 
(Maier et al., 1991). Moreover, the tPA concentrations in the ejaculate were 
also significantly higher compared with uPA, and the tPA and uPA 
concentrations in the ejaculate were comparable between normozoospermic 
and oligozoospermic men (Maier et al., 1991). This is in accordance with the 
findings of Arnaud et al. (1994).  
Considering the tPA and uPA activity in seminal plasma, Liu et al. (1996b) 
observed a significantly increased activity of these 2 factors in seminal plasma 
of 6 infertile compared with 4 fertile men. Furthermore, Maier et al. found uPA 
concentrations and PAI-1 activity in spermatozoa (Maier et al., 1991), while we 
did not detect these 2 components in our spermatozoa samples. However, we 
did observe tPA-PAI-1 complexes in spermatozoa indicating that PAI-1 has 
been present in the samples. Other authors report the presence of uPA, tPA 
and PAI-1 on human spermatozoa outer acrosomal and plasma membranes 
also using ELISA (Huang et al., 1997; Smokovitis et al., 1992). The differences 
between the results in our study in comparison with the results of others could 
be due to differences in detection limits of the assays, the different methods of 
spermatozoa washing and lysing, and differences in number and selection of 
patients and controls.  
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Regarding the correlations between the PA-components and semen 
characteristics only the PAI-1 concentration in the ejaculate was positively 
correlated with the sperm concentration. Other groups, however, found either 
no correlations between the PA-system components and semen parameters 
(Arnaud et al., 1994), or significant positive correlations between uPA in 
spermatozoa and sperm motility (Huang et al., 1997), and between PA activity, 
measured as the ability of the purified PAs to lyse fibrin, in seminal plasma, 
and immotility and azoospermia (Liu et al., 1996b). 
Although the pregnancy rate was only slightly higher in couples with lower tPA 
concentrations in spermatozoa, this effect was significant, and extremely 
interesting, since it may indicate a paternal influence on achieving pregnancy. 
To our knowledge we are the first reporting the association between tPA in 
spermatozoa and the chance of pregnancy after artificial reproduction 
techniques.  
 
Female study population 
Our study demonstrates a relative abundance of PAI-1 in FF compared with 
tPA and uPA concentrations. This is in concordance with observations made 
by Jones et al. (1989). These authors examined the presence of active (i.e., 
free) tPA and inactive tPA-PAI-1 complexes and found that the tPA measured 
is only present as tPA-PAI-1 complex (Jones et al., 1989). We could not verify 
this in our samples, but believe that it is very likely that the tPA concentrations 
measured indeed reflect inactive tPA considering the much higher free PAI-1 
concentrations as compared to the total tPA concentrations measured in FF.  
Another interesting result of our study is the apparently increased tPA 
concentration in the FF of women with FFS, Fallopian tube pathology and 
endometriosis. This has not been reported before and it is interesting to note 
that there is a trend towards higher FF tPA concentrations in women with 
Fallopian tube pathology as well as in women with endometriosis, since the 
pathogenesis of these 2 conditions is very different.  
We observed several correlations between uPA and PAI-1 in FF and fertility 
parameters in women undergoing the IVF treatment. We found a negative 
correlation between uPA and follicle number, oocyte number, and 
progesterone concentration in FF as a marker of follicular luteinization. This 
was unexpected as uPA has a function in angiogenesis-associated proteolysis,
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turning unvascularized preantral follicles into mature and highly vascularized 
Graafian follicles. 
Furthermore, our results indicate that tPA concentration in the FF is a 
significant predictor of the proportion of cleaved embryos on culture day 3. We 
are aware that the tPA measured in FF is probably tPA-PAI-1 complex, but this 
may still indirectly reflect the level of the original active tPA. Contrasting results 
are found regarding the relationship between PA and embryo cleavage. Rom et 
al. observed higher PA-activity in follicles yielding oocytes that did not cleave in 
vitro (Rom et al., 1987). Similar to our results is their finding that PA activity in 
FF cannot distinguish pregnant from non-pregnant cycles in IVF procedures 
(Rom et al., 1987). 
Other authors believe that measurement of tPA in FF has potential as a 
predictive parameter in clinical practice (Deutinger et al., 1988; Milwidsky et al., 
1989). Deutinger et al. observed higher levels of tPA in granulosa cell lysates 
of fertilized oocytes as compared to their unfertilized counterparts (Deutinger et 
al., 1988), while Milwidsky et al. (1989) found significantly higher PA-activity in 
FF from follicles yielding fertilized oocytes in an IVF program as compared to 
the PA-activity in FF from follicles yielding non-fertilized oocytes. In our 
material, we could not find any association between FF PA-content and the 
percent rate of fertilization in the retrieved oocytes.  
 
Some limitations of the present study have to be addressed. The FF samples 
collected were pooled samples from different follicles. Therefore, it may be 
incorrect to directly correlate the FF PA concentrations to the development of a 
specific follicle or embryo which may explain the absence of associations 
between FF PA concentrations and fertility outcome parameters. Also, data 
regarding the percentage of fertilized oocytes are influenced by the fact that the 
number of oocytes retrieved in conventional IVF patients included immature 
oocytes, whereas in ICSI cases, only the number of mature oocytes are in the 
denominator. Aside from the fact that in ICSI patients the oocytes are injected 
with a spermatozoon, the difference in maturity of the oocytes in the 
denominator of this variable may contribute to the higher fertilization rate in 
ICSI patients.  
The strengths of our study as compared to other studies in literature is the 
investigation of a relatively large number of couples, man and women, who are
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involved in an IVF or ICSI procedure. We only included couples who were 
unable to achieve a spontaneous conception within 1 year of regular, 
unprotected intercourse. Women with menstrual disorders were excluded, as 
were couples with both a male and a female factor explaining their subfertility, 
or patients with multiple causes for subfertility within 1 individual. 
 
Conclusion 
Subfertile men showed significantly higher mean tPA concentrations in 
spermatozoa compared with fertile men. Interestingly, a positive paternal 
influence on pregnancy rate was demonstrated in couples by significantly lower 
tPA concentrations in spermatozoa.  
A trend was observed towards higher tPA-protein ratios in FF of women 
with Fallopian tube pathology and endometriosis as compared to fertile and 
idiopathic subfertile women. Moreover, the tPA concentration in the FF 
were significantly associated with the proportion of cleaved embryos on 
culture day 3. Further studies are needed to investigate the validity and 
impact of these associations in the prediction of successful artificial 
reproduction techniques in clinical practice. 
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Abstract 
 
Background: Vascular endothelial growth factor (VEGF) is a mitogenic and 
permeability increasing growth factor which also seems to have important 
functions in human reproduction. Our aim was to investigate associations 
between VEGF concentrations in fluids involved in reproduction in men and 
women and fertility outcome parameters. 
Methods: We enrolled 156 couples undergoing assisted reproduction 
techniques and determined VEGF concentrations in the ejaculate, purified 
spermatozoa and follicular fluid (FF) and correlated the concentrations to the 
fertility outcome parameters percentage of cleaved embryos on culture day 3, 
embryo quality and pregnancy rate.  
Results: VEGF concentrations in ejaculate and FF were comparable between 
the diagnostic subgroups. However, VEGF concentrations in spermatozoa from 
men with male factor subfertility (geometrical mean 73.9 pg/million 
spermatozoa, 25th-75th percentile (37.5-176.2) were significantly higher as 
compared to those in fertile (4.6 (1.7-9.3) and idiopathic subfertile men (6.4 
(1.8-14.0), P < 0.001)). High VEGF concentrations in the ejaculate tend to be 
negatively associated with the percentage of cleaved embryos on culture day 3 
(r = -0.08, P = 0.06). In addition VEGF concentrations in spermatozoa were 
positively associated with embryo quality (OR = 0.17, P = 0.09), and pregnancy 
rate (OR = 0.07, P = 0.06). No significant associations were found between 
VEGF concentrations in FF and fertility outcome parameters.  
Conclusions: VEGF in spermatozoa may be a new biomarker for subfertility. 
Of interest are the potential associations between VEGF in spermatozoa and 
ejaculate and various fertility outcome parameters, which supports the need for 
more research in this field. 
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Introduction 
Vascular endothelial growth factor (VEGF) also called vascular permeability 
factor (VPF), is a protein produced by many different tissues in response to 
hypoxia, with the endothelial cell as its main target (Shweiki et al., 1992; Keck 
et al., 1989). Its actions are mostly mitogenic and permeability-increasing 
(Senger et al., 1990). At least five different human VEGF isoforms are known, 
resulting from alternative splicing of the VEGF gene on chromosome 6. These 
splice variants consist of 121, 145, 165, 189, and 206 amino acids and have 
surprisingly identical biological activities whereas others have demonstrated 
that VEGF-A isoforms differ in angiogenic properties (Ferrara and Davis-
Smyth, 1997; Küsters et al., 2003).  
VEGF is best known for its actions in tumour-induced angiogenesis (Kim et al., 
1993), but it also seems to have important functions in male and female 
reproduction.  
In the male reproductive organs VEGF is expressed by Leydig and Sertoli cells 
of the testis and in the prostate and seminal vesicle epithelium (Ergun et al., 
1997; Ergun et al., 1998). Prostate and seminal vesicles seem to be the main 
source of VEGF, resulting in very high concentrations of VEGF in seminal 
plasma, even exceeding the highest concentration of VEGF measured so far in 
malignant effusions (Brown et al., 1995;Yeo et al., 1993). The exact role of 
VEGF in seminal plasma is currently unknown, but the presence of very high 
concentrations in seminal plasma argues for an important role in male fertility 
and reproduction.  
One study showed that the concentration of VEGF in seminal plasma 
correlated with the chance of pregnancy in patients undergoing assisted 
reproduction techniques (Obermair et al., 1999). Furthermore, these authors 
could localize a VEGF-receptor on the spermatozoa themselves, indicating that 
spermatozoa could be a target for the high VEGF concentrations in seminal 
plasma (Obermair et al., 1999). Also, VEGF-receptors were localized on Leydig 
and Sertoli cells (Ergun et al., 1997). Other authors found that overexpression 
of VEGF in male mice resulted in a disruption of sperm maturation and male 
infertility (Korpelainen et al., 1998; Huminiecki et al., 2001).  
In the female reproductive organs periodical growth and regression of tissues 
is regarded as a physiological process involved in normal reproduction, in 
which angiogenesis is necessary (Reynolds et al., 1992; Christenson and
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Stouffer, 1996). Several studies have indicated that VEGF is involved in 
angiogenesis. Especially the increase in vascular supply of the ovary, 
important for folliculogenesis, ovulation of the dominant follicle and subsequent 
formation of the corpus luteum seems to be mediated by VEGF (Shweiki et al., 
1993; Koos, 1995; Ferrara et al., 1998).  
Both granulosa and theca cells of the ovary produce VEGF (Kamat et al., 1995; 
Gordon et al., 1996) and the production of VEGF is increased in response to 
FSH, LH and hCG (Dissen et al., 1994; Neulen et al., 1995). Therefore, women 
undergoing assisted reproduction, receiving gonadotropin stimulation 
demonstrate very high concentrations of VEGF in the follicular fluids (Ferrari et 
al., 2006). Furthermore, the development of ovarian hyperstimulation syndrome 
(OHSS) has been related to the overproduction of VEGF by the multiple 
formed corpora lutea (Abramov et al., 1997; Ludwig et al., 1999). 
The significance of VEGF concentrations in follicular fluid (FF) is unknown. 
Some authors suggest that high VEGF concentrations in FF reflect high 
vascularization and therefore oxygenation of the follicle, which results in 
“healthy” oocytes with superior pregnancy potential (Van Blerkom 1998). This 
is in contrast to others claiming that high VEGF concentrations in FF reflect 
follicular hypoxia and is therefore a marker of a hostile follicular environment, 
resulting in oocytes with diminished pregnancy potential (Friedman et al., 1998; 
Barroso et al., 1999; Malamitsi-Puchner et al., 2001).  
From this background, the aims of the current study were: (i) to measure VEGF 
concentrations in the ejaculate and purified spermatozoa and in FF at the day 
of oocyte retrieval of a relatively large number of couples undergoing an IVF or 
ICSI treatment; (ii) to determine whether differences exist in the VEGF 
concentrations between different diagnostic subfertile subgroups; and (iii) to 
explore associations between semen and FF VEGF concentrations and fertility 
outcome parameters. 
 
Materials and Methods 
 
Patient selection 
From April 2002 until May 2003, all patient couples visiting the fertility clinic of 
the Radboud University Nijmegen Medical Centre were considered for 
participation. The selection criteria for participation comprised the following
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diagnostic categories: (i) idiopathic subfertility, absence of abnormalities in both 
man and woman regarding semen and edocrine analyses, menstrual cycle, 
Chlamycia serology and hysterosalpingogram, but no spontaneous conception 
within 1 year of unprotected intercourse; (ii) female factor subfertility (FFS) 
consisting of endometriosis or Fallopian tube pathology (any condition leading 
to an impediment of oocyte pick-up or transport); or (iii) male factor subfertility 
(MFS) defined by the presence of at least one of the sperm anomalies 
oligozoo-, asthenozoo-, and/or teratozoospermia. Couples with both a male 
and a female factor explaining their subfertility and patients first visiting other 
hospitals for fertility treatment were excluded from the study. The group of 
fertile men was defined as the male partners without abnormal semen 
parameters of the women suffering from Fallopian tube pathology or 
endometriosis. The group of fertile women without tubal and menstrual cycle 
abnormalities comprised the partners of the men with MFS.  
All materials collected were anonymized. The patients were notified about the 
study by brochures available in the waiting room of the IVF treatment unit. 
Information was given on the background and objectives of the study, inclusion 
criteria, study periods and other relevant procedures. It was acknowledged that 
the decision whether or not to participate in the study would neither interfere 
nor have any consequences for the IVF or ICSI treatment.  
The materials have been collected in accordance with the guidelines of the 
ethical and institutional board of the Radboud University Nijmegen Medical 
Centre. 
A total of 156 couples were enrolled in the study and information concerning 
age, smoking behaviour, type of treatment (IVF or ICSI), 17β-estradiol (E2) 
concentration in serum of the women and FSH dose (Puregon, Organon, Oss, 
The Netherlands) administered for ovarian stimulation treatment was made 
available from the medical records. 
 
Ejaculate and spermatozoa collection 
Participants provided the ejaculates in polypropylene containers produced via 
masturbation at home or in the hospital, after an abstinence period of 3-5 days. 
After liquefaction for 20 minutes, the total volume was measured and the main 
part of the sample was prepared for IVF or ICSI. Two hundred microlitres of the 
remaining semen sample was obtained for semen analysis and VEGF
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measurements. Semen analysis was performed according to the guidelines of 
the World Health Organization (Guzick et al., 2001; World Health Organization, 
1992). Thus, sperm concentration was determined using a Makler counting 
chamber, designed in a 10-by-10 compartments frame format. Motility was 
expressed as the proportion of motile spermatozoa, and morphology was 
determined after incubation of the sample with trypsin (10 minutes at room 
temperature), staining with methylene blue/eosin, feathering, and fixation by 
flame. The sample was frozen without preservatives and stored at –80 °C until 
assay for VEGF concentrations.  
The ejaculate provided for the IVF or ICSI procedure (minus the 200 microlitre 
obtained for this study) was purified by means of centrifugation on 80% Pure 
Sperm reagent (Nidacon International AB, Sweden). After isolation, the 
concentration and motility of spermatozoa was determined according to the 
guidelines of the WHO. In the following step, the spermatozoa were diluted 
with culture medium (Human Tubal Fluid, Cambrex Company, Belgium) to the 
concentrations required for the IVF or ICSI procedure. Residual concentrated 
sperm was collected, frozen without preservatives and stored at –80 °C until 
assay for VEGF concentrations. 
 
Follicular fluid collection 
After oocyte retrieval for the IVF or ICSI procedure, a sample of the FF (diluted 
with 10 IU/ml heparin, and phosphate buffer, pH 7.4) was centrifuged for 10 
minutes at 2000 g to separate red blood cells, leukocytes and granulosa cells 
from the FF. The FF was frozen without preservatives and stored at –80 °C 
until assay for VEGF, 17β-E2, progesterone and protein concentrations.  
 
Fertility outcome parameters 
The number of follicles and the number of follicles > 15 mm were determined 
by using ultrasound 2 days before the follicles were punctured. One day after 
the IVF or ICSI procedure, fertilization was determined by counting the number 
of pronuclei formed in the oocyte. The percentage of fertilized oocytes was 
calculated by dividing the number of oocytes with two pronuclei by the total 
number of oocytes retrieved (IVF), or by the total number of oocytes injected 
(ICSI).
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On the following 2 days, the embryos were examined once a day for their 
development. On day 3 the proportion of cleaved embryos was calculated 
following division of the number of cleaved embryos by the total number of 
oocytes retrieved (IVF) or the total number of oocytes injected (ICSI). On the 
following 2 days, the embryos were examined once a day for development. 
The proportion of cleaved embryos was calculated following division of the 
number of celaved embryos on day 3 by the total number of oocytes retrieved 
(IVF) or the total number of oocytes injected (ICSI). Furthermore, embryo 
quality was established by judgment of fragmentation and cleavage activity of 
the embryos after 3 days of culturing and was denoted as low, moderate, 
reasonable or high.  
An hCG-based pregnancy test was performed in first-morning voided urine 
from the woman on day 15 after the embryo transfer. The result of this test was 
communicated by phone to the personnel of the fertility clinic. 
 
17β-Estradiol and progesterone in FF 
The concentrations of 17β-E2 and progesterone in FF were measured by a 
specific procedure described previously (Thomas et al., 1977). Fifty microlitres 
of a FF specimen was extracted twice with diethylether, and after drying, the 
residue containing 17β-E2 and progesterone was further purified by 
chromatography on Sephadex LH-20 columns. The steroids were quantified by 
specific radioimmunoassays. 
 
Protein concentration in FF 
The FFs were assayed for protein concentration using the Pierce BCA Protein 
Assay reagent kit (Pierce, Rockford, IL). Absorptions were read at 540 nm in 
an automatic microtiter plate reader (Multiskan Ascent, Labsystems). The 
protein content of the follicle was determined as a biomarker for the maturity of 
the follicle (Spitzer et al., 1996).  
 
VEGF concentrations 
Vascular endothelial growth factor concentrations were measured in ejaculate, 
purified spermatozoa, and FF samples using a four-stage/two-site ELISA as 
described previously by Manders et al. (2003). This assay is based on a combi- 
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nation of four polyclonal antibodies (raised in four different animal species 
including duck, chicken, rabbit and goat), which were employed in a sandwich 
assay form. The polyclonal antibodies raised in chickens and rabbits are 
specifically directed against VEGF. To increase the sensitivity of the assay, the 
colour detection was replaced by a fluorometric detection using the biotin-
streptavidin-labelled β-Galactosidase detection. The spermatozoa samples 
were frozen in liquid nitrogen and subsequently thawed, for five times to lyse 
the spermatozoa (checked under a microscope) before the ELISA was 
performed. Furthermore, prior to the analysis the total ejaculate samples were 
diluted 3,200- and 6,400-fold, the spermatozoa samples were diluted 5-fold, 
and the FF samples were diluted 20- and 40-fold. All samples were analysed in 
duplicate. In the VEGF assay distinct molecular forms of VEGF are measured. 
There is no cross-reactivity with VEGF B, VEGF C, VEGF D, Platelet Derived 
Growth Factor AB (PDGF AB), Insulin Growth Factor type 1 (IGF-1), human 
Growth Factor (hGH), Placental Growth Factor (PGF), Nerve Growth Factor 
(NGF), Tumor Necrosis Factor (TNF-alpha) and Transforming Growth Factor 
(TGF). The analytical sensitivity for VEGF is 0.005 ng/ml, whereas the 
functional sensitivity for VEGF amount to 0.010 ng/ml. For VEGF the within-run 
CV and between-run CV are found to be 4.3% and 11.6%, respectively. 
 
Statistical analyses 
The fertility outcome parameters were normally distributed and the results are 
expressed as means and standard deviation (SD). The proportion of fertilized 
embryos, cleaved embryos and mean embryo quality between the different 
diagnostic subgroups were compared using the one-way analysis of variance 
(ANOVA). The number of clinical pregnancies occurring in the different 
subgroups was compared using the Chi-square test.  
Because of the skewed distributions of the VEGF concentrations measured in 
this study, natural logarithmic transformations were performed and data are 
expressed as geometrical means and 25th-75th percentiles. The VEGF 
concentrations between groups were compared using one-way analysis of 
variance (ANOVA) and further analysed using post hoc Bonferroni 
comparisons.  
In the pooled group of men, Pearson correlations were calculated between the 
natural logarithmic transformed VEGF concentrations in the ejaculate and the
VEGF and human reproduction 
 
 
161 
logarithmic transformed characteristics of the study population, age, sperm 
concentration, motility percentage and percentage abnormal cells. In the 
pooled group of women, Pearson correlations were calculated between the 
logarithmic transformed VEGF-protein ratios in FF and the study population 
characteristics described in Table II.  
Linear regression analyses were performed in the pooled group of men or 
women to find associations between the different fertility outcome parameters, 
being the proportion of oocytes fertilized and the proportion of cleaved embryos 
on culture day 3 as the dependent variables and the VEGF concentrations in 
the ejaculate, in purified spermatozoa and in FF as the independent variables. 
Also, logistic regression analyses were carried out in the pooled group of men 
or women to find associations between the dependent variables such as 
embryo quality on culture day 3 (expressed as low-moderate, or reasonable-
high), and achievement of pregnancy (yes or no) and the independent 
continuous variables such as VEGF concentrations in ejaculate, purified 
spermatozoa and FF. Potential confounders were included in the linear and 
logistic regression models, and the factors that substantially affected the 
association between the dependent variable and the VEGF concentration 
variable (a change in the regression coefficient of more than 10%) were 
maintained in the final models. 
A P-value of ≤ 0.05 was considered statistically significant. Statistical analyses 
were performed using SPSS 12.0 for Windows software (SPSS Inc, Chicago, 
IL, USA). 
 
Results 
The basic characteristics of the male study group are summarized in Table 
I. Age of the subjects and the volume of the ejaculate were comparable 
between the three groups. As expected, sperm concentration, motility and 
morphology were substantially different in the male factor subfertility (MFS) 
group as compared to the fertile and idiopathic subfertile men.  
The basic characteristics of the female study group are summarized in Table II. 
The only difference between the four diagnostic subgroups was age. Women 
with endometriosis were slightly younger as compared to idiopathic subfertile 
women.  
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Table I Characteristics of the male study population 
Characteristics Fertile (n = 52) IS (n = 52) MFS (n = 52) 
Age (years) 35.0 (32.0-37.7) 35.7 (34.0-38.0) 34.7 (32.0-37.7) 
Volume ejaculate (mL) 2.8 (2.1-3.5) 2.9 (2.2-4.4) 3.3 (2.5-4.8) 
Sperm conc (x106/ml) 66.1 (45.5-100.0) 55.6 (31.3-100.0) 3.8 (1.2-14.5) 
Motility (%) 56.2 (50.0-65.0) 54.0 (50.0-63.8) 18.9 (10.0-30.0) 
Abnormal cells (%) 78.7 (72.0-87.0) 81.1 (75.0-87.8) 93.0 (89.0-97.0) 
Note: values are given as geometrical mean and (25th –75th percentile). IS = idiopathic subfertility, MFS 
= male factor subfertility. 
 
Table II Characteristics of the female study population  
Characteristics Fertile (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
Age women (years) 32.8 (30.3-36.0) 34.3 (32.0-36.0) 33.2 (31.0-38.0) 31.5 (29.0-35.3) 
Puregon dose (IU) 179 (150-250) 173 (150-200) 182 (150-300) 170 (144-263) 
E2 in blood (pmol/l) 5114 (3725-7575) 5499 (3925-8350) 5545 (5025-7025) 5603 (4050-8500) 
E2 in FF (nmol/l) 871 (660-1350) 924 (683-1300) 971 (763-1400) 849 (540-1425) 
Prog in FF (µmol/l) 24.7 (19.0-36.8) 27.3 (22.5-35.8) 22.2 (16.0-32.3) 23.5 (19.0-33.0) 
Protein in FF (µg/l) 38.2 (34.0-43.5) 39.1 (35.8-45.8) 38.7 (33.6-47.2) 38.9 (32.7-49.1) 
Follicles (n) 12.0 (9.0-20.8) 14.1 (10.0-21.0) 13.3 (10.8-17.0) 14.4 (13.0-20.3) 
Follicles > 15mm (n) 6.2 (5.0-10.0) 6.5 (5.0-10.0) 7.1 (6.0-9.0) 6.9 (4.8-11.3) 
Oocytes (n) 8.5 (6.0-13.0) 9.2 (7.0-13.8) 8.6 (6.0-13.0) 8.2 (5.8-13.0) 
Note: values are given as geometric mean and (25th –75th percentile. E2 = 17β-estradiol, FF = follicular 
fluid, FTP = Fallopian tube pathology, IS = idiopathic subfertility, EM = endometriosis.  
 
 
In Table III the fertility outcome parameters for the different subgroups are 
summarized. All the fertility outcome parameters were comparable between the 
different subgroups. 
 
Table III Fertility outcome parameters 
 MFS (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
Fertilization rate (%) 57.5 (28.8) 56.9 (24.5) 60.3 (27.3) 63.9 (25.9) 
Cleavage rate (%) 67.1 (26.3) 67.4 (26.9) 75.5 (20.9) 71.0 (26.5) 
Mean embryo quality † 2.06 (0.82) 2.19 (0.72) 2.08 (0.72) 2.08 (0.72) 
No. of pregnancies (%) 15 (30.6) 17 (35.4) 5 (19.2) 13 (52.0) 
Note: values are given as mean and (SD) unless otherwise indicated. EM = endometriosis, FTP = 
Fallopian tube pathology, IS = idiopathic subfertility, MFS = male factor subfertility.  
†
 Embryo quality is scored on a scale of 0 to 3; 0 = low, 1 = moderate, 2 = reasonable and 3 = good 
embryo quality. 
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The VEGF concentrations measured in the ejaculate and spermatozoa are 
presented in Table IV. The VEGF concentrations in ejaculate were comparable 
between the three diagnostic subgroups. Furthermore, VEGF concentrations in 
the ejaculate were much higher than the concentrations in spermatozoa. The 
VEGF concentrations measured in spermatozoa were below the detection limit 
in 11 fertile men, 14 idiopathic subfertile men, and 8 oligoasthenoteratozoo-
spermic men, thus 33 out of 156 samples.  
 
Table IV VEGF concentrations in ejaculate and spermatozoa 
 Fertile (n = 52) IS (n = 52) MFS (n = 51) 
VEGF in ejaculate (ng/ml) 945 (640-1318) 1025 (755-1288) 905 (693-1176) 
VEGF in spermatozoa (ng/ml) 0.09 (0.04-0.23) 0.08 (0.02-0.19) 0.16 (0.11-0.32)a 
VEGF in spermatozoa (pg/million cells) 4.6 (1.7-9.3) 6.4 (1.8-14.0) 73.9 (37.5-176.2)b 
Note: values are given as geometrical mean and (25th and 75th percentile). ). a P = 0.005, b P < 0.001 in 
Oneway ANOVA. IS = idiopathic subfertility, MFS = male factor subfertility. One missing case in the 
MFS group. 
 
Spermatozoa of men in the MFS group contained significantly higher VEGF 
concentrations per million spermatozoa (geometrical mean 73.9 (25th-75th 
percentile 37.5-176.2) compared with the concentrations in fertile men (4.6 
(1.7-9.3), and in idiopathic subfertile men (6.4 (1.8-14.0); (P < 0.001 in one-way 
ANOVA). Post hoc Bonferroni comparisons revealed that VEGF concentrations 
in spermatozoa of men in the MFS group were significantly higher compared 
with both fertile (mean difference 2.78, (95% CI 2.04-3.51); Bonferroni, P < 
0.001), and idiopathic subfertile men (mean difference 2.45, (95% CI 1.72-
3.19); Bonferroni P < 0.001).  
The VEGF concentrations measured in FFs are presented in Table V. Vascular 
endothelial growth factor measured in FF was expressed as pg VEGF/mg 
protein to adjust for the maturity of the follicle. No significant differences in 
VEGF concentrations were observed between the four diagnostic subgroups.  
 
Table V VEGF concentrations (pg/mg protein) in follicular fluid 
  Fertile (n = 52) IS (n = 52) FTP (n = 26) EM (n = 26) 
VEGF   86.8 (53.9-148.3) 98.5 (65.7-133.6) 90.6 (73.5-147.2) 79.7 (55.4-119.6) 
Note: values are given as median and (25th and 75th percentile). IS = idiopathic subfertility, FTP = 
Fallopian tube pathology, EM = endometriosis. 
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In the pooled group of men or women, we investigated whether smoking status 
influenced the VEGF concentrations and observed that spermatozoa of male 
smokers contained significantly higher VEGF concentrations (geometrical 
mean = 35.9 pg VEGF/million cells, 25th-75th percentile (7.4-97.8) compared 
with non-smokers (18.3 pg VEGF/million cells (5.0-83.0); P < 0.01). In the FF 
comparable results were observed, however the results were of borderline 
statistical significance (smokers 112.6 pg VEGF/mg protein (82.9-160.5) and 
non-smokers 87.5 pg VEGF/mg protein (59.8-132.8); P = 0.06).  
Furthermore, we calculated correlation coefficients between the VEGF 
concentrations in the ejaculate and spermatozoa versus the various basic 
characteristics. The VEGF concentration in the ejaculate of all the subjects was 
inversely correlated with age (r = -0.27; P = 0.001). Likewise, correlations were 
evaluated between the VEGF-protein ratios in the FF versus the various basic 
characteristics, of which the results are presented in Table VI. The VEGF-
protein ratio was positively correlated with age, Puregon dose received, and 
progesterone concentrations in the FF, while inverse correlations were 
observed between the VEGF-protein ratio and 17β-E2 concentration in serum, 
and the number of follicles grown (both total number of follicles and number of 
follicles > 15 mm) during the stimulation procedure. 
 
Table VI Pearson correlation coefficients between the natural logarithms of 
VEGF in FF and basic characteristics of the pooled data of 156 women  
 VEGF (pg /mg protein) 
Age (years) 0.22 (0.005) 
Puregon dose (IU) 0.33 (< 0.001) 
E2 in serum (pmol/l) -0.19 (0.02) 
E2 in FF (nmol/l) -0.003 (0.97) 
Progesterone in FF (µmol/l) 0.54 (< 0.001) 
Follicles (n) -0.25 (0.002) 
Follicles > 15mm (n) -0.27 (0.001) 
Oocytes (n) -0.06 (0.47) 
Note: data are given as r-value (P-value).  
 
To investigate whether the VEGF concentrations in the ejaculate and 
spermatozoa were associated with the proportion of fertilized oocytes, the 
proportion of cleaved embryos, embryo quality or pregnancy, linear and logistic 
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regression analyses were performed. No significant associations were found 
between VEGF concentration in men and these fertility outcome parameters. 
The only association may exist between the VEGF concentration in the 
ejaculate and the proportion of cleaved embryos (r = -0.08; P = 0.06).  
Confounders included in the regression model were the percentage of fertilized 
oocytes, and the artificial reproduction method IVF or ICSI. Also, VEGF in the 
spermatozoa may be associated with embryo quality on culture day 3, 
expressed as reasonable/high or moderate/low quality (OR = 0.17, 95% CI 
0.02-1.29; P = 0.09). Included confounders in the regression model were both 
the sperm concentration in the ejaculate and in the purified spermatozoa 
sample used for insemination, and the proportion of motile spermatozoa in the 
purified spermatozoa sample.  
Finally, VEFG in spermatozoa may be associated with pregnancy (OR = 0.07, 
95% CI 0.004-1.13; P = 0.06). This regression model included the proportion of 
motile spermatozoa in the ejaculate, smoking status, age, the sperm 
concentration in the purified spermatozoa sample and the median embryo 
quality on culture day 3 as confounders. However, these associations between 
VEGF and these fertility outcome parameters were not statistically significant.  
Finally, similar regression analyses were performed for the female parameters. 
It revealed that VEGF in FF was not significantly associated with any of the 
fertility outcome parameters. 
 
Discussion 
This study demonstrates that VEGF concentrations in the ejaculate were 
substantially higher than in spermatozoa. Also, the VEGF concentration was 
significantly higher in purified spermatozoa of men with MFS, as compared to 
fertile and idiopathic subfertile men. No significant associations could be found 
between VEGF concentrations in the ejaculate and in spermatozoa and the 
fertility outcome parameters in an IVF or ICSI procedure. However, trends 
could be found for negative associations between VEGF in the ejaculate and 
the proportion of cleaved embryos in culture day 3, between VEGF in 
spermatozoa and embryo quality, and between VEGF in spermatozoa and 
pregnancy rates.  
There are only 2 studies in literature on VEGF in the male reproductive tract. 
Similar to our observations, the study by Brown et al. reported that seminal
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plasma contained extremely high levels of VEGF (Brown et al., 1995). The 
other study by Obermair et al. did not observe a correlation between seminal 
plasma VEGF and male factor subfertility, which is similar to our observations. 
Furthermore, these authors state that the VEGF concentration in seminal 
plasma is a significant predictor for pregnancy. We did not find such a 
correlation, but we observed a weak correlation between VEGF in spermato-
zoa and pregnancy rate. No data are available on VEGF concentrations in 
spermatozoa.  
We observed that in women, VEGF concentrations in FF were comparable 
between fertile and subfertile patients. No significant associations could be 
found between VEGF concentrations in FF and the fertility outcome 
parameters in an IVF or ICSI procedure. In literature, several studies report on 
VEGF concentrations in women and (sub)fertility. We did not find an 
association between FF VEGF concentrations and subfertility, which is similar 
to observations by Benifla et al. (2001) and Kim et al. (2004). However, some 
authors have found higher or lower VEGF concentrations in the FF of women 
with endometriosis (Pellicer et al., 1998; Attar et al., 2003), a finding that we 
cannot confirm. The correlations we found between VEGF and the different 
basic characteristics are in line with previous data. Our findings suggest that 
VEGF concentration in FF is an indirect marker of follicular hypoxia and 
ovarian aging, which is in line with the results found by several other groups 
(Friedman et al., 1998; Battaglia et al., 2000; Ocal et al., 2004). However a 
limitation of our study is that we did not determine direct markers of hypoxia or 
oxidative stress. In spite of the indications that VEGF concentration in FF is a 
marker of follicular hypoxia, we did not find any association with the IVF/ICSI 
outcome parameters. Similar to our results are reports stating that VEGF in FF 
is not correlated to the fertilization rate of the oocytes after IVF or ICSI 
(Friedman et al., 1998; Barroso et al., 1999; Manau et al., 2000; Attar et al., 
2003), nor with embryo quality (Manau et al., 2000; Ocal et al., 2004), or 
pregnancy rate (Benifla et al., 2001; Dorn et al., 2003; Kim et al., 2004; Cunha-
Filho et al., 2005). However, other authors observed inverse correlations with 
embryo quality (Barroso et al., 1999) and pregnancy rate (Friedman et al., 
1998; Battaglia et al., 2000; Ocal et al., 2004).  
Some limitations of the present study have to be addressed. The FF samples 
collected were pooled samples from different follicles. Therefore, it may be in- 
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correct to directly correlate the FF VEGF concentrations to the development of 
a specific follicle or embryo, which may explain the absence of associations 
between FF VEGF concentrations and fertility outcome parameters. However, 
we could not change the method of FF collection, because we had to adhere to 
the regular IVF and ICSI protocols.  
The strengths of our study as compared to other studies in literature is the 
investigation of a relatively large number of couples, man and woman, who are 
involved in an IVF or ICSI procedure. Furthermore, our study group is 
homogeneous and subfertile and fertile men or women are very comparable 
since we applied strict selection criteria. We only included couples who were 
unable to achieve a spontaneous conception within 1 year of regular, 
unprotected intercourse. Women with menstrual disorders were excluded, as 
were couples with both a male and a female factor explaining their subfertility, 
or patients with multiple causes for subfertility within one individual.  
In conclusion, VEGF concentrations in spermatozoa of subfertile men are 
significantly higher than those of fertile men. The implications of these high 
VEGF concentrations for spermatozoa function and fertility are yet 
unknown, but might be related to embryo quality and pregnancy rate in an 
IVF/ICSI procedure. Furthermore, VEGF in FF is not suitable as a predictor 
for IVF/ICSI outcome parameters.  
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The studies described in this thesis were performed to gain more insight into 
the pathophysiology of human subfertility. The first objective of the studies 
described in part I was to provide an explanation for the previously demon-
strated increase in sperm count after 26 weeks of folic acid and zinc sulphate 
intervention in subfertile men. The objective of part II was to study the involve-
ment of several determinants of the oxidative pathway as thiol antioxidants and 
VEGF and of the plasminogen pathway, tPA, uPA and PAI-1 in human sub-
fertility and outcome of the IVF/ICSI procedure.  
In this chapter we generally discuss the studies described in this thesis and 
elaborate on the findings. Furthermore, implications for clinical practice and 
future research are discussed.  
 
Study population: selection, confounders and generalizability  
In part I, subfertile men comprised men with oligozoospermia as determined by 
the first routine semen analysis in the fertility laboratory. Furthermore, subfertile 
males with a known cause for subfertility or with a sperm concentration of less 
than 5 million spermatozoa per mL were excluded, thereby excluding males 
with a severe, possibly genetically caused, deranged spermatogenesis, since it 
is unlikely that the sperm parameters of these males will respond to micro-
nutrient interventions. Men in the fertile group, recruited in midwifery practices, 
where healthy and proven to be fertile. These 2 groups were comparable with 
regard to age, serum folate concentrations, and serum testosterone concen-
trations. Serum zinc concentrations were lower in subfertile compared with 
fertile men, though within the normal range. The data of our study are part of 
the study described by Wong et al. (2002), in which these zinc concentrations 
appeared to be comparable between subfertile and fertile men. This could be 
due to the differences in sample size. Fertile and subfertile men considerably 
differed in serum FSH and inhibin B concentrations, and semen parameters. 
This is as expected, since we aimed to recruit men with normal and abnormal 
semen- and endocrine parameters. Furthermore, it is important to realise that 
the differences between the fertile and subfertile men are not important to 
answer the research question whether folic acid and zinc sulphate intervention 
affects sperm parameters, since this is evaluated in the fertile and subfertile 
group separately.  
It is known that participation rates in sperm studies among men in the general 
General Discussion 
 
 
171 
population are very low, which can lead to selection bias. However, the fertile 
group comprised couples who conceived within 1 year of regular unprotected 
intercourse, and the men were not aware of their fertility potential. Furthermore, 
since fertile men served as their own controls regarding the effect of folic acid 
and zinc sulphate intervention, it is unlikely that selection bias is involved. 
 
In part II, several diagnostic subgroups of subfertility patients are compared 
with each other and with controls. The strength of this study is the relatively 
large number of men and women undergoing an IVF or ICSI procedure that 
were investigated, and also the investigation of both partners in the subfertile 
couple. Furthermore, the study subgroups are relatively homogeneous and 
subfertile and fertile men or women are very comparable since we applied strict 
selection criteria for (sub)fertility. We only included couples who were unable to 
achieve a spontaneous conception within 1 year of regular, unprotected inter-
course. Women with menstrual disorders were excluded, as were couples with 
both a male and a female factor explaining their subfertility, or patients with 
multiple causes for subfertility within 1 individual.  
The age and semen volume of the men was comparable and sperm 
concentration, -motility, and -morphology were significantly different between 
the case and control group. In women, the idiopathic subfertile group is slightly 
older compared with the endometriosis group. To overcome this difference, we 
evaluated age as a confounder in the subsequent analyses. The other basic 
characteristics in women, comprising the stimulation protocols, endocrine para-
meters, and outcome parameters, were comparable between the diagnostic 
subgroups. So far the limitations of most studies among subfertile couples is 
that they are not including and comparing data of the couple, both man and 
woman, and also no data are available on a proven fertile population. It is very 
difficult to obtain study material of a fertile population, especially of fertile 
women. However, Tielemans et al. (2002) states that the female partners of 
men with abnormal semen parameters seem to represent a population with a 
relatively normal fertility potential, while in couples with female factor 
subfertility, the male partners fertility potential is relatively normal.  
The population of fertility patients in our study are not a representation of the 
total subfertile population, since not all subfertile couples seek medical advice. 
Also, because of our exclusion criteria, our study group is not completely
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comparable to the subfertile population that does seek medical advice. In 
clinical practice often multiple causes for subfertility can be found in a couple or 
in an individual. Therefore caution has to be taken to relate our results to all 
subfertile couples.  
 
Quality of classification 
In part I we describe the intervention study with folic acid and zinc sulphate in 
fertile and subfertile men, in which the diagnosis of male subfertility was based 
on the evaluation of 1 semen sample only in couples attending the fertility 
clinics of 2 hospitals in Nijmegen, The Netherlands, because of 1 year of 
regular unprotected intercourse without conceiving. It would have been 
favourable to obtain multiple semen samples per male before and after 
intervention, however, this was not feasible in our study, particularly from the 
fertile men. It is well-known that semen parameters must be carefully 
interpreted because of wide intra-individual biological fluctuations (Tielemans 
et al., 1997; Neuwinger et al., 1990), intra- and interobserver variability, and 
limitations and inaccuracies of the methods used to measure them. Therefore, 
misclassification could have occurred in this study. However, this 
misclassification would equally affect both groups, and therefore the results will 
underestimate the actual effects of folic acid and zinc sulphate supplemen-
tation. The effects of folic acid and zinc sulphate intervention cannot be 
explained by regression towards the mean because a placebo group was 
included in both the fertile and the subfertile group.  
We describe in part II an observational hospital-based case (subfertile) and 
control (fertile) study in IVF and ICSI couples. In man at least 2 semen 
analyses were performed and the endocrine status was determined. In the 
women a basal body temperature curve chart was used to assess the 
menstrual cycle for ovulation disorders. In addition in these women we 
determined the endocrine status, Chlamydia serology and a hysterosalpingo-
gram or laparoscopy. The latter on indication only, to assess the uterine cavity 
and tubal patency. Because of these extensive examinations misclassification 
of cases and controls is limited. 
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Quality of measurements 
The differences in biochemical parameters found between fertile and subfertile 
groups in our studies are not due to differences in measurement errors. All 
semen samples were obtained via a similar method, that is, masturbation into 
polypropylene containers after an abstinence period of 3-5 days. The semen 
analyses were performed in a similar fashion by several experienced laboratory 
technicians using the WHO guidelines (1992). Possibly it would have been 
more accurate to define sperm morphology according to the strict (Tygerberg) 
criteria, since Menkveld and Kruger (1995) report that the strict criteria are a 
better prognosticator of male fertility potential, expected fertilization in vitro, and 
pregnancy rates in assisted reproduction in comparison with the WHO 
guidelines for sperm morphology. However, evaluation of sperm morphology 
according to strict criteria needs experience. We had to adhere to the regular 
IVF and ICSI protocols used in the fertility clinic of the Radboud University 
Nijmegen Medical Centre, where WHO guidelines are used to evaluate semen 
samples.  
All women were treated according to the same protocol in the IVF or ICSI 
program. Furthermore, all biological samples obtained were stored at 
comparable temperatures before analyses of the different biochemical 
parameters. The measurement of these biochemical parameters was 
conducted in a random fashion, using the same equipment and standards.  
 
In part II specific concentrations of a biochemical parameter in spermatozoa or 
follicular fluid (FF) are associated with outcome parameters in the IVF or ICSI 
program. For the determination of these parameters, FFs of several follicles 
were pooled, as well as the spermatozoa from which the fertilising 
spermatozoon originated. Therefore, we do not know the specific concentration 
of the biochemical parameter in the FF surrounding the oocyte, or in the 
spermatozoon that lead to the evaluated embryo. This hampered the 
interpretation of the independent determinant with fertility outcome. The 
consequence namely was that no direct association could be calculated 
between the concentration of the parameter in the FF of the oocyte and in the 
spermatozoon and the successful fertilisation and implantation of those 
gametes.
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Part I Main results 
The prevalence of the different C677T MTHFR polymorphism genotypes were 
comparable in fertile and subfertile men. Furthermore, in the pooled group of 
men, only wild-types show improved sperm counts after folic acid and zinc 
sulphate intervention. Men with the heterozygous or homozygous poly-
morphism did not benefit from folic acid and zinc sulphate intervention (Chapter 
3). These observations are different from the results of Bezold et al. (2001) 
who found an almost twofold higher prevalence rate of C677T MTHFR 
homozygotes in infertile men compared with fertile men, and who suggested a 
beneficial effect of folic acid supplementation on sperm count in infertile men. 
Apparently, the residual MTHFR activity in homozygote and heterozygote 
patients is insufficient to improve spermatogenesis after supplementation. 
Therefore we conclude that a higher prevalence rate of the C677T MTHFR 
homozygosity in subfertile men, accompanied with an altered folate 
metabolism, responsive to folic acid (and zinc sulphate) intervention is not the 
most important underlying mechanism explaining the beneficial effect of this 
intervention treatment on sperm count found in our previous study (Wong et al., 
2002). 
The observation that the hormones FSH, testosterone and inhibin B did not 
significantly change after intervention with folic acid and zinc sulphate in both 
fertile and subfertile men (Chapter 4) strongly suggest that the beneficial effect 
of this intervention on sperm count is not regulated through an effect on the 
endocrine status of these men. 
Finally, the annexin A5 concentration in seminal plasma used as a marker of 
apoptosis (Chapter 5), did not change after folic acid and zinc sulphate 
intervention in both fertile and subfertile men. Since we did not assess the 
amount of apoptosis in spermatozoa themselves, we cannot conclude that the 
beneficial effect of the intervention treatment did not affect the rate of apoptosis 
in spermatozoa of these men.  
 
Part II Main results 
Since the oxidative pathway is important in human reproduction (Chapter 2), 
we hypothesized that the endogenous family of thiol antioxidants could be 
involved in idiopathic subfertility. Therefore we measured the concentrations of 
these thiols in several biological fluids of both the men and women participating
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in an IVF or ICSI program (Chapter 7). It revealed that the spermatozoa of men 
with oligoasthenoteratozoospermia contain much higher thiol concentrations 
than in idiopathic subfertile and fertile men. This suggests that the oxidative 
pathway is more triggered than in men with normal semen parameters. 
Because the thiol levels are not depleted, we conclude that the trigger of 
oxidative activation is either mild, taking place during a short period, or a rich 
source of antioxidants is available in the male reproductive tract. The high thiol 
concentrations are very likely a result of the counter balance between these 
antioxidants and reactive oxygen species (ROS) in spermatozoa. We did not 
measure ROS concentrations in our specimen samples, but there are now 
enough indications to study the balance between these determinants. 
Moreover, it is known from literature that the sperm of subfertile men often 
contains higher ROS levels as compared to those of fertile men (Sharma and 
Agarwal, 1996; Taylor, 2001). An important question still is whether the amount 
of thiols in the spermatozoa of these subfertile men is high enough to prevent 
major damage to their spermatozoa. If not, this could be a cause of defective 
sperm function and subfertility.  
In addition, we observed that a high concentration of the specific thiol 
homocysteine (Hcy) both in the ejaculate and in FF of all participants was 
associated with a higher risk of moderate to low embryo quality on culture day 
3. This is in line with the known teratogenic effects of hyperhomocysteinemia 
(Boot et al., 2004a; Greene et al., 2003; Rosenquist et al., 1996) and suggests 
that Hcy may be a biomarker for fertility outcome in an IVF/ICSI procedure. 
However, the underlying mechanism of this detrimental effect of Hcy in the 
ejaculate and FF on embryo quality is not clear yet. Hyperhomocysteinemia 
can be regarded as an oxidant and in the ejaculate and/or FF may results in 
damage to membranes or DNA of the spermatozoa or oocytes. It has been 
shown that auto-oxidation of Hcy results in the generation of the reactive 
oxygen radical hydrogen peroxide, which in turn leads to oxidative damage to 
DNA and plasma membranes eventually leading to apoptosis (Huang et al., 
2001). Szymanski and Kazdepka-Zieminska (2003) concluded that folic acid 
supplementation reduces the FF concentrations of Hcy, and that women with 
low compared with high Hcy concentrations in FF have oocytes of better quality 
and maturity. No detailed information about the effects of Hcy on spermatozoa 
is available in literature.  
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The plasminogen activator system (PA-system) plays a role in human 
reproduction (Chapter 6). Therefore, we investigated some of the determinants 
in the ejaculate, spermatozoa and FF of couples with different causes of 
subfertility and associated the concentrations of the determinants with fertility 
outcome parameters of an IVF/ICSI program (Chapter 8). We observed that 
the tissue-type plasminogen activator (tPA) concentration was higher in 
spermatozoa of men with oligoasthenoteratozoospermia compared with men 
with normal semen analysis. Furthermore, there was a trend towards higher 
tPA concentrations in FF of females with Fallopian tube pathology or 
endometriosis compared with fertile women. Also, tPA in spermatozoa was 
negatively associated with the chance of pregnancy, and tPA in FF was 
positively associated with the proportion of cleaved embryos on culture day 3 
of the IVF/ICSI program. Literature reveals that tPA in the male has several 
important functions in sperm maturation and fertilization (Chapter 6). It can be 
concluded from our data, however, that an excess of tPA seems to have 
detrimental effects on sperm concentration and success of pregnancy. In 
literature, only the study by Maier et al. (1991) also investigated the difference 
in tPA concentration in lysed spermatozoa between fertile and subfertile males. 
These authors also observed higher tPA concentrations in men with 
oligoasthenoteratozoospermia. They postulate that the high concentrations of 
tPA could result in premature detachment of the spermatozoa from the basal 
lamina in the seminiferous tubules. This could lead to more precursors of 
spermatozoa in semen. We cannot verify this in our study, since we did not 
independently score the number of precursor sperm cells in the ejaculate. 
Another possible explanation is that the balance between tPA and its inhibitor 
PAI-1 in spermatozoa is disturbed in subfertile men, leading to an excess of 
tPA activity (Chapter 8), thereby damaging the spermatozoa resulting in a 
diminished capacity of the subsequent embryo to implant. This hypothesis is 
consistent with the new finding of a negative association between tPA 
concentrations in spermatozoa and successful pregnancy we observed. 
However, we did not observe a correlation between tPA concentration in 
spermatozoa and embryo quality in culture. 
Our observation that the FF of women with female factor subfertility due to 
Fallopian tube pathology or endometriosis contain slightly higher 
concentrations of tPA compared with fertile women, and that this FF tPA
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concentration is positively correlated with the percentage of cleaved embryos 
on culture day 3 in an IVF/ICSI program is new and cannot be verified in 
literature. Rom et al. (1987) suggested that a high follicular PA activity, 
indicative of impending ovulation, could be used as an index of follicular 
maturation. This idea is consistent with our finding that high FF tPA 
concentrations are associated with a higher percentage of embryo cleavage in 
culture. However, Rom et al. found opposite results, indicating that follicles with 
the highest PA activity yielded oocytes that did not cleave in vitro. We suggest 
that as for most biochemical parameters will hold true that there is a Gauss 
distribution in which too low or too high concentrations are detrimental. 
Dependent on the place of the curve and background influences the determi-
nants will have a biological effect. We measured protein concentrations in FF 
as an established measure of follicular maturity (Spitzer et al., 1996) and found 
no difference in these concentrations between the different diagnostic 
subgroups. Therefore, the difference in tPA concentration observed cannot be 
explained by a difference in follicle maturity. Since the pathogenesis of 
Fallopian tube pathology and endometriosis are very different, we do not have 
an explanation for the higher FF tPA concentrations in these subfertile women 
as compared to those in fertile women.  
 
Finally, we observed higher VEGF concentrations in spermatozoa of subfertile 
men compared with fertile men. This finding was substantiated by an inverse 
trend between VEGF in the ejaculate and the percentage of cleaved embryos 
on culture day 3. Also, inverse trends between VEGF concentration in 
spermatozoa and embryo quality on culture day 3, and pregnancy after 
IVF/ICSI were found. These data are new and cannot be related to that of other 
authors. On the contrary, it is known that spermatozoa express the Flt-1 and 
KDR VEGF receptors on their surface (Obermair et al., 1999) thereby implying 
that VEGF acts directly on spermatogenic cells. The function of VEGF in 
spermatozoa is unknown. Hypoxia and thus oxidative stress triggers the 
expression of the growth factor VEGF which has mitogenic, permeability 
increasing, and anti-apoptotic properties. Our results indicate that high VEGF 
concentrations have a negative effect on fertility outcome parameters in an 
IVF/ICSI program, and, therefore, may reflect the presence of oxidative stress 
and subsequent damage to cell structures leading to a diminished fertilizing
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potential of spermatozoa.  
In women, no differences were observed in VEGF concentrations between the 
diagnostic subgroups. The correlations between VEGF in FF and basic 
characteristics correspond with the hypothesis that VEGF in FF is a marker of 
ovarian aging and hypoxia, resulting in oocytes of diminished quality. However 
we did not find any correlation between FF VEGF concentrations and fertility 
outcome parameters, such as embryo quality or pregnancy.  
 
Links between part I and II 
This thesis consists of 2 separate studies: A double-blind, placebo-controlled 
randomised intervention study in part I and an observational hospital-based 
case-control study in part II. Regarding the different biochemical parameters 
discussed in part II, Hcy, tPA and VEGF were observed to be associated with 
fertility outcome parameters in an IVF/ICSI program. It is interesting to note 
that Hcy induces VEGF transcription and expression in vitro (Roybal et al., 
2004). In turn, VEGF is known to be an inducer of tPA expression in vitro 
(Mandriota et al., 1995; Pepper et al., 1991).  
Several links can be made between Hcy, VEGF and tPA (Part II) and folate 
and zinc discussed in part I of this thesis. It is well-known that a deficiency in 
folate results in hyperhomocysteinemia which is implicated in several obstetric 
and gynaecologic complications (de la Calle et al., 2003), however, no specific 
literature information is available concerning the direct relationship between 
hyperhomocysteinemia and subfertility. Furthermore, folic acid supple- 
mentation is an effective treatment for hyperhomocysteinemia and its intake by 
woman trying to conceive in order to prevent occurrence of neural-tube defects 
in their offspring is nowadays widely accepted. 
No direct links between tPA and folate are known today, however, folate 
related hyperhomocysteinemia is also associated with cardiovascular disease, 
characterised among others by extracellular matrix modifications. Interestingly, 
abnormal matrix deposition can be provoked in blood vessels of neural crest 
origin by homocysteine injections into the neural tube lumen of chick embryos 
(Boot et al., 2004a). Possibly, dysregulation of the plasminogen activator 
system is involved, however, no studies on this direct relationship have been 
conducted so far. This hypothesis is further supported by the notion that 
hyperhomocysteinemia results in a defect in fibrillin, an extracellular matrix
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protein (Bellamy and McDowell, 1997; Boot et al., 2004b). The hypothesis is 
that fibrillin is especially vulnerable to high levels of homocysteine because of 
its epidermal growth factor (EGF)-like domain (Krumdieck and Prince, 2000). 
Interestingly, tPA also contains such an EGF-like domain susceptible to 
homocysteine attack. 
In literature, no direct link is known between VEGF and folate. However, as 
already mentioned, folate deficiency can result in hyperhomocysteinemia, 
which in turn is responsible for the induction of VEGF transcription and 
expression. Furthermore, folate is known to have antioxidant functions (Joshi et 
al., 2001), by clearing reactive oxygen species (ROS). In turn, ROS molecules 
are inducers of VEGF expression. Hypothetically, a deficiency in folate could 
result in an oxidant state, resulting in higher VEGF levels.  
 
The relationships between zinc and the different biochemical parameters dis-
cussed here are less straightforward. A common characteristic of enzymes 
involved in methyl transfers to thiols is the essential role of zinc incorporated in 
these enzymes (Matthews and Goulding, 1997). Methionine synthetase (MS) 
and betaine-homocysteine methyltransferase (BHMT), 2 enzymes involved in 
the conversion of homocysteine to methionine, accomplished by the addition of 
a methyl group to homocysteine (a thiol), are zinc dependent (Goulding and 
Matthews, 1997; Millian and Garrow, 1998). Surprisingly, Hong et al. (2000) 
observed that dietary zinc deficiency in rats resulted in an increase in hepatic 
MS activity, subsequently leading to lower plasma homocysteine and folate 
concentrations in the zinc deficient animals.  
In a study investigating the effects of zinc and tPA on neural toxicity in mice 
and rats, it was observed that zinc is capable of binding strongly and dose-
dependently to both active and inactive tPA resulting in an inhibition of its 
proteolytic activity (Siddiq and Tsirka, 2004).  
Finally, no direct link is known between zinc and VEGF. As was mentioned in 
the paragraph discussing the possible link between folic acid and VEGF, zinc 
which is a known antioxidant (Zago and Oteiza, 2001) could lower ROS levels, 
which are inducers of VEGF expression. 
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Conclusions 
Male and female factor subfertility are complex entities. The aim of the present 
thesis was to gain more insight into the complex pathophysiology of human 
subfertility. Despite some negative findings we have found indeed some new 
and intriguing determinants in pathways involved in male and female 
subfertility. However, the causality of these associations have to be investi-
gated and confirmed in further studies. Also, since subfertility is regarded as a 
multifactorial condition, of which we tried to elucidate some aspects involved, 
many other involved facets of this condition remain unknown. There is a need 
for more basic research into the causes of human subfertility to elucidate these 
facets, reducing the percentage of couples faced with idiopathic subfertility. 
This could facilitate the development of more suitable treatments for subfertile 
couples or even lead to preventative measures for subfertility. 
 
In part I we ascertained that the beneficial effect of folic acid and zinc sulphate 
cannot be explained by differences in folate related gene polymorphism C677T 
in the MTHFR gene, neither by an influence on the endocrine status of these 
men, nor as a result of an effect on annexin A5 concentrations in seminal 
plasma. The studies in part II show that thiols, tPA and VEGF in males and tPA 
in females are important in the pathophysiology of subfertility. Whether the 
difference in these concentrations is a cause or a consequence of impaired 
semen or oocyte quality and how these mechanisms act cannot be answered 
yet.  
The three biochemical parameters, Hcy, tPA and VEGF are interrelated, and 
differences or deficiencies in folate and zinc levels can (hypothetically) affect 
Hcy, tPA and VEGF concentrations. Since we did not find an explanation for 
the earlier observed increase in sperm count after folic acid and zinc sulphate 
intervention, along with our observations that the concentrations of endoge-
nous thiols, plasminogen activator system parameters, and VEGF are higher in 
subfertile men, and inversely associated with fertility outcome parameters, it 
would have been interesting to evaluate the parameters discussed in part II in 
the intervention study presented in part I. Possibly, the beneficial mechanism of 
this intervention is caused by an effect on Hcy, tPA or VEGF levels.  
 
General Discussion 
 
 
181 
Implications for clinical practice and future research 
We did not unravel the underlying mechanism of the beneficial effect of folic 
acid and zinc sulphate on sperm count. Also, possible side effects are not 
known yet. For instance Wong et al. (2002) observed next to the 74% increase 
in the total normal sperm count a 4% increase of abnormal sperm count in 
subfertile men after folic acid and zinc sulphate intervention. Furthermore, it is 
not clear yet whether the improvement in total normal sperm count actually 
leads to an increase in pregnancy rates, since an increase in total normal 
sperm count of 74% does not necessarily mean that the sperm concentration 
of these subfertile men increases above 20 million per mL. Furthermore, an 
increase in sperm quantity alone does not necessarily lead to higher pregnancy 
rates. The quality of spermatozoa is a very important factor for fertilization. 
However, the beneficial effect on the quantitative aspect of spermatogenesis 
could result in an IVF treatment instead of an ICSI treatment for subfertile 
couples coping with male factor subfertility. An IVF treatment is preferable over 
an ICSI treatment because the aspect of natural selection of a spermatozoon 
for fertilization is preserved in an IVF treatment, thereby assuring that a high 
quality spermatozoon fertilizes the oocyte. Because of the uncertainties 
outlined above, we do not find it justified to implement the supply of folic acid 
and zinc sulphate to subfertile males in clinical practice. However, we do 
believe that improvements of diet, i.e. increased intake of fruits and vegetables, 
should also be recommended to subfertile men since a healthy lifestyle is 
advisable to everyone.  
Also, the measurement of Hcy, tPA or VEGF in biological fluids of men and 
women participating in an IVF or ICSI program to assess their chances of 
successful conceiving is not indicated yet. Further research is needed to 
confirm that the observed associations in part II are causally related to 
subfertility and IVF/ICSI outcome. This will be difficult to achieve in men and 
women participating in these artificial reproductive techniques for obvious 
ethical reasons, but possibly these relationships could be investigated in 
laboratory animals, or in in vitro experiments. In these experiments one could 
change concentrations of Hcy, tPA or VEGF and investigate the effects on 
fertility outcome parameters. If Hcy, tPA and VEGF are causally related to 
subfertility and IVF/ICSI outcome, an assessment should be made what the 
contribution of these factors is in predicting IVF/ICSI outcome in different
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subtypes of subfertility. If the contribution of these parameters is large enough, 
the assessment of these variables could be implemented in clinical practice to 
assess the chance of success for a subfertile couple. A logical and interesting 
next step would then be to investigate the possible modifying effects of folic 
acid and zinc sulphate on these parameters in a new randomised, double-
blind, placebo-controlled trial. Also, other methods for the lowering of these 
components could be tested for their ultimate effect on natural or artificial 
fertility potential and outcome.  
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Summary 
Subfertility is defined as the failure to conceive after 1 year of regular, 
unprotected intercourse with the same partner. It is a prevalent disorder 
affecting approximately 10-17% of all couples in the Western world. The World 
Health Organization (WHO) reports that in 20% of cases the cause of 
subfertility is predominantly originating from the male, and in 38% is mainly of 
female origin. In 27% of cases fertility abnormalities are found in both partners. 
Although there are many known causes of subfertility, ranging from congenital, 
genetic, endocrine, infective and environmental factors, in up to 15% of 
couples the aetiology of subfertility remains unknown. This group is termed 
idiopathic subfertile. 
Since involuntary childlessness is a heavy burden for most subfertile couples, 
many couples seek help in the form of in vitro fertilization (IVF) or intracytoplas-
mic sperm injection (ICSI) to achieve pregnancy. Although these techniques 
have improved the treatment of subfertile couples, the success rate is still low 
(around 25%), and hardly any alternative treatment options exist. Moreover, 
ART is a symptomatic, rather than a causal treatment for subfertility. Targeted 
treatment and, possibly, prevention of subfertility is indicated. To that end we 
need more knowledge and understanding of the pathophysiology and the 
causal determinants of (the large group of idiopathic) subfertility. 
Of particular interest are the environmental and lifestyle factors implicated in 
subfertility, because these can be targeted for curative or preventive measures.  
 
A significant but largely neglected lifestyle factor is nutrition, being a source of 
micronutrients, and exogenous antioxidants like vitamins C and E. Also, 
several endogenously synthesized antioxidants are essential. Furthermore, it is 
hypothesized in literature that matrix degradation by the plasminogen activator 
system and vascularization induced by the vascular endothelial growth factor 
(VEGF) are causally involved in subfertility.  
Part I of this thesis focuses on the role of folic acid and zinc sulphate on sperm 
parameters, while Part II of this thesis discusses the role of antioxidants, the 
plasminogen activator system and VEGF.  
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Part I 
An overview of the role of the micronutrients folate and zinc, the antioxidants 
glutathione and related thiols in biological processes involved in (sub)fertility 
are described In Chapter 2 of this thesis. In the remaining three Chapters of 
Part I the results of an extension of our previously conducted double-blind, 
placebo-controlled intervention study investigating the effects of folic acid and 
zinc sulphate treatment on semen parameters in fertile and subfertile males are 
discussed. In this previous study, the participants were assigned to four 
different intervention groups consisting of 26 weeks of a daily dose of folic acid 
(5 mg) and placebo, zinc sulphate (66 mg) and placebo, zinc sulphate and folic 
acid (combined), or placebo and placebo. We demonstrated from this 
intervention study that total normal sperm count significantly increased after 
intervention with folic acid and zinc sulphate in subfertile males. However, the 
precise mechanism of this beneficial effect was not clear.  
In Chapter 3 the prevalence of C677T methylenetetrahydrofolate reductase 
(MTHFR) polymorphism was determined in 113 fertile and 77 subfertile males, 
and the MTHFR-dependent response of sperm concentration after folic acid 
and/or zinc sulphate intervention was evaluated. MTHFR is one of the key 
enzymes in folate metabolism. The C677T MTHFR polymorphism is common, 
the prevalence of the heterozygous and homozygous state is approximately 
40% and 10% in Caucasians, respectively. The C677T polymorphism in the 
MTHFR-gene is accompanied by an altered folate metabolism.  
The prevalence of the different C677T MTHFR polymorphism genotypes are 
comparable in fertile and subfertile men, indicating that C677T MTHFR 
polymorphism is not a risk factor for male factor subfertility. Furthermore, 
independent of fertility state, only wild-types show improved sperm counts after 
folic acid and zinc sulphate intervention. Men with the heterozygous or 
homozygous polymorphism do not benefit from folic acid and zinc sulphate 
intervention. Apparently, the residual MTHFR activity in homozygote and 
heterozygote patients is insufficient to improve spermatogenesis after 
supplementation. In conclusion, a higher prevalence rate of the C677T MTHFR 
homozygosity in our subfertile group of men, accompanied with an altered 
folate metabolism, responsive to folic acid (and zinc sulphate) intervention is 
not the underlying mechanism explaining the beneficial effect of this 
intervention treatment on sperm count found in our previous study. 
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In Chapter 4 we investigated the hypothesis that folic acid and zinc sulphate 
affect endocrine parameters in 47 fertile, and 40 subfertile males, for example 
by stimulating the function of the Sertoli cells, thereby facilitating higher sperm 
production. Sertoli cells provide the essential microenvironment for normal 
germ cell production and are the main producers of inhibin B in the human 
body. The serum inhibin B concentration can be used as a sensitive marker for 
the quality of the Sertoli cell function and spermatogenesis in humans. The 
observation that the hormones FSH, testosterone and inhibin B did not 
significantly change after intervention with folic acid and zinc sulphate in both 
fertile and subfertile men, indicates that the beneficial effect of this intervention 
on sperm count is not regulated through an effect on the endocrine status of 
these men. 
Because our research group has not yet identified the underlying mechanism 
of the beneficial effect of folic acid and zinc sulphate on spermatogenesis, and 
because of the observation that annexin A5 is abundantly present in seminal 
plasma, we explored the possibility that endogenous annexin A5 is directly 
involved in male factor subfertility (Chapter 5). Annexin A5 is a member of the 
protein family of annexins, and is primarily known because of its world-wide 
use to detect apoptosis. We measured annexin A5 concentrations in seminal 
plasma as a marker of apoptosis before and after folic acid and zinc sulphate 
intervention in 86 fertile and 78 subfertile males. Seminal plasma annexin A5 
concentrations are not significantly different between fertile and subfertile 
males, indicating that seminal plasma annexin A5 concentration is not 
associated with male factor subfertility. Intervention with folic acid and zinc 
sulphate does not affect seminal plasma annexin A5 concentration. Therefore, 
it is not very likely that the observed increase in sperm count after intervention 
can be attributed to a possible decrease in apoptosis rate of cells involved in 
spermatogenesis by endogenous seminal plasma annexin A5 concentration. 
Since we did not directly assess the amount of apoptosis in spermatozoa 
themselves, we cannot conclude that the beneficial effect of the intervention 
treatment did not affect spermatozoal apoptosis in these men.  
In conclusions, we still cannot explain why supplementation of folic acid and 
zinc sulphate is beneficial for sperm count in subfertile men. However, we did 
find out that this beneficial effect is not likely to be explained by differences in 
the folate related gene polymorphism C677T in the MTHFR gene, neither by an
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influence on the endocrine status of these men, nor as a result of an effect on 
annexin A5 concentrations in seminal plasma. 
 
Part II 
The objective of part II was to study the involvement of the endogenous family 
of thiol antioxidants, the plasminogen activator system, and VEGF in human 
subfertility and in the outcome of the IVF or ICSI procedure.  
In Chapter 6 of this thesis the involvement of the plasminogen activation 
system and VEGF in reproduction are reviewed. 
In Chapters 7, 8 and 9 the results of a case-control study under couples 
applying for IVF or ICSI procedures are described. Cases consisted of 
idiopathic subfertile couples, women with Fallopian tube pathology or 
endometriosis, or men with the presence of at least one of the sperm 
anomalies oligozoo-, asthenozoo-, and/or teratozoospermia. Two control 
groups were defined. The male partners without abnormal semen parameters 
of the women suffering from Fallopian tube pathology or endometriosis, and 
the female partners without tube and menstrual cycle abnormalities of the men 
with male factor subfertility. A total of 156 couples were included, 52 idiopathic 
subfertile couples, 52 couples suffering from male factor subfertility, and 52 
couples suffering from female factor subfertility.  
In Chapter 7 we investigated our hypothesis that the endogenous family of thiol 
antioxidants could be involved in unexplained cases of subfertility. Thiols are 
scavengers of reactive oxygen species (ROS), and both thiols and ROS are 
implicated in human reproduction. In humans the thiol glutathione (GSH) 
functions as the most important endogenous antioxidant. Other endogenous 
thiols are cysteine (Cys), homocysteine (Hcy) and cysteinylglycine (CGS). 
Cysteine is a precursor amino acid of GSH. Cysteinylglycine is composed of 
cysteine and glycine and is a main intermediate in the transport or synthesis of 
GSH. Our results indicate that the spermatozoa of subfertile men contain much 
higher thiol concentrations as compared to the spermatozoa of idiopathic 
subfertile and fertile men. This finding suggests that oxidative defence 
mechanisms are triggered to a higher extent in subfertile men as those in men 
with normal semen parameters. These higher thiol concentrations could be a 
counter mechanism to balance higher ROS concentrations in spermatozoa of 
subfertile men. Whether the amount of thiols in the spermatozoa of these
  
211 
subfertile men is high enough to prevent major damage to their spermatozoa is 
not clear. If not, this could be a cause of their defective sperm function and 
subfertility. Furthermore, we observed that high concentrations of Hcy both in 
the ejaculate and in follicular fluid (FF) of couples participating in IVF or ICSI 
procedures was associated with a higher chance of a moderate/low embryo 
quality. This result suggests that Hcy is a biomarker for fertility outcome in an 
IVF/ICSI procedure. However, the underlying mechanism of this detrimental 
effect of Hcy in the ejaculate and FF on embryo quality is not clear. 
In Chapter 8 we investigated the importance of the plasminogen activator 
system (PA-system) in human subfertility. The PA-system is important in matrix 
degradation and is known to be involved in a variety of reproductive processes 
in both males and females. We observed that tissue-type plasminogen 
activator (tPA) concentrations were higher in spermatozoa of men in the male 
factor subfertility group compared with these concentrations in spermatozoa of 
fertile and idiopathic subfertile men. Furthermore, there was a trend towards 
higher tPA concentrations in FF of females with Fallopian tube pathology or 
endometriosis compared with fertile women. Furthermore, tPA in spermatozoa 
was negatively associated with the chance of pregnancy, and tPA in FF was 
positively associated with the proportion of cleaved embryos on culture day 3 
of the IVF/ICSI program. Therefore we conclude that tPA in both males and 
females is important in the pathophysiology of subfertility.  
Chapter 9 presents the results of our study on the relationship between VEGF 
and human subfertility. VEGF is a mitogenic and permeability increasing 
growth factor, which also seems to have important functions in human 
reproduction. We observed higher VEGF concentrations in spermatozoa from 
men with male factor subfertility as compared to those in fertile and idiopathic 
subfertile men. High VEGF concentrations in the ejaculate tend to be 
negatively associated with the percentage of cleaved embryos on culture day 
3. Furthermore, high VEGF concentrations in spermatozoa tend to be 
negatively associated with embryo quality, and pregnancy rate. These results 
suggest that VEGF is a new biomarker for subfertility, and that VEGF affects 
fertility outcome parameters in an IVF/ICSI procedure.  
In conclusion, the studies in part II show that thiols, tPA and VEGF in males 
and tPA in females are important in the pathophysiology of subfertility. Whether 
the difference in these concentrations are causes or consequences of impaired
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semen or oocyte quality and how these mechanisms work cannot be answered 
yet.  
 
In the general discussion (Chapter 10) we reflect on all these different findings 
in the light of the methodological strengths and weaknesses, and in relation to 
literature we try to synthesise what knowledge about the pathophysiology of 
subfertility has been achieved and what the links can be between all the 
different hypotheses and results described in the separate chapters. 
This enables us to formulate recommendations for new research and potential 
clinical implications. 
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Samenvatting 
Subfertiliteit wordt gedefinieerd als het onvermogen zwanger te worden binnen 
een jaar van regelmatige, onbeschermde coïtus met dezelfde partner. Het is 
een veel voorkomende aandoening die ongeveer 10-17% van alle stellen in de 
westerse wereld treft. De wereldgezondheidsorganisatie rapporteert dat de 
oorzaak van subfertiliteit in 20% van de gevallen bij de man ligt en in 38% bij 
de vrouw. In 27% van de gevallen zijn oorzaken voor subfertiliteit te vinden in 
beide partners. Hoewel er veel bekende oorzaken zijn voor subfertiliteit, 
variërend van congenitaal, endocrien en infectieus tot omgevingsfactoren, blijft 
de etiologie voor de subfertiliteit in 15% van de gevallen toch onbekend. Dit 
wordt idiopathische subfertiliteit genoemd.  
Omdat ongewenste kinderloosheid een zware last is voor de meeste 
subfertiele koppels, zoeken vele van hen hulp in de vorm van in vitro fertilisatie 
(IVF) of intracytoplasmatische sperma injectie (ICSI) om toch zwanger te 
worden. Hoewel deze technieken de behandeling van subfertiele stellen 
verbeterd hebben, is het succespercentage nog steeds laag (rond 25%) en 
alternatieve behandelingsopties bestaan nauwelijks. Bovendien zijn artificiële 
reproductietechnieken een symptomatische in plaats van een causale 
behandeling voor subfertiliteit. Doelgerichte behandeling en zo mogelijk 
preventie van subfertiliteit is geïndiceerd. Om dat doel te bereiken is meer 
kennis en begrip van de pathofysiologie en de causale determinanten van (de 
grote groep van idiopathische) subfertiliteit noodzakelijk. 
Met name van belang zijn de omgevings- en leefstijlfactoren bij subfertiliteit, 
omdat deze factoren aangepakt kunnen worden in het kader van curatieve of 
preventieve maatregelen.  
 
Een significante, maar grotendeels genegeerde leefstijlfactor is voeding, een 
bron van micronutriënten en exogene antioxidanten zoals vitamine C en E. 
Ook essentieel zijn verschillende endogeen gesynthetiseerde antioxidanten. In 
de literatuur komt verder nog de hypothese naar voren dat matrix degradatie 
door het plasminogeen activator systeem en vascularisatie geïnduceerd door 
de vaatgroeifactor VEGF causale factoren zijn bij subfertiliteit. 
Deel I van dit proefschrift focust op de rol van foliumzuur en zinksulfaat op 
semenparameters, terwijl in Deel II de rol van antioxidanten, het plasminogeen 
activator systeem en VEGF bediscussieerd wordt.  
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Deel I 
In Hoofdstuk 2 van dit proefschrift wordt een overzicht gegeven van de rol van 
de micronutriënten foliumzuur en zink en de antioxidant glutathion en 
gerelateerde thiolen in biologische processen van belang bij (sub)fertiliteit. In 
de overgebleven drie hoofdstukken van Deel I worden de resultaten bedis-
cussieerd van een vervolgstudie op onze eerder uitgevoerde dubbel-blinde, 
placebo-gecontroleerde interventiestudie over de invloed van foliumzuur en 
zinksulfaat behandeling op semenparameters in fertiele en subfertiele mannen. 
In deze interventiestudie, werden de deelnemers ingedeeld in vier verschil-
lende interventiegroepen die respectievelijk een dagelijkse dosis foliumzuur (5 
mg) en placebo, zinksulfaat (66 mg) en placebo, zinksulfaat en foliumzuur 
(gecombineerd), of placebo en placebo, hebben ingenomen gedurende 26 
weken. Uit deze interventiestudie hebben we kunnen concluderen dat na 
inname van foliumzuur en zinksulfaat het totaal aantal normale spermatozoa 
van subfertiele mannen significant toenam. Het precieze mechanisme van dit 
positieve effect is echter nog niet duidelijk.  
in Hoofdstuk 3 wordt de prevalentie van het C677T methyleentetrahydrofolaat 
reductase (MTHFR) polymorfisme bepaald en wordt de MTHFR-afhankelijke 
respons van de spermaconcentratie na foliumzuur en/of zinksulfaat interventie 
geëvalueerd in 113 fertiele en 77 subfertiele mannen. MTHFR is een van de 
belangrijkste enzymen in het foliumzuurmetabolisme. Het C677T MTHFR 
polymorfisme komt veel voor, met een prevalentie van de heterozygote en 
homozygote status van respectievelijk ongeveer 40% en 10% in Caucasiërs. 
Het C677T polymorfisme in het MTHFR-gen gaat hand in hand met een 
veranderd foliumzuurmetabolisme.  
De prevalentie van de verschillende C677T MTHFR polymorfisme genotypes 
zijn vergelijkbaar in fertiele en subfertiele mannen, wat aangeeft dat C677T 
MTHFR polymorfisme geen risicofactor is voor mannelijke-factor-subfertiliteit. 
Voorts, onafhankelijk van fertiliteitstatus, hebben alleen mannen zonder 
polymorfisme baat bij foliumzuur en zinksulfaat interventie wat betreft hun 
spermatozoa-aantal. Noch mannen met een heterozygoot als met een homo-
zygoot polymorfisme hebben baat bij foliumzuur en zinksulfaat interventie. 
Klaarblijkelijk is de restactiviteit van MTHFR in homozygote en heterozygote 
patiënten onvoldoende om de spermatogenese te verbeteren na suppletie. 
Concluderend, een hogere prevalentie van C677T MTHFR homozygotie in
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onze subfertiele populatie, met als gevolg een veranderd foliumzuur-
metabolisme, gevoelig voor foliumzuur (en zinksulfaat) interventie, is niet het 
onderliggende mechanisme dat het positieve effect van deze interventie op 
spermatozoa-aantal, gevonden in onze eerdere studie, verklaart.  
In Hoofdstuk 4 hebben we in 47 fertiele en 40 subfertiele mannen de 
hypothese getest dat foliumzuur en zinksulfaat endocriene parameters 
beïnvloedt, bijvoorbeeld door stimulatie van de functie van Sertolicellen, 
waardoor een hogere spermatozoaproductie kan worden gerealiseerd. Sertoli-
cellen verschaffen het essentiële micromilieu voor normale kiemcelproductie 
en zijn de belangrijkste producenten van inhibine B in het menselijke lichaam. 
De serum inhibine B concentratie kan gebruikt worden als een gevoelige 
marker voor de kwaliteit van Sertolicelfunctie en spermatogenese in de mens. 
De observatie dat er geen verandering optreedt in de concentratie van de 
hormonen FSH, testosteron en inhibine B na foliumzuur en zinksulfaat 
interventie in zowel fertiele als subfertiele mannen, geeft aan dat het positieve 
effect van deze interventie op spermatozoa-aantal niet gereguleerd wordt door 
een effect op de endocriene status van deze mannen.  
Omdat onze onderzoeksgroep nog steeds geen verklaring heeft voor het 
onderliggende mechanisme van het positieve effect van foliumzuur en 
zinksulfaat op de spermatogenese en gezien de observatie dat annexine A5 in 
hoge concentraties aanwezig is in seminaal plasma, hebben we gekeken naar 
de mogelijkheid dat endogeen annexine A5 direct betrokken is bij mannelijke-
factor-subfertiliteit (Hoofdstuk 5). Annexine A5 is een lid van de eiwitfamilie van 
annexines en is met name bekend om zijn wereldwijde gebruik als apoptose 
detector. Wij hebben annexine A5 concentraties gemeten, als een marker voor 
apoptose, in het seminaal plasma van 86 fertiele en 78 subfertiele mannen. 
Seminaal plasma annexine A5 concentraties zijn niet significant verschillend 
tussen fertiele en subfertiele mannen, wat aangeeft dat de seminaal plasma 
annexine A5 concentratie niet geassocieerd is met mannelijke-factor-
subfertiliteit. Interventie met foliumzuur en zinksulfaat heeft geen invloed op  
seminaal plasma annexine A5 concentraties. Daarom is het niet erg 
waarschijnlijk dat de geobserveerde toename in spermatozoa-aantal na 
interventie, toegeschreven kan worden aan een mogelijke daling van apoptose 
van cellen van belang voor de spermatogenese door endogene seminaal 
plasma annexine A5 concentraties. Omdat we niet gekeken hebben naar de
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mate van apoptose van de spermatozoa zelf, kunnen we niet concluderen dat 
het positieve effect van de interventie geen effect heeft gehad op apoptose van 
spermatozoa in deze mannen.  
 
Concluderend kunnen we nog steeds niet verklaren waarom suppletie van 
foliumzuur en zinksulfaat een positief effect heeft op het spermatozoa-aantal 
van subfertiele mannen. Echter, we kunnen wel concluderen dat het niet 
waarschijnlijk is dat dit positieve effect verklaard wordt door verschillen in het 
foliumzuur gerelateerde genetische polymorfisme C677T in het MTHFR gen, 
door invloed op de endocriene status van deze mannen, of als resultaat van 
een effect op annexine A5 concentraties in seminaal plasma. 
 
Deel II 
Het doel van deel II van dit proefschrift was het bestuderen van de 
betrokkenheid van de endogene familie van thiol antioxidanten, het plasmino-
geen activator systeem, en VEGF, in subfertiliteit van de mens en in de 
uitkomst van de IVF/ICSI procedure.  
In Hoofdstuk 6 van dit proefschrift wordt de betrokkenheid van het 
plasminogeen activator systeem en VEGF in reproductie besproken. In 
Hoofdstuk 7, 8 en 9 worden de resultaten besproken van een patiënt-controle- 
onderzoek in stellen die in aanmerking komen voor een IVF of ICSI 
behandeling. Patiënten bestaan uit idiopathisch subfertiele stellen, vrouwen 
met een tubafactor of endometriose of mannen met de aanwezigheid van ten 
minste een van de sperma-abnormaliteiten oligozoö-, asthenozoö-, en/of 
teratozoöspermie. We hebben twee controlegroepen gedefinieerd. De man-
nelijke partners van vrouwen met een tubafactor of endometriose, zonder 
abnormale spermaparameters, en de vrouwen zonder afwijkingen in eileiders 
of menstruatiecylcus met een partner met mannelijke-factor-subfertiliteit. Een 
totaal aantal van 156 stellen werden in het onderzoek geïncludeerd, waarvan 
52 idiopatisch subfertiele stellen, 52 stellen lijdend aan mannelijke-factor-
subfertiliteit en 52 stellen met vrouwelijke-factor-subfertiliteit.  
In Hoofdstuk 7 hebben we onze hypothese onderzocht dat de endogene 
familie van thiol antioxidanten een rol speelt in de gevallen van onverklaarde 
subfertiliteit. Thiolen vangen reactieve zuurstofradicalen (ROS) weg, en zowel 
thiolen als ROS worden van belang geacht in de reproductie van de mens. In
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de mens functioneert de thiol glutathion (GSH) als de belangrijkste endogene 
antioxidant. Andere endogene antioxidanten zijn cysteïne (Cys), homocysteïne 
(Hcy) en cysteïnylglycine (CGS). Cysteïne is een voorloper aminozuur van 
GSH. Cysteïnylglycine is samengesteld uit cysteïne en glycine en is een 
belangrijke intermediair in het transport of de synthese van GSH. Onze 
resultaten laten zien dat de spermatozoa van subfertiele mannen veel hogere 
thiolconcentraties bevatten dan de spermatozoa van idiopathisch subfertiele en 
fertiele mannen. Deze bevindingen suggereren dat oxidatieve verdedigings-
mechanismen in subfertiele mannen in hogere mate gestimuleerd worden dan 
in mannen met normale semenparameters. Deze hogere thiolconcentraties 
zouden een verdedigingsmechanisme kunnen zijn ter compensatie van de 
hogere ROS concentraties in spermatozoa van subfertiele mannen. Of de 
thiolhoeveelheid in de spermatozoa van deze subfertiele mannen hoog genoeg 
is om ernstige schade aan de spermatozoa te voorkomen, is niet duidelijk. Is 
de thiolconcentratie relatief te laag, dan kan dat een oorzaak zijn voor hun 
slechtere spermafunctie en subfertiliteit. In deze studie hebben we ook gezien 
dat hogere concentraties van Hcy zowel in het ejaculaat als in de 
follikelvloeistof (FF) van stellen die deelnamen aan een IVF of ICSI procedure, 
geassocieerd was met een hogere kans op een matig/slechte embryokwaliteit. 
Dit resultaat suggereert dat Hcy een biomarker is voor fertiliteitsuitkomst in een 
IVF/ICSI procedure. Echter, het onderliggende mechanisme van dit negatieve 
effect van Hcy in ejaculaat en FF op embryo-kwaliteit is niet duidelijk.  
In Hoofdstuk 8 hebben we onderzocht wat het belang is van het plasminogeen 
activator systeem (PA-systeem) bij subfertiliteit van de mens. Het PA-systeem 
is van belang bij matrix degradatie en bekend om zijn betrokkenheid bij een 
veelheid aan reproductieprocessen in zowel mannen als vrouwen. Wij hebben 
gezien dat tissue-type plasminogeen activator (tPA) concentraties hoger waren 
in spermatozoa van subfertiele mannen dan in spermatozoa van mannen in de 
idiopathisch subfertiele en fertiele groep. In aanvulling hierop hebben we een 
trend gezien richting hogere tPA concentraties in FF van vrouwen met een 
tubafactor of endometriose in vergelijking met fertiele vrouwen. Een ander 
resultaat is dat tPA in spermatozoa negatief geassocieerd is met de kans op 
zwangerschap en tPA in FF positief geassocieerd is met het percentage 
gedeelde embryo’s op kweekdag 3 van het IVF/ICSI programma.  
Hieruit concluderen wij dat tPA in zowel mannen als vrouwen belangrijk is in de
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pathofysiologie van subfertiliteit.  
Hoofdstuk 9 presenteert de resultaten van onze studie naar de relatie tussen 
VEGF en subfertiliteit in de mens. VEGF is een vaatgroeifactor die ook de 
doorlaatbaarheid van vaten verhoogt. Deze functies zijn ook van belang in 
reproductie. Onze resultaten laten zien dat spermatozoa van subfertiele 
mannen hogere VEGF concentraties bevatten dan spermatozoa van idio-
pathisch subfertiele en fertiele mannen. Hoge VEGF concentraties in het 
ejaculaat leken negatief geassocieerd te zijn met het percentage gedeelde 
embryo’s op kweekdag 3. Tevens leken hoge VEGF concentraties in sper-
matozoa negatief geassocieerd te zijn met embryokwaliteit en zwangerschaps-
kans. Deze resultaten suggereren dat VEGF een nieuwe biomarker is voor 
subfertiliteit en dat VEGF de uitkomstparameters van een IVF/ICSI procedure 
beïnvloedt.  
 
Concluderend kunnen we stellen dat de resultaten gepresenteerd in deel II 
laten zien dat thiolen, tPA en VEGF in mannen en tPA in vrouwen belangrijk 
zijn in de pathofysiologie van subfertiliteit. Of de verschillen in concentratie van 
deze stoffen oorzaken of consequenties zijn van verminderde semen- of 
oocytkwaliteit en hoe deze mechanismen precies werken, is nu nog niet 
bekend.  
 
In de algehele discussie (Hoofdstuk 10) reflecteren we op al de verschillende 
bevindingen en bekijken we ze in het licht van de methodologische sterke en 
zwakke punten. In relatie tot de literatuur proberen we de kennis van de 
pathofysiologie van subfertiliteit verkregen middels dit proefschrift bij elkaar te 
brengen tot een geheel. Ook bediscussiëren we de samenhang tussen de 
verschillende hypothesen en resultaten in de verschillende hoofdstukken. Dit 
stelt ons in staat om aanbevelingen te doen voor toekomstig onderzoek en 
potentiële klinische implicaties van onze resultaten.  
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Dankwoord 
Het standaard begin van elk dankwoord dat ik tot nu toe gelezen heb, is dat 
geen enkel proefschrift tot stand komt door de inspanningen van de promo-
vendus alléén. Niets is meer waar, en gelukkig maar, want zonder de hulp van 
zovele begeleiders, collega’s, vrienden en familie had ik het niet gered! Reden 
genoeg om deze mensen bij naam te noemen. 
 
Als eerste wil ik mijn co-promotor en directe begeleidster Dr. Steegers-
Theunissen bedanken. Beste Régine, onze samenwerking begon tijdens mijn 
studie biomedische gezondheidswetenschappen toen ik onder jouw leiding een 
korte stage deed op het vakgebied van de reproductie. Sinds die tijd heb ik 
veel van jou geleerd. Jouw doorzettingsvermogen en niet aflatende interesse in 
de medische wetenschap in het algemeen en de reproductie in het bijzonder 
hebben ervoor gezorgd dat ik altijd mijn beste beentje voorzette. Dat heeft 
uiteindelijk geleid tot het afronden van dit proefschrift, waarna ik als doctor op 
eigen benen zal moeten staan. Ik heb onze samenwerking altijd als zeer prettig 
ervaren en wil je hiervoor dan ook graag bedanken.  
Mijn co-promotor Dr. Thomas. Beste Chris, ook onze samenwerking gaat terug 
naar de stageperioden tijdens mijn opleiding. Altijd stond jouw deur voor mij 
open en daar heb ik dan ook gebruik van gemaakt. Zowel voor peptalks of het 
oplossen van wetenschappelijke problemen, als voor een praatje over de 
dingen van het leven. Ik heb veel geleerd van jouw kritische blik en oog voor 
detail. Dat heeft zeker geleid tot een beter proefschrift. Bedankt daarvoor. 
Mijn promotor Prof. Dr. Braat. Beste Didi, wij hadden met name contact tijdens 
de voortgangsbesprekingen en in de laatste fase van het afronden van dit 
proefschrift. Ik wil je bedanken voor je interesse, begrip en vertrouwen alsook 
voor het voorbeeld dat je voor me bent als arts, onderzoeker en als mens. 
 
Prof. Dr. Verbeek, Prof. Dr. de Jong en Dr. Kremer, als leden van de 
manuscriptcommissie wil ik u bedanken voor het beoordelen van en nog 
belangrijker, goedkeuren van dit epistel. Beste Prof. Dr. de Jong, tevens wil ik 
u bedanken voor de coördinerende rol die u gespeeld hebt bij het tot stand 
komen van het "inhibine B artikel" en uw altijd snelle en vriendelijke reacties via 
de mail.  
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Prof. Dr. Zielhuis, beste Gerhard, jij bent altijd zijdelings betrokken geweest bij 
mijn proefschrift en hebt er mede voor gezorgd dat het op tijd af was. Het 
samen opstellen van deadlines is voor mij altijd een drijfveer geweest om te 
zorgen dat ik ze zou halen, hoe onmogelijk het soms ook leek en dat is 
(waarschijnlijk tot ons beider verbazing) altijd goed gelukt. Ook wil ik je 
bedanken voor de werkplek die ik heb gekregen op de afdeling epidemiologie 
en biostatistiek, het doorlezen van mijn artikelen en het becommentariëren 
ervan. 
 
Dr. van Heerde, beste Waander, het lijkt wel alsof het allemaal begonnen is bij 
mijn stages voor de studie biomedische gezondheidswetenschappen, want ook 
mijn eerste kennismaking met jou was in mijn stageperiode. Je was mijn 
directe begeleider bij mijn eerste kennismaking met de praktijk van onderzoek 
doen en dat is me goed bevallen. Ik heb in die periode veel geleerd en ook 
genoten van onze gesprekken over wetenschap en aanverwante zaken. Ik heb 
je nog vaak opgezocht om weer eens over ons "annexine A5 artikel" te praten 
en nu is het dan (eindelijk!) gepubliceerd. Bedankt voor het delen van al je 
kennis en ervaring en voor de fijne stageperiode. 
Selene Schoormans, mede door jou is mijn tijd op het centraal hematologisch 
laboratorium een leuke tijd geweest. Bedankt voor al je hulp bij praktische 
laboratoriumzaken en je oprechte interesse in de voortgang van mijn 
proefschrift. Succes met je eigen onderzoek en tot onze volgende ontmoeting 
in de gangen van het Radboud ziekenhuis!  
Dr. Peters, beste Wilbert, als mijn directe begeleider bij mijn tweede stage en 
tevens co-auteur van enkele van mijn artikelen, wil ik je graag bedanken voor 
je begeleiding en je kennis van zaken die hebben bijgedragen tot twee mooie 
artikelen. Ook onze gesprekken over de gang van zaken betreffende 
manuscriptcommissies en verdedigingen van proefschriften hebben mij 
geholpen.  
Dr. Raijmakers, beste Maarten, bedankt voor je kritische blik en je hulp bij het 
temmen van het HPLC-apparaat! Zonder jouw ervaring met dat apparaat had 
ik het niet gered. Ook wil ik Elise van der Logt, Réne te Morsche, Hennie 
Roelofs, Annie van Schaik en Mariëtte Verlaan bedanken voor hun praktische 
hulp en voor een gezellige stageperiode op het maag-darm-lever-lab. 
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Dr. Wong, beste Wai Yee, wij hebben elkaar maar één keer ontmoet, maar 
doordat jij mijn voorganger was op dit onderzoeksterrein kon ik het 
semenmateriaal en de gegevens die jij hebt verzameld, plus de behaalde 
resultaten ook voor mijn onderzoek gebruiken. Zonder dit materiaal had ik 
het eerste deel van mijn proefschrift niet kunnen schrijven! Bedankt 
daarvoor. 
Dr. van der Put, beste Nathalie, ik wil je als co-auteur graag bedanken voor je 
bijdrage aan het artikel over het MTHFR-polymorfisme in (sub)fertiele mannen.   
Dr. Pierik, beste Frank, door jou ben ik heel wat meer te weten gekomen over 
inhibine B. Ik wil je bedanken voor al het werk dat je gestoken hebt in het 
artikel dat hier uiteindelijk uit ontstaan is en ook voor je oprechte interesse in 
de voortgang van mijn proefschrift en mijn studie geneeskunde. Onze emailtjes 
hebben me gesterkt in mijn idee dat wetenschappelijk onderzoek en genees-
kunde een mooie combinatie is.  
 
En dan de mensen van het IVF-lab: Loes van Boesschoten, Suzanne 
Gommans, Leonie van den Hoven, Emiel Lindeman, Yvonne Opdam, Shanta 
Pherai, Anneke Punt, Liliana Ramos, Hannie Robben, Jozé Verbeet, Hans 
Westphal en Alex Wetzels. Jullie wil ik bedanken voor een ontzettend leuke 
tijd, zowel tijdens mijn stageperiode alsook in mijn jaartje als junior-
onderzoekster. Jullie zijn stuk voor stuk leuke en gezellige collega's waarmee 
ik ook na werktijd gezellige uurtjes heb doorgebracht. Het was niet alleen maar 
gezelligheid wat de klok sloeg, jullie hebben ook allemaal veel werk voor mij 
verzet. Van spermatozoa verzamelen en tellen, plaatjes zoeken, tot artikelen 
beoordelen, het was nooit teveel gevraagd. Bedankt voor de leuke plek op het 
IVF-lab en al jullie hulp en inzet. Suzanne en Leonie, bedankt dat jullie mijn 
paranimfen willen zijn, ik kan me geen betere wensen!  
Graag wil ik alle IVF-verpleegkundigen en secretaresses bedanken voor hun 
hulp bij het opzoeken van patiëntengegevens en andere praktische zaken.  
Dr. Willemsen, beste Wim, bedankt voor je interesse in mijn onderzoek, je 
inbreng in de voortgangsbesprekingen en je co-auteurschap.  
Mark Flink, onze eerste ontmoeting stond in het licht van een niet werkende 
floppy (waar is de tijd gebleven?!). Dankjewel voor je hulp met ICT-zaken waar 
ik geen verstand van heb, gegevens uit de LIR die je voor me hebt opgezocht 
en de lach die je zo vaak op mijn gezicht hebt getoverd. 
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Ans Bakker, voor alle hulp bij praktische zaken zoals afspraken maken met 
een heleboel drukbezette personen, brieven die de deur uit moesten, 
handtekeningen die verzameld moesten worden etc. Ik hoefde je maar te 
vragen en het werd vliegensvlug geregeld! Bedankt daarvoor. 
 
Mijn ex-kamergenootje en partner-in-crime Dr. Bretveld, beste Reini, ik vind het 
nog steeds jammer dat we geen duo-promotie hebben gedaan! Dat was vast 
leuk geweest. Ik had me geen betere kamergenote kunnen wensen. De andere 
medewerkers hebben zich vast en zeker vaak geërgerd aan het gelach uit 
onze kamer en zich afgevraagd of er ook nog gewerkt werd. Het afronden van 
ons beider proefschrift is daar echter het bewijs van. Hartelijk bedankt voor je 
hulp bij de statistiek, maar met name voor de gezellige tijd die we gehad 
hebben. 
Wim Lemmens, jou wil ik graag bedanken omdat je zo'n fijne collega voor me 
bent geweest. Hoeveel werk er zich ook op je bureau had opgestapeld, je 
maakte altijd tijd voor een praatje en had een luisterend oor, zowel bij 
statistische problemen als bij persoonlijke beslommeringen. Bedankt voor al je 
raad en steun. 
Dr. Peer, beste Nelly, jij bent niet altijd makkelijk te pakken te krijgen op de 
afdeling epidemiologie en biostatistiek, maar bij statistische problemen wist ik 
je altijd te vinden. Bedankt voor de moeite die je gedaan hebt om mijn 
onderzoek en de statistische problemen die daarbij naar boven kwamen te 
begrijpen en op te lossen, alsook voor je kritische blik bij het totstandkomen 
van de beschrijving van de gebruikte statistiek bij mijn artikelen. 
Ook wil ik alle andere collega's bij de afdeling epidemiologie en biostatistiek 
bedanken voor hun hulp, de leuke tijd die ik er heb doorgebracht en voor alle 
zelfgemaakte baksels die ik er op vrijdag tijdens de koffiepauze heb mogen 
nuttigen!  
 
Dr. Sweep, beste Fred, bedankt voor de stageplek op het algemeen chemisch 
endocrinologisch lab. Ik heb het er goed naar m'n zin gehad en er zijn drie 
mooie artikelen aan die tijd ontsproten. Ik wil je bedanken voor je deskundige 
en kritische blik en voor de snelle correcties van de artikelen. 
Anneke Geurts-Moespot en Doorlène van Tienoven. Jullie hebben me 
geholpen bij de bepaling van uPA, tPA en VEGF in alle monsters. Dat heeft
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veel tijd gekost en jullie waren altijd bereid mij te helpen. Bedankt daarvoor. 
Het waren gezellige uurtjes achter de ELISA's. Ook dank ik André Brandt en 
Rob van den Berg bedanken voor hun hulp bij het meten van hormoon-
concentraties in follikelvloeistof en Paul Span voor zijn hulp bij het trachten te 
doorgronden van het nut van RNA in spermatozoa.  
 
Na alle collega's wil ik ook graag mijn vrienden, vriendinnen, medestudenten, 
medeco-assistenten en familieleden bedanken die altijd geïnteresseerd wilden 
luisteren naar de frustraties die wetenschappelijk onderzoek doen soms bij me 
opriepen, maar die ook samen met mij de leuke kanten hebben gedeeld, zoals 
de vreugde van een eerste publicatie, congresbezoek en het uiteindelijke 
afronden van mijn proefschrift. Graag wil ik Jos Kranen bij naam noemen. Jos, 
ondanks je drukke programma en kunstzinnige bezigheden heb je tijd willen 
vrijmaken om de prachtige omslag te ontwerpen voor mijn proefschrift. Thanks! 
Een speciaal woord van dank spreek ik uit naar de Bouten groep, in het 
bijzonder naar ome Thijs. Jullie gulle bijdrage helpt mij de met een promotie 
gepaard gaande kosten te verlichten. Je mag hier met recht van "financiële 
dienstverlening" spreken. Heel veel dank! 
 
En dan is het nu de beurt aan de twee mensen waaraan ik dit proefschrift heb 
opgedragen. Lieve pap en mam, ik wil jullie oprecht bedanken voor het feit dat 
jullie mij opgevoed hebben tot een zelfstandige en verstandige jonge vrouw, 
die weet wat ze wil. Zonder jullie onvoorwaardelijke liefde en steun was ik 
zeker niet zover gekomen. Het doet mij goed dat ik jullie twee zo trots kan 
maken!   
Lieve Moniek, zo anders dan ik, maar toch zo hetzelfde! Bedankt kleine zus 
voor je steun, interesse en nuchterheid.  
 
En dan als laatste, maar zeker niet als minste, wil ik mijn partner Danny 
bedanken voor al zijn liefde, steun en vertrouwen. Jij hebt mij geleerd dat je het 
leven niet alleen moet baseren op harde feiten en logica, maar dat luisteren 
naar wat je hart je ingeeft minstens zo belangrijk is! Bedankt lieverd, ik hou van 
jou. 
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